ADVANCES IN CANCER RESEARCH VOLUME 60
This Page Intentionally Left Blank
ADVANCES IN CANCERRESEARCH Edited by
GEOR...
18 downloads
1392 Views
17MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
ADVANCES IN CANCER RESEARCH VOLUME 60
This Page Intentionally Left Blank
ADVANCES IN CANCERRESEARCH Edited by
GEORGE F. V A N E WOUOE ABL-Basic Research Program NCI-Frederick Cancer Research and Development Center Frederick, Maryland
GEORGE KLEIN Department of Tumor Biology Karolinska lnstitutet Stockholm, Sweden
Volume 60
ACADEMIC PRESS, INC. Harcourt Brace Jovanovich, Publishers
San Diego New York Boston London Sydney Tokyo Toronto
This book is printed on acid-free paper. @ Copyright
0 1993 by ACADEMIC PRESS, INC.
All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means. electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.
Academic Press, Inc. 1250 Sixth Avenue, San Diego. California 92101-431I L'nifedKingdom Edition published by
Academic Press Limited 24-28 Oval Road, London NW I 7DX
Library of Congress Catalog Number: 52-1 3360 International Standard Book Number: 0-12-006660-2
PKlNTED IN THE UNITED STATES OF AMERICA Y 2 9 3 9 4 9 S 9 6 9 7
BB
9
8
7
6
5
4
3
2
1
CONTENTS
CONTRIBUTORS TO VOLUME 60 ....................
..........
ix
Structural and Functional Diversity in the FGF Receptor Multigene Family DANIEL E . JOHNSON
AND
LEWIST. WILLIAMS
I . Introduction .................................................... I1. The FGF Family of Polypeptide Mitogens .......................... 111. Early Binding and Cross-Linking Studies of the FGF Receptor ...... IV. Nomenclature of the FGF Receptor Genes ......................... V. Purification. cDNA Cloning. and Characterization of FGFR 1 ....... VI . Characterization of EFGR 2. FGFR 3. and FGFR 4 ................. VII . Multiple Forms of FGFR 1 and FGFR 2 Are Generated by Alternative Splicing ........................................... VIII . Multiple Forms of FGFR 1 ....................................... IX . Multiple Forms of FGFR 2 .................................... X . FGFR 3 and FGFR 4 ...................... XI . Ligand Binding Specificities of the Cloned FGF Receptors . . . . . . . . . . XI1. Alternative Splicing in the Third Ig Domain Is Important for Determining Ligand Binding Specificities ...................... XI11. Analogous Splice Variants from Different FGF Receptor Genes Encode Receptor Forms with Different Ligand Binding Specificities ......... XIV. Regulation of FGF Receptor Expression ........................... xv. Cell- and Tissue-Specific Alternative Splicing of FGF Receptor mRNAs ........................................ XVI . Differential. Tissue-Specific Expression of the Different ' FGF Receptor Genes ......................................... XVII . The Drosophilu FGF Receptor ..................................... XVIII . FGF Receptor-Mediated Signal Transduction .......................
V
1 2 6
7 8 11
15 15 20 23 24 25 27 28 28 29 30 31
vi
CONTENTS
XIX. Concluding Remarks ............................................ References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33 35
Protein Tyrosine Kinase Growth Factor Receptors and Their Ligands in Development, Differentiation, and Cancer
ANDREW F. WILKS ............... I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . 11. Structure of Receptor Protein Tyrosine Kinases . . . . . . . . . . . . . . . . . . . . 111. RTKs in Development . . . , . . . . . . . . . V. CHnetics and Can
43 45 49 60 65 67
The Molecular and Genetic Characterization of Human Soft Tissue Tumors COLINS. COOPER I.
........................ 11. Tumor Etiology . . . . 111. Genetic Susceptibility to Soft Tissue Tumors . . . . . . . . . . . . . , . . . . . , . . .
Detection of nu Gene Activation . . . . Chromosomal Abnormalities . . . . . . . Tumor Suppressor Cxnes . . . . . . . . . . Gene Amplification . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . , . . . . . . . . Predictors of Tumor Behavior . . . . . . . . . . . . , . 1X. Molecular Cloning of Translocation Breakpoints . . . . . . . . . . . . . . . . . . . X. Future Developments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I v. V. VI. VII. VIII.
....................... .. . . . . . . .. . . . . . . . .. . . .
75 78 80 87 88 100 104
105 107 109 110 120
Genomic instability and Tumor Progression: Mechanistic Considerations
KEITH C. CHENGAND LAWRENCE A. LOEB I.
Introduction
....................................................
11. Genomic Stability and Instability: Background and Implications . . . . . 111. Mechanisms of Genomic Stability and Instability . . . . . . . . . . . . . . . . . . . IV. Quantitative Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
121 124 127 142
vii
CONTENTS
V. Summary and Perspectives ....................................... References ......................................................
145 148
Function and Regulation of the Human Multidrug Resistance Gene KHEW-VOON CHIN.IRAPASTAN.AND MICHAEL M . GOTTESMAN I . The Multidrug Transporter as a Cause of Multidrug Resistance ..... I1. Regulation of Expression of mdr Genes ............................ I11. Summary and Conclusions ....................................... References ......................................................
157 169 176 176
Relationship between MYC Oncogene Activation and MHC Class I Expression PETERI . SCHRIER AND LUCYT. C . PELTENBURG I . Introduction .................................................... I1 . MHC Class I Expression and Cancer .............................. I11. Modulation of MHC Class I Expression by Oncogenes ................................................... IV. Molecular Mechanism of MHC Class I Regulation by Oncogenes .... V. Biological Consequences of MHC Class I Downmodulation by Oncogenes ...................................................... VI . Concluding Remarks ............................................ References ......................................................
181 183
195 208 222 231 233
Immunosuppressive Factors in Human Cancer
Dov SULITZEANU Introduction .................................................... Immunosuppression in Cancer-Recent Evidence .................. Immunosuppressive Factors Produced by Tumor Cells/Cell Lines . . . . Well-Characterized Immunosuppressive Molecules .................. Partially Characterized Immunosuppressive Factors ................. VI . Immunosuppressive Factors in Sera and Effusions .................. VII . Other Immunosuppressive Factors ................................ VIII . Concluding Remarks: Immunosuppressor or Growth-Regulatory Cytokines? .................................... References ...................................................... I. I1. 111. IV. V.
247 248 248 249 254 254 255 257 262
...
Vlll
CONTENTS
Lysosomes. Lysosomal Enzymes. and Cancer
MICHAELJ . BOYERAND IAN F. TANNOCK I . Introduction ............................ ........................ I1 . Methods for Studying Lysosomes . . . . . . . . . ........................ 111. Lysosomal Enzyme Activity in Tumors . . . . ........................ 1V. Lysosomes. Tumor Invasion. and Metastasis ....................... V. Lysosomes and Tumor Microenvironment . ........................ VI . Lysosomes and Anticancer Therapy . . . . . . . ........................ ........................ VII . Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........................ References ..............................
269 270 271 275 278 281 286 287
INDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
293
CONTRIBUTORS
Numbers in parentheses indicate the pages on which the authors' contributions begin.
MICHAEL J . BOYER,Departments of Medicine and Medical Biophysics, Ontario Cancer Institute, Toronto, Ontario M4X lK9, Canada (269) KEITHC. CHENC,'Department o f Pathology,Joseph Gottstein Memorial Cancer Research Laboratory, University of Washington, Seattle, Washington 981 95 (121) KHEW-VOON CHIN,* Laboratory o f Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 (157) COLINS. COOPER,Molecular Carcinogenesis Section, The Institute of Cancer Research, The Haddow Laboratories, Belmont, Sutton, Surrey S M 2 5NG, England (75) MICHAELM. GOTTESMAN, Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 ( 157) DANIEL E. JOHNSON, Howard Hughes Medical Institute, Program of Excellence in Molecular Biology, and Cardiovascular Research Institute, University of California, San Francisco, California 94143 (1) LAWRENCE A. LOEB,Department of Pathology,Joseph Gottstein Memorial Cancer Research Laboratory, University of Washington, Seattle, Washington 98195 (121) IRAPASTAN,Laboratory of Molecular Biology, National Cancer Institute, National Institutes o f Health, Bethesda, Maryland 20892 (157) LUCYT. C. PELTENBURG, Department of Clinical Oncology, University Hospital, 2300 RC Leiden, The Netherlands (181) 'Present address: Department of Pathology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania 17033. "resent address: Genetics Center, University of Texas Health Science Center, Houston, Texas 77225.
ix
X
CONTRIBUTORS
PETERI. SCHRIER, Department of Clinical Oncology, University Hospital, 2300 RC Leiden, The Netherlady (181) Dov SULITLEANU, The Lautenberg Center for General and Tumor Immunology, Hadassah Medical School, The Hebrew University, Jerusalem 91010, Israel (247) IAN F. TANNOCK, Departments of Medicine and Medical Biophysics, Ontario Cancer Institute, Toronto, Ontario M4X 1K9, Canada (269) ANDREWF. WiLus, Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Victoria 3050, Australia (43) LEWIST. WILLIAMS, Howard Hughes Medical Institute, Program of Excellence in Molecular Biology, and Cardiovascular Research Institute, University of California, San Franctsco, California 9414? ( I )
STRUCTURAL AND FUNCTIONAL DIVERSITY IN THE FGF RECEPTOR MULTIGENE FAMILY Daniel E. Johnson and Lewis T. Williams Howard Hughes Medical Institute, Program of Excellence in Molecular Biology, and Cardiovascular Research Institute, University of California, San Francisco, California 94143-0724
I. Introduction 11. The FGF Family of Polypeptide Mitogens
111. IV. V. VI. VII.
VIII.
IX.
X. XI. XII. XIII. XIV. XV.
XVI. XVII. XVIII. XIX.
Early Binding and Cross-Linking Studies of the FGF Receptor Nomenclature of the FGF Receptor Genes Purification, cDNA Cloning, and Characterization of FGFR 1 Characterization of FGFR 2, FGFR 3, and FGFR 4 Multiple Forms of FGFR 1 and FGFR 2 Are Generated by Alternative Splicing Multiple Forms of FGFR 1 A. Variations Involving Ig Domain I B. The Inclusion or Exclusion of Two Amino Acids in the Extracellular Domain C. Three Alternative Exons for the Second Half of Ig Domain 111 Multiple Forms of FGFR 2 A. Variations Involving Ig Domain I B. Variations Involving the Acid Box Domain C. Alternative Exons for the Second Half of Ig Domain 111 D. The Inclusion or Exclusion of Two Amino Acids in the Juxtamembrane Domain E. Three Alternative Exons for the C-Tail Domain FGFR 3 and FGFR 4 Ligand Binding Specificities of the Cloned FGF Receptors Alternative Splicing in the Third Ig Domain Is Important for Determining Ligand Binding Specificities Analogous Splice Variants from Different FGF Receptor Genes Encode Receptor Forms with Different Ligand Binding Specificities Regulation of FGF Receptor Expression Cell- and Tissue-Specific Alternative Splicing of FGF Receptor mRNAs A. Cell- and Tissue-Specific Alternative Splicing of the Third Ig Domain B. Tissue-Specific Alternative Splicing Involving Ig Domain I Differential, Tissue-Specific Expression of the Different FGF Receptor Genes The Drosophila FGF Receptor FGF Receptor-Mediated Signal Transduction Concluding Remarks References
1 ADVANCES IN CANCER RESEARCH, VOL. 60
Copyright 8 1993 by Academic Press. Inc. All rights of reproduction in any form reserved.
2
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
1. introduction
The fibroblast growth factors (FGFs) constitute a family of closely related polypeptide mitogens (Burgess and Maciag, 1989; Folkman and Klagsbrun, 1987; Gospodarowicz et al., 1986b; Thomas, 1987). Currently, seven members of this family have been identified on the basis of amino acid sequence homologies. T h e FGF family has distinguished itself from other growth factor families by virtue of the pleiotropic actions of its members. In addition to their abilities to stimulate proliferation of a wide variety of cells, FGFs exhibit potent neurotrophic and angiogenic activities (R.S. Morrison et al., 1986; Walicke et al., 1986; Folkman and Klagsbrun, 1987; Anderson et al., 1988). FGFs also have the capacity to induce differentiation, inhibit differentiation, or maintain a differentiated phenotype of cells in culture (Linkhart et al., 1981; Serrero and Khoo, 1982; Broad and Ham, 1983; Lathrop et al., 1985; Togari et al., 1985; Wagner and DAmore, 1986; Anderson et al., 1988). Furthermore, a substantial body of evidence indicates that FGFs play important roles during development. The effects of FGFs are known to be mediated by high affinity receptor tyrosine kinases. T h e recent purification and cDNA cloning of FGF receptors have led to the discovery of a family of structurally related FGF receptor molecules. Within this family there is an enormous degree of complexity. Four distinct FGF receptor genes have been identified, and in the case of at least two of these genes, multiple mRNA transcripts are known to be generated by alternative splicing. A number of studies have now shown that the structurally diverse receptor molecules are also functionally different. Moreover, characterization of structural and functional diversity within the FGF receptor family is beginning to shed new light on differences in the mechanisms of action among members of the FGF familv.
II. The FGF Family of Polypeptide Mitogens The first members of the FGF family to be purified and characterized were acidic FGF (aFGF) and basic FGF (bFGF). Both factors were purified on the basis of their mitogenicity toward fibroblasts, using bovine pituitary (Armelin, 1973; Gospodarowicz et al., 1974; Gospodarowicz, 1975) and brain (Trowel1 et al., 1939; Hoffman, 1940; Gospodarowicz et al., 1978) as sources. In subsequent studies aFGF and bFGF were purified from a wide variety of sources including adrenal gland (Gospodarowicz et al., 1986a), bone (Hauschka et al., 1986), cartilage (Sullivan
FGF RECEPTOR MULTIGENE FAMILY
3
and Klagsbrun, 1985), corpus luteum (Gospodarowiczet al., 1985a), hypothalamus (Klagsbrun and Shing, 1985), kidney (Baird et al., 1985a), liver (Ueno et al., 1986), placenta (Gospodarowiczet al., 1985b), prostate (Nishi et al., 1985), retina (Baird et al., 1985b), testis (Ueno et al., 1987), and thymus (Gospodarowiczet al., 1986b).A significant improvement in the purification of aFGF and bFGF was made when it was discovered that both factors bind to heparin (Maciag et al., 1984; Shing et al., 1984). This led to the development of standardized purification protocols using heparin affinity chromatography (Shing et al., 1983; Lobb et al., 1986). The highly purified preparations of FGFs were subjected to amino acid sequencing, and this ultimately made possible the cloning of cDNAs for both aFGF (Gimenez-Gallegoet al., 1985; Thomas et al., 1985;Jaye et al., 1986) and bFGF (Esch et al., 1985; Abraham et al., 1986a,b; Kurokawa et al., 1987). The cloned cDNAs for aFGF and bFGF each encode proteins of 155 amino acids. Curiously, the predicted amino acid sequences of both factors do not contain signal peptide sequences. In this respect, aFGF and bFGF resemble the interleukin-1 (IL1) proteins, which also lack signal peptide sequences. Despite considerable attention to this issue, it remains unclear how growth factors without signal peptides are secreted from the cell. The predicted sequences for human aFGF and human bFGF are 55% identical at the amino acid level. Both proteins are also highly conserved across species (Thomas, 1987). Human and bovine aFGF differ by only 12 amino acids, and human and bovine bFGF differ by only 2 amino acids. The proteins also share limited homology to IL1-a and IL1-p (25-27% amino acid identity). The cDNAs encoding aFGF and bFGF are derived from distinct, single-copy genes. The human gene encoding aFGF is located on chromosome 5 Uaye et al., 1986),whereas the human bFGF gene is located on chromosome 4 (Mergia et al., 1986).Despite their different chromosomal loci, the FGF genes have a similar structural organization. Both genes are composed of three exons, and contain two large introns at similar locations (Mergia et al., 1986; Abraham et al., 198613). Biological studies using purified or recombinant aFGF and bFGF have shown that both factors are potent mitogens for a wide variety of cells of mesenchymal and neuroectodermal origin (Burgess and Maciag, 1989; Gospodarowicz et al., 1986b). Of particular interest has been the discovery that both factors act as mitogens and chemoattractants for endothelial cells in uitro (Burgess and Maciag, 1989), and exhibit potent angiogenic activity in uzuo (Folkman and Klagsbrun, 1987).Hence, FGFs may play an important role in the normal development of the vascular
4
DANIEL E. JOHNSON A N D LEWIS T. WILLIAMS
system through their action on endothelial cells. At the same time, however, aberrant production of FGFs or other aberrations in FGF response pathways may contribute to pathological conditions that result from either too much or too little vascularization. Thus, it is important to consider the potential involvement of FGFs in the vascularization of tumors, in wound healing, and in vascular diseases such as diabetic retinopathy. FGFs also stimulate cellular production of collagenases and plasminogen activator (Gross et al., 1982, 1983; Presta et al., 1985; Moscatelli et al., 1986; Mignatti et al., 1989), and this could help potentiate neovascularization or tumor invasiveness (Folkman and Klagsbrun, 1987). FGFs may also lead to cellular transformation through autocrine or paracrine mechanisms. Several groups have demonstrated that constitutive expression of exogenous FGF in transfected cells promotes growth in serum-free media and soft agar, and is tumorgenic in mice. The results that are obtained in these experiments, however, vary with the host cell line that is used. With some cell lines, certain parameters of transformation are highly dependent on the secretion of FGF Uaye et al., 1988; Rogelj et al., 1988; Sasada et al., 1988),whereas with other cell lines transformation is independent of FGF secretion (Neufeld et al., 1988; Jaye et al., 1988). In addition to their ability to promote cellular proliferation, FGFs also influence the differentiation of a variety of cell types. FGFs induce the differentiation of preadipocyte fibroblasts into adipocytes (Serrero and Khoo, 1982; Broad and Ham, 1983) and stimulate neurite outgrowth from hippocampal neurons (Walicke et at., 1986), cerebral cortical neurons (R. S. Morrison et al., 1986), and rat PC12 cells (Togari et al., 1985; Wagner and D’Amore, 1986). While both factors can act to induce a differentiated phenotype, they can also act to inhibit differentiation. This is the case in skeletal muscle myoblasts, where addition of FGFs acts to inhibit differentiation to myotubes (Linkhart et al., 1981; Lathrop et al., 1985).FGFs also support the survival of lesioned cholinergic neurons in vivo (Anderson et al., 1988), indicating a role in the maintenance of differentiated cells. The ability of FGFs to influence the differentiation of a variety of cell types suggests that these factors may play important roles during development. This idea is supported by experiments showing that addition of‘ FGFs to Xen@ embryos leads to mesoderm induction (Kimelman and Kirschner, 1987; Slack et al., 1987). The presence of FGF in early Xen0fni.s embryos indicates that FGFs may serve in this capacity during normal embryogenesis (Kimelman et al., 1988). Indeed, recent experiments have shown that selective disruption of FGF receptor-mediated
FGF RECEPTOR MULTIGENE FAMILY
5
signaling pathways in developing Xenopus embryos leads to dramatic inhibition of mesoderm formation and developmental defects in gastrulation and posterior development (Amaya et al., 1991). Over the last several years, five additional members of the FGF family have been identified on the basis of amino acid sequence homologies, These proteins are approximately 35 to 45% identical with aFGF and bFGF and include the product of the int-2 oncogene (Moore et al., 1986), the product of the hst oncogene (Kaposi sarcoma FGF) (Taira et al., 1987; Bovi et al., 1987), FGF-5 (Zhan et al., 1988), FGF-6 (Marks et al., 1989), and keratinocyte growth factor (KGF; Finch et al., 1989; Rubin et al., 1989). In addition to sequence homologies, these proteins also share some physical and biological properties with aFGF and bFGF, such as the ability to bind heparin and the ability to stimulate proliferation of a variety of cells of mesenchymal and neuroectodermal origin (Burgess and Maciag, 1989). In contrast to aFGF and bFGF, however, int-2 hstlKFGF, FGF-5, FGF-6, and KGF contain signal peptide sequences encoded by their mRNA transcripts. The int-2 oncogene was originally identified as a preferred site of integration for mouse mammary tumor virus (Peters et al., 1983). Mice containing viral integration near the int-2 gene frequently display transcriptional activation of the int-2 oncogene and develop mammary carcinomas (Peters et al., 1983, Dickson et al., 1984; Moore et al., 1986).The hst oncogene was identified in a focus forming assay following transfection of 3T3 cells with genomic DNA from a human stomach cancer cell line (Taira et al., 1987). The same gene was identified when DNA from Kaposi sarcoma cells was used to transfect cells (Bovi et al., 1987).We will refer to this gene as the hstlKFGF gene. FGF-5 was identified as a human gene whose fortuitous rearrangement during DNA transfection led to focus formation in 3T3 cells (Zhan et al., 1988). cDNAs for FGF-6 were isolated on the basis of nucleic acid hybridization with a hstlKFGF probe (Marks et al., 1989). Keratinocyte growth factor was cloned using amino acid sequence data obtained from the purified protein (Finch et al., 1989; Rubin et al., 1989). The FGFs are known to exert their effects by binding to high affinity receptors on the surface of responsive cell types. The existence of multiple members of the FGF family has raised the question whether all members of this family bind to a common receptor molecule. Alternatively, there could be multiple FGF receptors, each possessing different ligand binding properties. Recent advances in the FGF receptor field have shown that both of these possibilities are partially correct.
6
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
Ill. Early Binding and Cross-Linking Studies of the FGF Receptor Early characterization of FGF receptors focused on binding and cross-linking studies using iodinated aFGF or bFGF. These studies revealed that a variety of cells express saturable high affinity receptors with Kds of 50-500 pM and 10-200 pM for aFGF (Schreiber et al., 1985; Baird et al., 1986; Libermann el al., 1987) and bFGF (Neufeld and Gospodarowicz, 1985; Moenner et al., 1986; Olwin and Hauschka, 1986; Moscatelli, 1987), respectively. Competition analyses demonstrated that either ligand was able to compete for high affinity binding of the other ligand (Neufeld and Gospodarowicz, 1986; Olwin and Hauschka, 1986). This provided the first indication that aFGF and bFGF might share a common receptor. A related study has also shown that hstlKFGF causes downregulation of high affinity binding sites for bFGF, indicating that hstIKFGF also binds to the same receptor (Moscatelli and Quarto, 1989). When either aFGF or bFGF was used in cross-linking experiments, receptor species in the range 125-165 kDa were detected on SDS-polyacrylamide gels (G. Neufeld and Gospodarowicz, 1985; G. Neufeld and Gospodarowicz, 1986; Friesel et al., 1986; Moenner et al., 1986; Olwin and Hauschka, 1986, 1989; Libermann et al., 1987; Courty et al., 1988). Frequently two prominent cross-linked bands of 125 and 145 kDa were seen. Initially it was thought that the 125-kDa protein represented a proteolytic cleavage product of the 145-kDa protein. Recent evidence, however, indicates that the two proteins are derived from different alternatively spliced forms of the FGF receptor mRNA (see discussion in Section VII1,A). As expected, either ligand was able to block the crosslinking of the same or different radiolabeled ligand to both the 125-kDa and the 145-kDa proteins (Neufeld and Gospodarowicz, 1986; Olwin and Hauschka, 1986). In summary, the results of binding and crosslinking studies strongly supported the hypothesis that different members of the FGF family shared a common receptor. The idea of a common receptor for all members of the FGF family did not fit, however, with data obtained for KGF. This growth factor, although potently mitogenic for epithelial cells, failed to stimulate the growth of endothelial cells and fibroblasts, cells that are responsive to both aFGF and bFGF (Rubin et al., 1989). Thus, KGF did not appear capable of binding to the receptors for aFGF and bFGF that are present on these cells (Bottaro et al., 1990). As will be described in further sections, the KGF receptor represents a unique splice variant of an FGF receptor gene. Before the discussion on the binding of FGFs to cell surface receptors
7
FGF RECEPTOR MULTIGENE FAMILY
is concluded, it should be noted that cells also express a large number of low affinity binding sites for FGFs (Neufeld and Gospodarowicz, 1985; Moenner et al., 1986; Olwin and Hauschka, 1986; Clegg et al., 1987; Moscatelli, 1987). Considerable evidence indicates that the low affinity sites represent heparan sulfate proteoglycan molecules located on the cell surface or in the extracellular matrix (Moscatelli, 1987, 1988; Bashkin et al., 1989). Binding to low affinity sites occurs with a Kd of 2 to 10 nM and can be removed by incubation with heparin, washing with 2.0 M NaC1, or treatment with heparinase (Moscatelli, 1987). Recent evidence indicates that the binding of FGFs to low affinity sites plays a role in potentiating binding of FGFs to high affinity receptors (Rapraeger et al., 1991; Yayon et al., 1991). This information has recently been reviewed elsewhere (Klagsbrun and Baird, 1991)and will not be discussed further. Instead, this review will focus on the high affinity cell surface FGF receptors. IV. Nomenclature of the FGF Receptor Genes
Since the isolation of the first complete FGF receptor cDNA in 1989 (Lee et al., 1989),our understanding of the complexity of the FGF receptor field has increased dramatically. To date, four distinct FGF receptor genes have been identified. Furthermore, in the case of at least two of these genes it is clear that alternative splicing gives rise to multiple forms of the receptor. The different FGF receptor genes and splice variants of these genes are described in the literature using many different names (see Table I and Fig. 5). In an effort to simplify our understanding of TABLE I NOMENCLATURE OF THE DIFFERENT FGF RECEPTORGENES FGFR 1
FGFR 2
FGFR 3
FGFR 4
"g bFGFR Cekl N-bFGFR h2, h3, h4, h5 FGFR 1
bek Cek3 K-Sam K-Sam K-Sam' TK14 TK25 KGFR FGFR 2
Cek2 FGFR 3
FGFR 4
Note. The table shows some of the names that have been used to describe the different FGF receptor genes and cDNAs derived from alternatively spliced FGF receptor mRNA transcripts. The publications that were used to compile this list are referenced in the text.
8
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
FGF receptor diversity, we will refer to the different FGFR genes as FGFR 1, FGFR 2, FGFR 3, and FGFR 4, in the chronological order in which they were first identified and characterized. V. Purification, cDNA Cloning, and Characterization of FGFR 1
The first FGF receptor (FGFR 1) to be characterized in detail was purified from chicken embryos. In the purification scheme that was used, extracts from chicken embryos were incubated with biotinylated FGF in the presence of heparin (Lee et al., 1989). Biotin-FGF/FGFR complexes were then purified on an avidin-agarose column. Different ligand-affinity purification schemes have been employed by other laboratories (Imamura et al., 1988; Burrus and Olwin, 1989). The inclusion of heparin in the original purification protocol appears to have been critically important for purifying the high affinity receptor, as other approaches that have not included heparin have resulted in the isolation of low affinity binding proteins (Kiefer et al., 1990). The amino acid sequence obtained from peptides of the purified chicken FGF receptor showed striking similarity with the predicted amino acid sequences of two previously published partial cDNA clones: humanflg (Ruta et al., 1988)and mouse bek (Kornbluth et al., 1988).The human flg (fm-like gene) cDNA had been isolated from an endothelial cell cDNA by virtue of it hybridization with a c-fm probe. The region of cross-hybridization of this probe is presumably in the coding sequence for the tyrosine kinase domain of flg; otherwise JEg and c$m are not homologous. The mouse bek (bacterially expressed kinase) cDNA had been isolated from a cDNA expression library by probing with antiphosphotyrosine antibodies. Although the function of the flg and bek proteins was unknown at the time of the discovery of their partial cDNAs, it has since come to light that the full-length fig and bek cDNA clones represent specific splice variants of the FGFR 1 and FGFR 2 genes, respectively (see Sections V I I I and IX, and Fig. 5). A cDNA encoding the chicken FGFR 1 was isolated using oligonucleotide probes based on the amino acid sequence from the purified protein (Lee et al., 1989). The cDNA encoded a protein with a deduced molecular mass of 92 kDa (not including carbohydrate side chains) that contained several features commonly found in growth factor receptors (see Fig. 1). The protein contained a single membranespanning region, an amino-terminal signal peptide, and three extracellular immunoglobulin-like (Ig-like) domains (Williams and Barclay, 1988). Between the first (I) and the second (11) Ig-like domain, the
FGF RECEPTOR MULTIGENE FAMILY
9
FIG. 1. Schematic diagram of the chicken FGFR 1 structure. The following structural features are identified: hydrophobic leader sequence (striped box), three extracellular Iglike domains (labeled I, 11, and 111), acid box domain (open box), transmembrane domain (solid box), kinase 1 and kinase 2 domains (stippled boxes).
receptor contained a unique domain that has not been seen in other growth factor receptors. This domain consists of eight consecutive acidic residues and is referred to as the “acid box.” The intracellular domain of the FGFR 1 protein contained consensus tyrosine kinase sequences. This confirmed earlier biochemical evidence which indicated that the receptor was a tyrosine-specific protein kinase (Huang and Huang, 1986; Coughlin et al., 1988).The tyrosine kinase sequence of FGFR 1 is split by an insertion of 14 amino acids. The length of this kinase insert region is considerably shorter than those of the PDGF-P (Yarden et al., 1986) and CSF-1 (Coussens et al., 1986) receptors (104 and 70 amino acids, respectively), but comparable to those of the insulin and insulin-like growth factor-1 receptors (Ullrich et al., 1985, 1986). Another interesting feature of the chicken FGFR 1 protein is the length of the juxtamembrane domain. This domain consists of the region between the transmembrane domain and the first kinase domain (kinase 1). The FGFR 1juxtamembrane domain is 79 amino acids long, compared with juxtamembrane domains of 49 to 5 1 amino acids for the PDGF-f3 (Yarden et al., 1986),CSF-1 (Coussens et al., 1986),EGF (Ullrich et al., 1984), HER1 (Coussens et al., 1985), and insulin (Ullrich et al., 1985) receptors. Complementary DNA clones encoding similar FGFR 1 forms have subsequently been isolated from a variety of species including human (Dionne et a,!., 1990; Johnson et al., 1990; Eisemann et al., 1991; Hou et al., 1991), mouse (Mansukhani et al., 1990; Reid et al., 1990; Werner et al., 1992a),chicken (Pasquale and Singer, 1989),and Xenopus (Musci et al., 1990). The degree of amino acid identity between FGFR 1 proteins from different species is striking (see Fig. 2). Overall, when compared to the human FGFR 1 protein, the mouse, chicken, and Xenopls FGFR 1 proteins are 98, 91, and 78% identical, respectively. The most highly conserved regions of the receptor molecule are the kinase 1 and kinase 2 domains (92 and 95% identity, respectively, between human and Xenopus). The least conserved regions are the signal peptide region (50%, human to Xenopw), Ig domain I (54%), the membrane-proximal
10
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
HUMAN
vs
MOUSE
HUMAN
vs
HUMAN
vs
CHICKEN XENOPUS
Signal peptide
93 %
70
Yo
50 Yo
lg domain I
93 Yo
80 Yo
54 Yo
97
Oh
83 %
73 Yo
100 Yo
95 %
79 Yo
97 Yo
98 Yo
79 Yo
Membraneproximal TM
100 % 90 %
75 Yo 86 %
44 Yo
JM
100 Yo
92 Yo
81 Yo
Kinase 1
100 Yo
99 Yo
92 Yo
93
Oh
71 Yo
50 Yo
99 %
99 Yo
95 Yo
95 Yo
80 %
75 Yo
98 %
91 Yo
78 Yo
(119)
Acid box
(149)
Ig domain I1 (248)
Ig domain 111
Kinase insert Kinase 2
C-tail
57 Oh
FIG.2. Comparison of FGFR 1 proteins from different species. The figure shows the degree of amino acid identity between different domains of the human FGFR 1 protein (Dionne et al., 1990) and the corresponding domains of FGFR 1 proteins from mouse (Reid ~t al., 1990), chicken (Lee et al., 1989). and Xenopvs (Musci et al., 1990). All of the proteins compared represent 3 Ig domain receptor forms containing IIIc-type sequences in the third Ig domain. The numbers in parentheses indicate the last amino acid of each domain
FGF RECEPTOR MULTIGENE FAMILY
11
domain (44%), the transmembrane domain (57%),and the kinase insert domain (50%).
VI. Characterization of FGFR 2, FGFR 3, and FGFR 4 Following the isolation of the chicken FGFR 1 cDNA, cDNAs derived from three additional FGFR genes (2,3,and 4) were isolated and characterized by several laboratories. The proteins encoded by these genes are structurally similar to the FGFR 1 protein and are highly conserved at the amino acid level. Comparison of the mouse FGFR 1 sequence and the partial sequence of mouse bek revealed several differences at the amino acid and nucleotide levels. The isolation of full-length bek clones led to the discovery that bek was in fact the product of a different gene (Dionne et al., 1990). We will refer to this gene as FGFR 2 for the remainder of this review. Additional FGFR 2 cDNAs have been isolated as cDNAs hybridizing with amplified DNA fragments from a human stomach cancer cell line (Hattori et al., 1990). Also, cDNA clones encoding the receptor for keratinocyte growth factor, a unique splice variant of FGFR 2 (see further sections), were isolated using a novel expression cloning strategy (Miki et al., 1991). Even more FGFR 2 cDNA clones have been isolated using PCR or library screening (Saiki et al., 1988; Pasquale, 1990; Houssaint et al., 1990; Champion-Arnaud et al., 1991; Crumley et al., 1991; Raz et al., 1991; Sat0 et al., 1991; Dell and Williams, 1992). Complementary DNA clones derived from a third FGFR gene (FGFR 3) were obtained by low stringency screening of a human K-562 (chronic myelogenous leukemia cell line) cDNA library with a v-sea oncogene probe (Keegan et al., 1991). Human cDNA clones derived from a fourth
in the human FGFR 1 protein (numbering based on Fig. 3). The signal peptide region contains signal peptide sequences as well as sequences between the signal peptide and the beginning of Ig domain I. The boundaries of Ig domain I, the acid box domain, and Ig domains I1 and 111 were defined by intron/exon junctions (see Fig. 6 and Johnson et al., 1991). The boundaries of the membrane-proximal domain were defined by the introdexon junction at the end of Ig domain 111 (N-terminus) and the beginning of the transmembrane domain (C-terminus). The boundaries of the juxtamembrane domain were defined by the end of the transmembrane domain (N-terminus) and the beginning of the kinase 1 domain (C-terminus). The boundaries of the kinase 1, kinase insert, and kinase 2 domains were defined by comparison with consensus kinase sequences as reported by Hanks et al. (1988). Sequences following the end of the kinase 2 domain constitute the C-tail domain.
FGFRl MWSWKCLLFWAVLVTAT--LCTARPSPTLPEQAQ------PWGAPVEVESFLVH-PGDLL FGFRZ .V..GRFICLV.VTM..--.SL....FS.V.DTTLEPEEP.TKYQISQPEVY.AA..ES. FGFR3 .GRPA.A.ALC.A.AIVAGASSESLGTEQRWGRAAEVPG.EPGQQ.Q---..FGS..AV FGFR4 .RLLLA..GVLLS.PGPPV.SLEASEEVEL.PCLA-----.SLEQQEQELT-VA-L.QPV
51 58 57 53
FGFRl QLRCRLRDDV--QSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGS FGFR2 EV . . L.K .AA--- V.S.TK ...H.GPN ...VLI ..YLQ1KGAT.R....... TA.RTVD. FGFR3 E.S.PPPGGGPMGP TV.VX.. TG .VP. E.VLVGPQRLP.LNASHE...A.S.RQRLTQRV FGFR4 R.-.CG.AERG---GH.YKE.SR..PAG.V.GWRGRL.IASFL.E.A.R.L.LARGSMIV
109 115 117 109
FGFRl FGFR2 FGFR3 FGFR4
DTTYFSVNVSDALPSSEDDDDDDDSSSEE-KETDNTKPNRMPVAPYWTSPEKMEKKLHAV E.W ..M ...T..I-..G..E..T.GAE.FVS.NS.NS.N.R-----.....NT.....R.... LC-H ...R.T ..-...G..E.GE.EAEDTGVD.G--------- .....R..R.D ...L.. LQ-NLTL1TG.S.T ..N ..E.PK-.HRDPSNRHSYPQQ----- .....H.QR
........
168 169 166 162
FGFRl PAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSWPSDKGNY 228 F G F R ~ ...N ....R..AG.N.M..M..........QE.........NQH..L..E.......... 229 FGFR3 . . .N ..R . R . . A A . N.T.SIS .....R..RGE.....I.L.HQQ..LV.E......R... 226 FGFR4 . .GN ....R . . A A . N.T ..I....D.QA.HGEN....IRL.HQH..LV.E......R. T. 222 FGFRl FGFRZ FGFR3 FGFR4
.....
288 289 206 282
FGFRl WLKHIEVNGSKIGPDNLPWQILKTAGVNTTDKEMEVLHLRSFEDAGEYTCLAGNSIG FGFRZ .I..V.K .... Y...G...LKV..A. ........ I...YI...T................ FGFR3 .... V . . . . . . V...GT...TV.....A ...... L...S.H..T................ FGFR4 .....VI ... SF.AVGF....V. ...DI.SS--.V...Y.....A.... ...........
348 349 346 340
FGFRl FGFR2 FGFR3 FGFR4
LSHHSAWLTVLEALEER-PAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSD
1.F ........ P.PGRE-KEITA..D ....A...I.V...A...VT..LCR..NT...P. F . . . . . . . V..P.E..LVE.DEAGSV.AG.LS.GV.F..FILV.AA.TLCRLR.PP.. GL . .YQ .......PEEDPTWT.AAPEAR.TD..L.AS.SLALAVLLLLAGL.RGQALHGRHP
407 408 406 400
FGFRl FGFW FGFR3 FGFR4
FHSQMAVHKLAKSIPLRRQIPPVSADSSASMNSGVLLVR-PSRLSS-SGTPMLAGVSEYEL .S . .P.....T.R...........E..S....NTP...ITT....TAD............ --GSPT IS-RF.. K...SLESNA.--.S.NTP...I-A....-GEG.T..N...L.. -RPPAT.Q..S-RF..A..FSLESG..G--K.SSS...-GV....-..PAL...LVSLD.
465 468 459 454
FGFRl FGFR2 FGFR3 FGFR4
PEDPRWELPRDRLVLGKPLGEGCFGOVVLAEAIGLDKDKPL
525 528 519 514
TCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQ . .V H....................ASTW.GD...V......A..... V ...KF RQ T. ..L................Q.AV...D...H......A..... L...AV...RYN.L. ..L...... T . A W D..LL...... A
............ .. ... .. ..
..........
..
...
....K ..F...K.T..............M...V.I.....KEAVT.......D.......
.A..K...S.A..T..............M.....I...RAAKPVT.......D...D... .L..L..F....................R...F.M.PAR.DQAST.......DN.SD...
FIG.3. The amino acid sequences of four human FGF receptor proteins derived from distinct receptor genes. The amino acid sequences of the human FCFR 2 protein (Dionne ~t al., 1990), the human FGFR 3 protein (Keegan el al., 1991), and the human FGFR 4 protein (Partanen et al., 1991) are shown in comparison to the sequence of the human FGFR 1 protein (Dionne el al., 1990). Each sequence represents a 3 Ig domain receptor form containing IIIc t y p e sequences in the third Ig domain. For FGFRs 2, 3, and 4, only sequences which differ from the FGFR 1 sequence are shown. Dashed lines indicate gaps that have been introduced into the sequence.
13
FGF RECEPTOR MULTIGENE FAMILY
FGFRl SDLISEMEMMKMIGKHKNIINLLGACTQDGPLWIVEYASKGNLREYLQAPGLEYCY FGFR2 V... R ......M.. S. FGFR3 ...V G.....L....A......F.R....... D.SF FGFR4 A..V....V ..L..R .........V ...E........C.A......F.R...... PDLSP
...
......................................... ........................
585 588 579 574
FGFRl FGFR2 FGFR3 FGFR4
NPSHNPEEQLSSKDLVSCAYQVARGUEYLASKKCIHRDLAAFUWLVTEDNVMKIADFGLA 645 648 DINRV ....MTF ......T ..L.........Q................N........... DTCKP TF.. Q. 639 DGPRSS.GP ..FPV Q E.R................ ............ 634
FGFRl FGFR2 FGFR3 FGFR4
RDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVP V M............. I. V.NL V................. ..........I. .GV S.................V...........I............... I.
.....
................. ........................... ............ ..
............................. .. ........................ .........
.............
705 708 699 694
FGFRl VEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQ~TFKQLVEDLDRIVALTSNQE 765 LT..T. E. 768 FGFR2 .................A HD. ..I..E. ...A................VLTV..T D. 759 FGFR3 .................A E. 753 FGFR4 .....S ..R......R.PH.PP...GL..E....A............A..KVL-.AVS
.................................. ...
FGFRl FGFR2 FGFR3 FGFR4
YLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR .....Q ..E.....Y....-.S....D.....PD.M.Y.....QY.HI--.. S-VKT .....A.FE ....GGQ..P-.SS...D....AHDL..----- .AP.SS---. .S-.T ....RLTFGP ....GG.AS-.....S- ......D...--LGSSSF.F----.SGVQT
822 821 806 802
FIG.3. (cont.)
FGFR gene (FGFR 4)were isolated using PCR with tyrosine kinase specific primers followed by library screening with the amplified fragments (Partanen et al., 1991). The amino acid sequences of 3 Ig domain forms of human FGFR 2, FGFR 3, and FGFR 4 proteins in comparison to the human FGFR 1 protein are shown in Fig. 3. Table I1 shows the overall level of amino TABLE I1 COMPARISON OF THE DIFFERENT HUMANFGF RECEPTORGENES FGFR 1 FGFR 2 FGFR 3
FGFR 2 72%
FGFR 3 62% 66%
FGFR 4 55% 57% 61%
Note. The table shows the overall degree of amino acid identity between the four amino acid sequences shown in Fig. 3. All of the proteins compared represent 3 Ig domain receptor forms containing lIIc type sequences in the third Ig domain. Percentage identity was calculated by dividing the number of identities by the number of amino acids in the larger of the two receptor proteins being compared.
14
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
FGFR 1
FGFR 1
FGFR 1
FGFR 2
FGFR 3
FGFR 4
43 Yo
17 Yo
20 %
40
Yo
27 Yo
19 Yo
43
Yo
33 Yo
27
79 Yo
64 %
61 Yo
78 Oh
81 %
74
Yo
38 62
31 Yo 33 Yo
13 24
Yo Yo
76 Yo
46
39 Yo
88%
83 Yo
75 Yo
50 Yo
43 Yo
7 Yo
62 Yo
46 %
42 Yo
vs
Signal peptide
q-
(30)
Ig domain I
vs
vs
(119)
Acid box
(149)
Ig domain I1
Yo
(248)
Ig domain I11 Membrane-
-.=
lPiloxima' JM
Kinase 1 Kinase insert
C-tail
I
(360) (376) (397)
. _..: ...... ........ ...... .__._. ......... ;:.:. ..... ........ :.:...... ...... ........ .:::._
(476)
...... ..... .._._. ..... ..... _..: ......
(580)
.... ........
(594)
...... .:....... ....... ..... .,I._ .: ... ......
FIG.4. Comparison of human FGF receptor proteins derived from four different receptor genes. The figure shows the degree of amino acid identity between different domains of the human FGFR 1 protein (Dionne et nl., 1990) and the corresponding domains of human FGFR 2 (Dionne et al., 1990). human FGFR 3 (Keegan et al., 1991), and humall FGFR 4 (Partanen et al., 1991). All of the proteins compared represent 3 Ig domain receptor forms containing 1IIc-type sequences in the third Ig domain. The numbers in parentheses indicate the last amino acid of each domain in the human FGFR 1 protein (numbering based on Fig. 3). Domain boundaries were defined as described in the legend tor Fig. 2.
FCF RECEPTOR MULTIGENE FAMILY
15
acid identity between the different human FGFR gene products, and Fig. 4 shows a domain by domain comparison of all four human receptor proteins. Overall, the proteins encoded by the four different human genes are strikingly similar. The most closely related proteins are FGFR 1 and FGFR 2 (72% amino acid identity), whereas FGFR 1 and FGFR 4 are the least closely related (55% identity). It is interesting to note that these levels of identity are considerably higher than those observed among different members of the FGF family (35 to 55%). A comparison of the domains of the different human FGF receptors (Fig. 4) reveals a pattern of conservation similar to that observed when comparing FGFR 1 domains across species (Fig. 2). The most highly conserved regions of the different human proteins are the kinase 1 and kinase 2 domains (75 and 84% identity, respectively, between FGFR 1 and FGFR 4). The least conserved regions are the signal peptide region (20%), Ig domain I (19%), the membrane-proximal domain (13%), the transmembrane domain (24%),and the kinase insert domain (7%).
VII. Multiple Forms of FGFR 1 and FGFR 2 Are Generated by Alternative Splicing A striking discovery in the FGF receptor field has been the isolation by several groups of multiple, distinct cDNAs encoding variant forms of FGFR 1 and FGFR 2 (Dionne et al., 1990;Johnson et al., 1990; Reid et al., 1990; Champion-Arnaud et al., 1991; Eisemann et al., 1991; Hou et al., 1991; Miki et al., 1991). Evidence obtained from studies of the organization of the FGFR 1 and FGFR 2 genes indicates that alternative splicing of mRNA is responsible for generating the diverse receptor forms (Champion-Arnaud et al., 1991; Johnson et al., 1991). Although alternative splicing is not unprecedented in the growth factor receptor field, the sheer number of alternative FGF receptor forms far outweighs that seen for any other growth factor receptor. Figure 5 shows a schematic diagram of the different FGF receptor proteins encoded by FGF receptor cDNAs that have been isolated to date. As shown in the figure, alternative splicing results in either (a) the inclusionlexclusion of additional amino acids or (b) the use of alternate coding exons with no net gain or loss of amino acids. In either case, the resultant proteins are structurally different. In subsequent sections of this review, the different splice variants and the potential function of these variants are discussed. VIII. Multiple Forms of FGFR 1 This section discusses the various regions of diversity that have been observed for FGFR 1, beginning at the amino terminus and proceeding
FGFR 1 1
I
h4
*
FGFR 2 1
iQbFGFR
I K-sarn’
KGFR
K-sarn
~
BEWTKl4
FGFR 3 BEK
TK25
I
FGFR 4
nn
(Vlll)
(xtii)
FIG. 5. Schematic diagram of FGF receptor protein structures. The figure shows the structure of variant receptor forms predicted by published cDNAs. T h e names of some receptor variants as they appear in the literature are written directly above the structure. Although cDNAs encoding the receptor variant depicted by an asterisk (iii) have not been isolated, PCR and Northern blotting experiments have identified mRNA transcripts encoding this receptor form (Johnsonet al., 199 1 ; Werner et al., 1992a). Furthermore, both 3 Ig and 2 Ig domain forms of this receptor mRNA appear to exist. T h e following structural features are identified in the figure: the 32 unique amino acids at the C-terminus of the FGFR 1 Ig domain I secreted form (solid oval), acid box domains (open boxes), alternative sequences for the second half of Ig domain 111 labeled IIIa, IIIb, or IIIc (thick black line), transmembrane domains (solid boxes), kinase 1 and kinase 2 domains (stippled boxes), and the unique C-tail domains of 2 FGFR 2 proteins (checkered box and striped box). The following sources were used to compile this figure: (i, Eisemann et al., 1991),(ii,Johnson et al., 1990), (iv, Lee et al., 1989; Pasquale and Singer, 1989), (v, Johnson e l al., 1990; Mansukhani et al., 1990; Reid el al., 1990). (vi, Champion-Arnaud et al., 1991). (vii, Miki el al., 1991), (viii, Hattori et al., 1990), (ix, Dionne et al., 1990; Houssaint et al., 1990), (x, Champion-Arnaud et al., 1991), (xi, Champion-Arnaud et al., 1991), (xii, Keegan et al., 1991), and (xiii, Partanen et al., 1991). It is predicted that more structures will be added to this figure in the coming years.
FGF RECEPTOR MULTIGENE FAMILY
17
toward the carboxyl terminus. Also, reference will be made to published information regarding the organization of exons and introns in the human FGFR 1 gene (Johnson et al., 1991). A. VARIATIONS INVOLVING IG DOMAIN I The first region of FGFR 1 receptor diversity that was observed was in the first Ig-like domain (I). Although the first reported FGFR 1 cDNA encoded a protein with three Ig domains (Fig. 5, iv), several laboratories have subsequently reported the isolation of cDNAs encoding FGFR 1 proteins that are missing Ig domain I (Fig. 5, ii and v) (Johnson et al., 1990; Mansukhani et al., 1990; Reid et al., 1990).Analysis of the FGFR 1 gene revealed the presence of an intron separating Ig domain I from the remainder of the FGFR 1 coding sequence (Fig. 6) (Johnson et al., 1991). Thus it appears likely that the presence or absence of Ig domain I is mediated by alternative splicing. Binding studies have shown that the 3 Ig domain form of FGFR 1 has affinities of 20-80 pM and 50- 150 pM for aFGF and bFGF, respectively (Dionne et al., 1990; Johnson et al., 1990). Similarly, the 2 Ig domain form of FGFR 1 has affinities of 50 and 100 pM for aFGF and bFGF, respectively (Johnson et al., 1990). Thus, Ig domain I does not appear to be necessary for high affinity binding of aFGF and bFGF. Currently, the function of this domain remains unknown. The existence of FGF receptor forms containing 3 or 2 Ig-like domains helps to explain earlier results obtained from cross-linking studies. As discussed previously (Section 111), two prominent bands of 145
111.
FIG.6. The human FGFR 1 gene. The figure shows the arrangement of introns and exons in the human FGFR 1 gene as described by Johnson et al. (1991). The figure also contains one additional exon that was not included in the original description of the gene (solid oval). Arrows indicate the positions of introns and numbers above the arrows indicate the size of the intron in kilobases. The following structural features are identified: the exon encoding the 32 unique amino acids at the C-tail of the Ig domain I secreted form (solid oval), the acid box domain (open box), the three alternative exons for the second half of Ig domain I11 (thick black line; labeled IIIa, IIIb, or IIIc), stop codons at the end of the secreted and membrane-spanning forms (asterisks), the 3’ nontranslated region that is unique to secreted form mRNA transcripts (dashed line), the transmembrane domain (solid box), and the kinase 1 and kinase 2 domains (stippled boxes).
18
DANIEL E. JOHNSON AND LEWIS
T. WILLIAMS
and 125 kDa were frequently seen when aFGF or bFGF were crosslinked to cell surface receptors. More recent studies have utilized cell lines transfected with cDNAs encoding either 3 Ig or 2 Ig domain forms of the receptor (Dionne el al., 1990; Johnson et al., 1990; Mansukhani et al., 1990). The results of these experiments show that cross-linked receptors containing 3 Ig domains are about 145 kDa in size, while crosslinked receptors containing 2 Ig domains are about 125 kDa in size. Thus it appears likely that the 145- and 125-kDa bands originally detected in cross-linking experiments represent the 3 Ig and 2 Ig receptor forms, respectively. In support of this, coexpression of 3 Ig and 2 Ig mRNA transcripts has been detected in a variety of cell lines using PCR (Johnson et al., 1990; Eisemann et al., 1991), Northern blotting (Reid et al., 1990; Eisemann et al., 1991), and RNase protection analyses (Werner et a!., 1992b).
Another receptor variant involving the first Ig domain has been described by Eisemann et al. (1991). The cDNA isolated by this group encodes a complete signal peptide and a complete Ig domain I, followed by 32 unique amino acids and a stop codon (Fig. 5, i). The 32 unique amino acids are encoded by an separate exon located between the exon for Ig domain I and the exon encoding the acid box domain (Fig. 6). Presumably the protein encoded by this cDNA represents a secreted form of Ig domain I. Although the function of this protein is unknown, it is interesting that similar forms of N-CAM molecules are generated via alternative splicing (Cunningham et al., 1987).
B. THEINCLUSION OR EXCLUSION OF Two AMINO ACIDS IN THE EXTRACELLULAR DOMAIN Several groups have reported the isolation of cDNA clones encoding proteins containing (or missing) two additional amino acids just downstream from the acid box Uohnson et al., 1990; Eisemann et al., 1991). In the human FGFR 1 sequence (Fig. 3), these amino acids correspond to Arg (148) and Met (149). Clones encoding proteins containing these amino acids and clones encoding proteins missing these amino acids have been identified for both the 3 Ig and the 2 Ig receptor forms (Johnson et al., 1990; Eisemann et al., 1991). Analysis of genomic DNA indicates that this dipeptide variation does not reflect an allelic difference. Instead, these amino acids are encoded at the immediate 3' end of the acid box domain exon. Therefore, it seems likely that the inclusion or exclusion of these amino acids results from the use of slightly different splice donor sites at this exon/intron boundary (Eisemann et
FGF RECEPTOR MULTIGENE FAMILY
19
al., 1991).The functional significance of this subtle variation in receptor structure is not known. C. THREE ALTERNATIVE EXONS FOR 111 HALFOF Ig DOMAIN
THE
SECOND
Johnson et al. (1990) have reported the isolation of a human cDNA encoding a protein that is identical to the 2 Ig membrane-spanning form of FGFR 1 until a point approximately halfway through Ig domain 111 (Johnson et al., 1990). At this point, the novel protein (see Fig. 5 , ii) diverges completely and then terminates 79 amino acids downstream. The novel protein does not contain a hydrophobic membrane-spanning domain and represents an additional secreted form of the receptor protein. Further studies have shown that a 3 Ig domain form of this secreted protein also exists. Although the function of the secreted FGF receptor is currently unknown, Duan et al. (1992) have shown that this protein binds bFGF. It is possible that the secreted FGF receptor acts as an extracellular reservoir of FGF, regulating the availability of FGFs to cell surface receptors. In the human FGFR 1 gene, sequences encoding the second half of Ig domain I11 which are unique for the secreted receptor form (labeled exon IIIa in Fig. 6) follow immediately downstream from sequences encoding the first half of Ig domain 111 (Johnson et al., 1991). In contrast, sequences encoding the second half of Ig domain I11 which are associated with the membrane-spanning receptor form (labeled exon IIIc in Fig. 6) are located several kilobases downstream. Also, in the process of sequencing this region of the human gene an additional exon was discovered that is highly homologous to the IIIc exon (labeled exon IIIb in Fig. 6). At the amino acid level, the IIIb and IIIc sequences exhibit 45% amino acid identity. PCR and Northern blotting analyses indicate that this new exon is part of mRNA transcripts encoding a membrane-spanning receptor. Thus, there are three alternative exons for the second half of Ig domain 111. One of these exons (IIIa) is a part of mRNA transcripts encoding a secreted receptor form, while the other two (IIIb and IIIc) are a part of transcripts encoding membrane-spanning receptor forms. These three exons have been named in the order of their linear appearance in the FGFR 1 gene (Fig. 6; Johnson et al,, 1991). As will be discussed shortly, corresponding IIIb and IIIc exons are also seen in the FGFR 2 gene. Furthermore, the IIIb and IIIc sequences confer distinct ligand binding specificities to the membrane-spanning forms of both FGFR 1 and FGFR 2.
20
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
IX. Multiple Forms of FGFR 2 A. VARIATIONSINVOLVING Ig DOMAIN As is the case for FGFR 1, cDNAs encoding 3 Ig domain and 2 Ig domain forms of FGFR 2 have also been identified (see Fig. 5 ) (Dionne et al., 1990; Hattori et al., 1990; Houssaint et al., 1990; Champion-Arnaud et al., 1991; Crumley et al., 1991; Miki et al., 1991). Binding studies have shown that both forms of FGFR 2 exhibit similar high affinities for aFGF and bFGF (Dionne et al., 1990; Crumley et at., 1991).Thus, Ig domain I of FGFR 2 does not appear to be necessary for high affinity binding of aFGF and bFGF. Crumley et al. (1991) have reported the isolation of an FGFR 2 cDNA that encodes a signal peptide, a single Ig-like domain, an acid box domain, and a stop codon. Comparison of this protein to the secreted Ig domain I form of FGFR 1 (Fig. 5, i) indicates that these two proteins are structurally related, but not identical.
B. VARIATIONSINVOLVING THE ACIDBox DOMAIN
To identify cDNA clones for the KGF receptor Miki et al. (1991) employed a novel expression cloning strategy. The approach that was taken involved transfecting 3T3 cells expressing KGF, but not the KGF receptor, with cDNAs derived from cells that express the receptor. Transformed foci that were obtained were then studied in further detail. Cells from one of the transformed foci were found to express high affinity binding sites for KGF. This led to the isolation of a KGF receptor (KGFR) cDNA. Interestingly, the cDNA encoding the KGF receptor represents a unique splice variant of the FGFR 2 gene (Fig. 5, vii). The protein predicted by this cDNA is missing both Ig domain I and the acid box domain, and contains sequences corresponding to the IIIb exon in the third Ig domain. This represented the first example of an FGF receptor protein that was missing the acid box domain. In the FGFR 1 gene, the acid box domain is encoded by a single distinct exon (Fig. 6). It remains to be seen, however, whether alternatively spliced mRNAs that code for FGFR 1 proteins without the acid box domain exist. The acid box represents a peculiar hallmark feature of the FGF receptors. At present, though, the function of this domain remains unclear. Since the KGF receptor also contained sequences in the third Ig domain different from sequences in other FGFR 2 proteins (Fig. 5 , ix and x) whose binding properties were known to be different, the differences in ligand binding specificities between these receptors could not be attributed solely to the presence or absence of the acid box domain.
FGF RECEPTOR MULTIGENE FAMILY
21
In the case of FGFR 1, however, deletion of this domain from 3 Ig or 2 Ig receptor forms does not affect the affinity of these receptors for either aFGF or bFGF (de Vries and Williams, 1992).
C. ALTERNATIVE EXONS FOR I11 HALFOF Ig DOMAIN
THE
SECOND
Several groups have reported the isolation of cDNAs encoding FGFR 2 proteins with different amino acid sequences in the second half of the Ig domain 111. Some of these cDNAs contain sequences corresponding to the IIIb exon of FGFR 1 [Hattori et al. (K-Sam), 1990; ChampionArnaud et al. (K-Sam’), 1991; Miki et al. (KGFR), 1991; Sat0 et al., 1991; Dell and Williams, 19921, whereas the others contain sequences corresponding to the IIIc exon of FGFR 1 [Dionne et al. (BEK), 1990; Houssaint et al. (TK14), 1990; Pasquale (CekS), 1990; Champion-Arnaud et al. (TK25), 1991; Raz et al., 19911. No FGFR 2 cDNAs that contain sequences corresponding to the IIIa (secreted form) exon of FGFR 1 have been reported. Thus, at a minimum there are at least two alternative exons for the second half of Ig domain I11 in FGFR 2. Analyses of the region of the human FGFR 2 gene encoding Ig domain I11 have revealed that the FGFR 2 gene is organized in a fashion nearly identical to that of the FGFR 1 gene (Champion-Arnaud et al., 1991;Johnson et al., 1991). The linear arrangement of the IIIb and IIIc exons in the FGFR 1 and FGFR 2 genes is identical, and the positions and sizes of intron sequences are also similar. In contrast, the putative IIIa exon of the FGFR 2 gene (based on corresponding location to that of the FGFR 1 IIIa exon) would contain an open reading frame that codes for only four amino acids (Johnson et al., 1991). Thus, a putative FGFR 2 (IIIa) secreted form would be considerably shorter than the FGFR 1 (IIIa) secreted form. More studies are needed to determine whether an authentic FGFR 2 IIIa exon is present in the FGFR 2 gene and whether this exon is expressed in vivo. Figure 7 shows a comparison of the IIIb and IIIc sequences of FGFR 1 and FGFR 2. It is interesting to note that the FGFR 1 IIIb sequence is more closely related to the FGFR 2 IIIb sequence (78% identity) than to the FGFR 1 IIIc sequence (45%). Also, the FGFR 1 IIIc sequence is more closely related to the FGFR 2 IIIc sequence (83%) than to the FGFR 1 IIIb sequence (45%). The FGFR 2 IIIb and IIIc sequences exhibit 51% identity. These numbers demonstrate that there is greater divergence between similar exons of the same gene than between corresponding exons of different genes. This suggests that the existence of the IIIb and IIIc exons is primordial to the existence of a multigene family.
22
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
A
LL.U
LLLC
IUh ~~
I..I.,k
-HSGINSSDAE--VLTLFNVTEAQSGEYVCKVSNYIGEANQSAWLTVTRP I I I I II I II I l l 1 I l l IIIIII -TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE
45
HSGINSSNAE--VLALFNVTEADAGEYICKVSNYIGQANQSAWLTVLPK00 __ I I I II Ill I I I I I I I l l IIIIIIII AAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLP
51 %
%
C FGFR 1 Luh
U
HSGINSSDAEVLTLFNVTEAQSGEYVCKVSNYIGEANQSAWLTVTRP IIIIIII IIII IIIIIII I l l IIIIIIII IIIIIIII1 HSGINSSNAEVLALFNIPPEADAGEYICKVSNYIGQANQSAWLTVLPKQQ
78
%
D k X J 3 X m TAGVNTTDKEHEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE IIIIIIIII Ill Ill 111lI1IIIIlIIIII I OIIIIII FGFR 2 IIIC AAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLP
83 %
FIG. 7. Comparison of the IIIb and IIIc amino acid sequences of human FGFR 1 and human FGFR 2. The figure shows (A) an alignment of the FGFR 1 IIIb and FGFR 1 IIIc sequences; (b) an alignment of the FGFR 2 IIIb and FGFR 2 IIIc sequences; (C) an alignment of the FGFR 1 IIIb and FGFR 2 IIIb sequences; and (D) an alignment of the FGFR 1 IIIc and FGFR 2 IIIc sequences. The numbers on the right indicate the degree of amino acid identity between the two sequences. The FGFR 1 IIIb sequence was derived from sequences in the human FGFR 1 gene Uohnson el al., 1991). The remaining sequences were derived from cDNA sequences discussed in the text.
D. THEINCLUSIONOR EXCLUSION OF Two AMINO ACIDSIN THE JUXTAMEMBRANE DOMAIN The isolation of FGFR 2 cDNAs encoding proteins containing (or missing) two additional amino acids in the juxtamembrane region has been reported by several groups (Hattori et al., 1990; Houssaint et al., 1990; Champion-Arnaud et al., 1991). In the human FGFR 2 sequence shown in Fig. 3 these amino acids correspond to T h r (429) and Val (430). The location of this dipeptide corresponds precisely to the location of an
FGF RECEPTOR MULTIGENE FAMILY
23
exonhntron boundary in the FGFR 1 gene. It remains to be seen whether the presence or absence of this dipeptide results from the use of slightly different splice donor sites.
E. THREE ALTERNATIVE EXONSFOR THE C-TAILDOMAIN The FGFR 2 sequence shown in Fig. 3 (also Fig. 5, ix) contains a C-tail domain of 61 amino acids. Two additional cDNA clones have been isolated from human tumor cDNA libraries that encode two distinct C-tail domains [Fig. 5 , viii (K-Sam)and Fig. 5, xi (TK25); Hattori et al., 1990; Champion-Arnaud et al., 19911. The two distinct C-tail domains both diverge from the FGFR 2 (Fig. 3) sequence following amino acid 760 (Ile). The sequence of one of these C-tail domains [Fig. 5, viii (K-sam)]is only 12 amino acids long and is highly divergent from the C-tail sequences of other members of this family (Fig. 5). The sequence of the other C-tail domain [Fig. 5, xi (TK25)] is 27 amino acids long and bears considerable homology to a portion of the C-tail sequence found in other FGFR 2 proteins. It remains to be determined whether these shorter, variant C-tail domains are expressed in normal cells. This is an important point, since previous studies have shown that mutations in the C-tail domains of receptor tyrosine kinases can lead to increased transforming potential of these proteins (Ullrich and Schlessinger, 1990).
X. FGFR 3 and FGFR 4 Currently, only single cDNAs have been isolated for FGFR 3 and FGFR 4 (Fig. 3 and Fig. 5, xii and xiii). In each case, the cloned cDNAs encode 3 Ig domain receptor forms containing IIIc type sequences in the third Ig domain (Keegan et al., 1991; Partanen et al., 1991). The FGFR 4 protein is somewhat unique in that it contains a core of only four consecutive (or five of seven) acidic residues in the acid box domain (see Fig. 3). This is somewhat shorter than the core sequence found in the acid box domains of FGFR 1 (eight consecutive acidic residues), FGFR 2 (six of seven acidic residues), or FGFR 3 (seven of eight acidic residues). In general, though, the structures of FGFR 3 and FGFR 4 closely resemble those of FGFR 1 and FGFR 2. In the future it will be interesting to determine whether multiple forms of FGFR 3 and FGFR 4 mRNA transcripts also exist.
24
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
XI. Ligand Binding Specificities of the Cloned FGF Receptors
Prior to the cloning of FGF receptor cDNAs, it was unclear whether multiple members of the FGF family could bind to a common receptor, and whether multiple forms of the receptor, if they existed, would exhibit different ligand binding specificities. Binding studies on cells transfected with cloned FGF receptor cDNAs have now provided conclusive answers to these questions. Initial studies demonstrated that 3 Ig and 2 Ig FGFR 1 forms containing IIIc-type sequences (Fig. 5, iv and v) bind either aFGF (Kd = 20-80 pM) or bFGF (Kd = 50-150 pM) with high affinity (Dionne et al., 1990; Johnson et al., 1990). Both ligands also activate receptor tyrosine kinase activity and receptor-mediated signaling (Dionne et al., 1990; Johnson et al., 1990; Mansukhani et al., 1990). Additional experiments have shown that both receptor forms also bind hstlKFGF, albeit with reduced affinity compared to the binding of aFGF and bFGF (Dionne et al., 1990; Mansukhani et al., 1990). Taken together, these experiments make two important points: (a) Multiple members of the FGF family can bind to the same receptor species and ( 6 ) the first Ig domain (I) of FGFR 1 is not essential for high affinity binding of aFGF or bFGF. Similar conclusions can also be drawn from studies of FGFR 2. In this case, a 3 Ig FGFR 2 form containing IIIc-type sequences (we will use the following nomenclature to refer to this receptor: 3 Ig/IIIc/FGFR 2; see Fig. 5, ix) has been shown to bind and become activated by aFGF (Kd = 40-100 pM), bFGF (Kd = 80-150 pM), and hstlKFGF (Dionne et al., 1990). Acidic and basic FGF also stimulate FGFR 3 activation (Keegan et al., 1991). Thus, as with FGFR 1, multiple members of the FGF family bind and activate both FGFR 2 and FGFR 3 proteins. In view of the fact that multiple FGF receptor proteins can bind multiple FGFs, how then could cells o r tissues selectively respond to individual members of the FGF family? Selective responsiveness to individual FGFs would seem to make sense if it is important to maintain such a large family of closely related ligands. indeed, several examples of ligand-specific responsiveness have been observed. Basic FGF, but not aFGF, is reported to stimulate mitogenesis in human melanocytes (Halaban et al., 1987). Also, aFGF and bFGF stimulate the proliferation of fibroblast and endothelial cells, whereas KGF does not (Rubin e l al., 1989).Thus, there must be mechanisms for achieving selective responsiveness to different members of the FGF family. One possibility is that variant receptor forms derived from the same gene by alternative splicing could exhibit different Iigand binding characteristics. Tissue-specific
FGF RECEPTOR MULTIGENE FAMILY
25
responsiveness to different FGFs could then be achieved by tissue-specific alternative splicing. Another possibility is that analogous splice variants derived from different FGF receptor genes encode receptor proteins with different ligand binding properties. In this case selective responsiveness could be achieved by tissue-specific expression of the different genes. As it turns out, both of these possibilities appear to be true. XII. Alternative Splicing in the Third lg Domain Is Important for Determining Ligand Binding Specificities
The isolation of cDNAs encoding a receptor for KGF provided a starting point for answering questions regarding the role of alternative splicing in determining receptor-ligand interactions. The receptor encoded by the KGFR cDNA (Fig. 5, vii) binds KGF (Kd = 180-480 pM) and aFGF with equal and high affinity (Miki et al., 1991). However, bFGF is 15- to 20-fold less effective than KGF or aFGF at competing with the binding of iodinated KGF to this receptor (Bottaro et al., 1990; Miki et al., 1991). These results differ from those obtained with a 3 Ig form of FGFR 2 containing IIIc sequences (3 Ig/IIIc/FGFR 2; Fig. 5, ix) (Dionne et al., 1990). This receptor protein binds aFGF (Kd = 40-100 pM) and bFGF (Kd = 80-150 pM) with high affinity, but presumably does not bind KGF (since fibroblasts that express this receptor are nonresponsive to KGF). These two receptor species differ in three regions: (a) KGFR is missing Ig domain I; (b) KGFR is missing the acid box domain; and (c) KGFR contains IIIb-type sequences in the third Ig domain, whereas the 3 Ig/IIIc/FGFR 2 form contains IIIc-type sequences. Hence, the different binding specificities of these proteins must be due to one or more of these three domains. Experiments with FGFR 1 proteins have helped to clarify the importance of the aforementioned three domains for ligand binding. As previously discussed (Section XI), both the 3 Ig and the 2 Ig forms of FGFR 1 bind aFGF and bFGF with nearly equal affinities (Dionne et al., 1990; Johnson et al., 1990). Thus Ig domain I is not essential for high affinity binding of these two ligands. Likewise, removal, via mutagenesis, of the acid box domain from either receptor form does not affect binding affinities for aFGF and bFGF (de Vries and Williams, 1992). These results suggested that the reduced affinity of the KGF receptor for bFGF may be due the presence of IIIb (as opposed to IIIc) sequences in this receptor form. To examine the functional importance of the second half
26
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
of Ig domain 111, Werner et al. (1992a) replaced IIIc sequences in the 2 Ig/IIIc/FGFR 1 (Fig. 5 , v) protein with IIIb sequences. T h e resulting 2 Ig/IIIb/FGFR 1 protein bound aFGF with high affinity, but had a much weaker affinity for bFGF. Thus, binding specificity for bFGF can be determined on the basis of which exon (IIIb or IIIc) is used to code for the second half of Ig domain I. Further experiments are needed to determine whether the 2 Ig/IIIb/FGFR 1 protein will also bind KGF. A summary of binding data for FGFR 1 and FGFR 2 forms containing different sequences in the third Ig domain is shown in Table 111. In a further series of experiments, Duan et al. (1992) have shown that a secreted FGFR 1 form containing IIIa sequences in the third Ig domain binds bFGF with higher affinity than aFGF. This leads to the conclusion that alternative splicing in the third Ig domain also is important for determining binding specificity for aFGF. Additional convincing evidence regarding the importance of alternative splicing in the third Ig domain has been demonstrated for the FGFR 2 proteins. Crumley et al. (1991) have recently isolated a cDNA encoding an FGFR 2 protein that is identical to the KGF receptor (Fig. 5 , vii) except that it contains IIIc-type sequences instead of IIIb-type sequences in the third Ig domain. This protein binds both aFGF and bFGF with high affinity. Thus, from these experiments, it can be concluded that alternative splicing in the third Ig domain of FGFR 2 is important for determining binding specificity for bFGF. In a related study, Dell and Williams (1992) have isolated a cDNA encoding an FGFR 2 protein that
TABLE 111 BINDING OF FGFs TO FGFR 1 A N D FGFR 2 FORMS CONTAINING DIFFERENT SEQUENCES IN THE THIRD Ig DOMAIN (111) FGFR 1 IIIa IIIb IIIC
bFGF > aFGF aFGF > bFGF aFGF = bFGF
FGFR 2 IIIb IIIC
aFGF = KGF > bFGF aFGF = bFGF (KGF does not bind)
Nofolu. This fable s h o w the relative affinities of different FGF receptor forms for aFGF, bFGF, and KGF. The depicted receptors differ in the sequences of their third Ig domains, containing either IIla. Illb, or IIlc sequences. The following sources were used to compile this figure: Dionne el al. (1990); Johnson ef al. (1990): Mansukhani et 01. (1990);kliki d al. (1991);Crumley et al. (1991); Werner et af. (l992a); and Dell and Williams (1992).
FGF RECEPTOR MULTIGENE FAMILY
27
is identical to 3 Ig/IIIc/FGFR 2 (Fig. 5, ix) except that it contains IIIbtype sequences. This protein binds aFGF with high affinity but exhibits only low affinity binding for bFGF. The findings presented above can be summarized as follows (see Table 111): (a) Acidic FGF binds with high affinity to FGFR 1 and FGFR 2 forms containing either IIIb or IIIc sequences regardless of whether Ig domain I and the acid box domain are also present. In contrast, aFGF binds with only low affinity to a 2 Ig FGFR 1 form containing IIIa sequences. (b) Basic FGF binds with high affinity to FGFR 1 and FGFR 2 forms containing IIIc sequences regardless of the presence or absence of Ig domain I and the acid box domain. Also, bFGF binds to the 2 Ig FGFR 1 form containing IIIa sequences. In contrast, bFGF binds with only low affinity to FGFR 1 and FGFR 2 forms that contain IIIb-type sequences. (c) KGF binds with high affinity to an FGFR 2 form that is missing Ig domain I and the acid box domain, and contains IIIb type sequences. In contrast, KGF does not bind to FGFR 1 and FGFR 2 proteins containing IIIc-type sequences. It remains to be determined whether the presence or absence of Ig domain I and the acid box domain have any additional influence on KGF binding (although one might predict that they do not). Furthermore it remains to be determined whether KGF binds to FGFR 1 forms containing either IIIa or IIIb sequences. At any rate, these binding experiments clearly demonstrate that alternative splicing in the third Ig domain is important for determining receptor binding specificities for all three FGFs that have been comparatively studied. XIII. Analogous Splice Variants from Different FGF Receptor Genes Encode Receptor Forms with Different Ligand Binding Specificities Two observations can be cited as proof that analogous receptor forms from different genes exhibit different ligand binding specificities: (a)A 3 Ig FGFR 4 form containing IIIc sequences (3 Ig/IIIc/FGFR 4; Fig. 5, xiii) binds aFGF with high affinity but does not bind bFGF (Partanen et al., 1991). Thus, the FGFR 4 receptor differs from corresponding 3 Ig/IIIc forms of FGFR 1 (Fig. 5, iv) and FGFR 2 (Fig. 5 , ix) which are known to bind aFGF and bFGF with comparable affinities (Dionne et al., 1990;Johnson et al., 1990). Since these three proteins are identical with respect to domain structure, the difference in affinities for bFGF cannot be attributed to alternative splicing and must be the result of other differences between the genes encoding these proteins. (b) It has been reported that hst/KFGF binds with high affinity to the 3 Ig/IIIc/FGFR 2 form (Fig. 5 , ix), but with reduced affinity to 3 IglIIIclFGFR 1 and 2
28
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
Ig/IIIc/FGFR 1 forms (Fig. 5, iv and v) (Dionne et al., 1990; Mansukhani et al., 1990). This difference also cannot be attributed to alternative splicing and must be the result of additional differences between the FGFR 1 and FGFR 2 genes. XIV. Regulation of FGF Receptor Expression
The hypothesis that cells or tissues could potentially achieve selective responsiveness to different FGFs by mechanisms involving alternative splicing or preferential expression of different FGF receptor genes is well supported by the binding studies presented above. The prediction that differential expression of different FGF receptor forms and genes actually occurs in nivo has recently been verified by studies from several laboratories. These studies have revealed several examples of cell- and tissue-specific alternative splicing as well as differential expression of the different FGF receptor genes in a variety of tissues. XV. Cell- and Tissue-Specific Alternative Splicing of FGF Receptor mRNAs
A. CELL-AND TISSUE-SPECIFIC ALTERNATIVE SPLICING OF THE THIRD Ig DOMAIN In their original studies with KGF, Rubin et al. (1989) noted that keratinocytes express receptors for KGF, but fibroblasts and endothelial cells do not. In contrast, fibroblast and endothelial cells express receptors that bind bFGF. From the binding studies discussed above it is clear that KGF binds to FGFR 2 (and possibly FGFR 1) forms that contain IIIb sequences and not IIIc sequences, whereas bFGF binds to FGFR 1 and FGFR 2 forms that contain IIIc sequences and not IIIb sequences. Therefore the different binding properties of keratinocytes and fibrohlasts/endothelial cells most likely reflect differential expression of IIIb and IIIc exons in these cells. Johnson et al. (1991) have shown that several human cell lines simultaneously express transcripts containing the IIIa, IIIb, or IIIc exons of FGFR 1. In each of these cell lines, however, expression levels of the IIIc exon appear to be much higher than those of the IIIa or IIIb exons. One cell line, foreskin fibroblasts, was found to express only the IIIc exon. Werner et al. (1992a) have demonstrated differential expression of the IIIa, IIIb, and IIIc exons of FGFR 1 in mouse tissues. Whereas the IIIc exon was expressed in all tissues examined with the exception of liver, the IIIa and IIIb exons exhibit more restricted patterns of expression.
FGF RECEPTOR MULTIGENE FAMILY
29
The IIIa exon was expressed in brain, skeletal muscle, and skin. The IIIb exon was expressed predominantly in skin, and at lower levels in brain, kidney, muscle, and placenta. As was observed in studies of human cell lines, in all cases where there is simultaneous expression of more than one exon, expression levels of the IIIc exon appear to be much higher than those of the IIIa or IIIb exons.
B. TISSUE-SPECIFIC ALTERNATIVE SPLICING INVOLVING Ig DOMAIN I Although the first Ig domain of the FGFR 1 may prove unimportant for ligand binding, it is clear that removal of this domain via alternative splicing occurs in a tissue-specific fashion. Northern blotting and RNase protection assays show that 3 Ig domain forms of FGFR 1 are the predominant forms of receptor expressed during mouse embryogenesis (Reid et al., 1990; Werner et al., 1992b). In fact, 2 Ig domain forms are not detected by protection analyses until after birth. Following birth, 3 Ig and 2 Ig forms are simultaneously expressed at nearly equal levels in a number of different tissues, including heart, lung, and muscle (Werner et al., 1992b).In brain and kidney, however, 3 Ig domain forms continue to be the predominant, if not exclusive, form expressed.
XVI. Differential, Tissue-Specific Expression of the Different FGF Receptor Genes Several studies that help to document differential expression of the different FGF receptor genes in a variety of tissues have been completed (Kornbluth et al., 1988; Reid et al., 1990; Heuer et al., 1990; Wanaka et al., 1990, 1991; Sat0 et al., 1991; Stark et al., 1991; Peters et al., 1992a,b; Werner et al., 1992b). These studies have utilized the techniques of Northern blotting, RNase protection analyses, and in situ hybridization, and have used a variety of probes. It is important to note that although these studies clearly delineate expression patterns of the different FGF receptor genes, typically they do not provide information on expression of specific alternatively spliced mRNAs. In general, the FGFR 1 and FGFR 2 genes exhibit broad but distinct patterns of expression during development and in adult animals. On the other hand, the FGFR 3 and FGFR 4 genes appear to have more restricted patterns of expression. In the developing embryo, FGFR 1 transcripts are expressed predominantly in the brain and mesenchymal tissues (Heuer et al., 1990; Wanaka et al., 1990, 1991; Peters et al., 1992a),
30
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
whereas FGFR 2 transcripts are expressed predominantly in brain and epithelium (Peters el al., 1992a; Werner et al., 1992b). FGFR 3 transcripts are expressed predominantly in brain, spinal chord, and cartilage rudiments of developing bone (Peters et al., 1992c). FGFR 4 transcripts are expressed in developing endoderm and the myotomal component of the somite, as well as myotomally derived skeletal muscle (Stark et al., 1991). N o expression of FGFR 4 transcripts was seen in cardiac muscle, however (Stark et al., 1991). In adult animals, FGFR 1 transcripts are detected in brain, bone, kidney, skin, lung, heart, and muscle, but not in liver (Heuer et al., 1990; Wanaka et al., 1990, 1991; Peters et al., 1992a; Werner et al., 1992b). FGFR 2 transcripts in adult animals are detected in brain, kidney, skin, lung, and liver, but not in heart, spleen, or muscle (Kornbluth et al., 1988; Peters et al., 1992a; Werner et al., 1992b). The pattern of expression of FGFR 1 in the central nervous system is consistent with neuronal expression, whereas the pattern of FGFR 2 expression in the CNS is more consistent with glial cell expression (Heuer et al., 1990; Wanaka et al., 1990, 1991; Peters et al., 1992a,b). FGFR 3 transcripts are detected in adult animals in brain, kidney, skin, and lung (Peters et al., 1992c).
XVII. The Drosophila FGF Receptor Glazer and Shilo ( 1 99 1) have recently reported the isolation of genomic clones for a Drosophila FGF receptor gene by low stringency screening of a Drosophila genomic library with a mouse FGFR 1 cDNA probe. The genomic clones were then used to isolate a nearly full-length cDNA clone (missing 5' nontranslated and signal peptide sequences) from a Drosophzla cDNA library. The protein encoded by this cDNA is structurally similar to the other membrane-spanning FGF receptors w e have discussed. The extracellular region of the Drosophilu FGF receptor contains 3 Ig-like domains and an acid box domain (core sequence: EDNDDDVE). The intracellular regon contains a relatively long juxtamembrane domain of approximately 90 amino acids, a tyrosine kinase domain that is interrupted by a kinase insert region of 22 amino acids, and a C-tail domain of approximately 70 amino acids. Comparison of the genomic and cDNA clones revealed that they are colinear with the exception of a single 85-bp intron in the kinase domain. The location of this intron is conserved in the human FGFR 1 gene (Johnson et al., 1991). What is striking about the genomic sequence of the Drosophila FGF receptor is the lack of introns in the extracellular coding region. This finding allows two conclusions to be drawn regarding the complexity of
FGF RECEPTOR MULTIGENE FAMILY
31
FGF receptor expression in Drosophila. First, since the coding region for the first Ig domain (I) is not separated from the remainder of the receptor gene by intron sequences, the potential for removing this domain via alternative splicing appears to be restricted to higher eukaryotes. The fact that higher eukaryotes express predominantly 3 Ig receptor forms (as opposed to 2 Ig) during development suggests that Ig domain I may have a function that is critically important during development. Experiments using Drosophila embryos may help to identify the function of this domain. Second, because the extracellular domain of the Drosophila gene does not contain introns, there is only one coding sequence for the second half of Ig domain 111. The amino acid sequence of this domain exhibits nearly equal identity with the human FGFR 1 IIIb sequence (38%) and the human FGFR 1 IIIc sequence (40%). In higher eukaryotes, receptors containing different sequences ( M a , IIIb, or IIIc) in this region exhibit distinctive ligand binding specificities (see Section XII). The existence of only one alternative for Ig domain I11 in the Drosophila FGF receptor indicates that this receptor is considerably less flexible, and suggests that the Drosophila FGF family may be less complex than that of higher eukaryotes. Glazer and Shilo (1991) also conclude that there is only one FGF receptor homolog in Drosophila based on their inability to isolate more than one class of FGFR clones. This conclusion also draws support from studies of FGF receptors from higher eukaryotes. As discussed in Section IX,C, comparison of alternative exons for Ig domain 111, both within the same gene and also between different genes, suggests that the existence of alternative exons for this receptor region is primordial to the existence of a multigene family. Since the Drosophila FGF receptor does not contain alternative exons in this region, it makes sensqto argue that there is only one FGF receptor gene in Drosophila. It seems likely, therefore, that both the FGF family and the FGF receptor family are considerably less complex in Drosophila than they are in higher eukaryotes.
XVIII. FGF Receptor-Mediated Signal Transduction Treatment of cells with FGFs leads to increased intracellular pH and intracellular Ca2+ levels (Tsuda et al., 1985; Halperin and Lobb, 1987); increased hydrolysis of polyphosphoinositides (Brown et al., 1989); increased phosphorylation of cellular proteins (Huang and Huang, 1986; Pelech et al., 1986; Coughlin et al., 1988); and increased transcription of a subset of cellular genes, including c-myc and c-fos (Kruijer et al., 1984; Muller et al., 1984; Stumpo and Blackshear, 1986). Depending on the
32
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
cell type, exposure to FGFs ultimately leads to proliferation, differentiation, inhibition of differentiation, or maintenance of a differentiated phenotype. The signaling mechanisms that give rise to these ultimate manifestations, however, remain largely unknown. It is known that FGF-dependent signaling is initiated immediately following the binding of FGF to its receptor. The binding of aFGF or bFGF to its receptor induces receptor dimerization (Bellot et al., 1991; Ueno et al., 1992), similar to what has been observed for several other growth factor receptors (Williams, 1989; Ullrich and Schlessinger, 1990). Interestingly, both homodimeric and heterodimeric receptor species can be formed between the FGFR 1, the FGFR 2, and the FGFR 3 proteins (Bellot et at., 1991; Ueno et al., 1992). Binding also leads to activation of FGF receptor tyrosine kinase activity and receptor autophosphorylation (Huang and Huang, 1986; Coughlin et al., 1988; Mansukhani et al., 1990). Phosphorylation of dimerized receptors appears to occur via an intermolecular transphosphorylation mechanism (Bellot et al., 1991).Activation of the receptor tyrosine kinase also leads to increased tyrosine phosphorylation of a number of cellular proteins (Huang and Huang, 1986; Coughlin et al., 1988; Bottaro et al., 1990; Burgess et al., 1990; Mansukhani et al., 1990; Miki et al., 1991; Peters et al., 1992d). Phosphorylation of a 90-kDa protein (and possibly others) may be unique to FGF receptor signaling pathways (Coughlin et al., 1988). It remains unclear, however, how many (if any) of these proteins associate with and are directly phosphorylated by the FGF receptor. Proteins that are known to associate with other growth factor receptors include: Raf-1 (Morrison et al., 1989), GTPase-activating protein (GAP) (Molloy et al., 1989; Ellis et al., 1990; Kaplan et al., 1990; Kazlauskas et al., 1990), pp60c-src (Krypta et al., 1990), the p85 subunit of phosphatidylinositol 3-kinase (Coughlin et al., 1989; Bjorge et al., 1990; Kazlauskas and Cooper, 1990; Escobedo et al., 1991; Otsu et al., 1991),v-Crk (Matsuda et al., 1990; Mayer and Hanafusa, 1990), and phospholipase C-y (PLC-y) (Wahl et al., 1988, 1989; Kumijan et al., 1989; Margolis et al., 1989; Meisenhelder et al., 1989; Burgess el al., 1990; Morrison et al., 1990). Currently, only one protein, PLC-y has been identified as a candidate substrate of an FGF receptor. PLC-y is phosphorylated on tyrosine residues following FGF stimulation (Burgess et al., 1990) and direct association with the receptor has been demonstrated (Mohammadi et al., 1991; Peters et al., 1992d). Mohammadi et al. (1991) have shown that the SH2 (src homology region 2) domain of PLC-y mediates binding to the FGF receptor. In addition, a 28 amino acid peptide derived from the C-tail region of FGFR 1 has been shown to bind to the SH2 domain of PLC-y (Mohammadi et al., 1991). This peptide contained phosphorylated Tyr
FGF RECEPTOR MULTIGENE FAMILY
33
(766) (see Fig. 3). This tyrosine residue is conserved across all four FGF receptor genes. Mutation of Tyr (766) to Phe generates a receptor protein that does not associate with or phosphorylate PLC-y and does not mediate FGF-dependent phosphotidylinositol turnover (Peters et al., 1992d). The mutant receptor does, however, autophosphorylate and mediate increased tyrosine phophorylation of other cellular proteins (Peters et al., 1992d). Additional experiments with this mutant receptor should help to determine the role of PLC-y in FGF receptor-mediated signaling. Although the experiments described above have shed new light on the interaction between PLC-y and FGF receptors, the precise role of PLC-y in FGF receptor-mediated signaling remains unclear. In CCL39 cells (Chinese hamster lung fibroblasts),for instance, FGF does not stimulate hydrolysis of polyphosphoinositides (Magnaldo et al., 1986), indicating that the FGF receptors on these cells do not couple to PLC-y signaling pathways. Also, in cells where FGF does stimulate polyphosphoinositide breakdown, the magnitude of this response is much less than that observed following stimulation with other growth factors, such as PDGF (Peters et al., 1992d). Furthermore, cells expressing the Tyr (766) to Phe (766) mutant FGF receptor proliferate in response to FGF (Peters et al., 1992d), indicating that PLC-y may not be important for pathways leading to FGF-induced mitogenesis. The potential involvement of other signaling molecules in FGF receptor-mediated signaling remains largely untested. It appears likely though, that GAP protein, in contrast to its interaction with the PDGF receptor, does not associate with the FGF receptor (Molloy et al., 1989). Stimulation of cells with FGF does, however, lead to hyperphosphorylation of c-Raf-1 (Morrison et al., 1988). Currently, it is not known whether c-Raf-1 is directly phosphorylated by the receptor, or whether the phosphorylation of c-Raf-1 affects its kinase activity. Finally, although several cellular proteins are known to become phosphorylated on tyrosine residues in response to FGF treatment, the identities of these proteins (with the exception of PLC-y) remain unknown. XIX. Concluding Remarks
The FGF receptor field has grown increasingly complex in recent years with the discovery of four distinct FGFR genes. Alternative splicing of mRNA transcripts from at least two of these genes has introduced even further complexity. Binding studies discussed in this review have shown that although the multiple FGF receptor forms exhibit some common binding properties, considerable differences in binding specificities
34
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
also exist. Functional differences between the different receptor forms were observed at two levels. First, different FGF receptor forms derived from the same gene via alternative splicing have different ligand binding properties. Specifically, the binding properties of a receptor can be determined in part by which exon (IIIa, IIIb, or IIIc) is used to code for the second half of Ig domain 111. Second, analogous splice variants from different FGF receptor genes bind different members of the FGF family. For instance, FGFR 1 and FGFR 4 forms that are identical with respect to domain structure show differences in their ability to bind bFGF. Recently, studies of FGFR mRNA localization have demonstrated tissuespecific alternative splicing of FGFR mRNA transcripts as well as tissuespecific expression of different FGFR genes. Thus, it can be concluded that mechanisms involving alternative splicing or differential expression of genes can be used to achieve selective responsiveness of different tissues to different members of the FGF family. The discovery of multiple forms of the FGF receptor raises many important questions for future investigations. It is particularly important to elucidate the roles of each of the different FGF receptor forms, particularly during development. Based on preliminary studies of FGFR mRNA localization, it seems likely that the different receptor forms have distinct roles. To determine these roles, it will be necessary to selectively knock out, by genetic or other means, specific receptor forms. Amaya et al. (199 1) and Ueno et al. (1992) have already achieved some success in knocking out FGFR function using dominant negative technology. However, it is clear that new approaches will be needed to selectively knock out individual receptor forms. Other questions that need to be addressed concern the nature of FGF receptor-mediated signal transduction. What are the signaling pathways (and molecules) used by the FGF receptors? Do the products of different FGFR genes couple to different signaling molecules and pathways? Do receptor forms that differ only in the sequences of their third Ig domain or C-tail region couple to different pathways? Do different members of the FGF family induce distinct signaling mechanisms? These and other questions need to be addressed in order to understand how FGFs can exert such a wide variety of effects in responsive cells types. Answers to these questions will provide a basis for understanding which receptor forms and which signaling pathways are involved in FGF-dependent cellular responses such as mitogenesis, chemotaxis, neurite outgrowth, neuronal maintainance, and inhibition of differentiation. Another important avenue for future research is the rational design of agonists and antagonists of FGF actions. The design of such molecules will benefit greatly from studies of the ligand binding domains of the
FGF RECEPTOR MULTIGENE FAMILY
35
different FGF receptor forms. Initially these studies will be complicated by the fact that there are several members in the PGF family, and by the fact that there are multiple FGFR genes and multiple exons for the second half of the third Ig domain. The advantage of studying FGFFGFR interactions, however, is that ligand binding is defined by a relatively short region of amino acids. Specifically, it has been demonstrated that 2 Ig domain forms of the FGF receptor can bind aFGF, bFGF, hstlKFGF, or KGF. Thus, ligand binding requires a maximum of 2 Ig domains (227 amino acids). Furthermore, binding studies of receptor forms with different sequences in the second half of the third Ig domain show that specificity for different FGFs can be achieved by minor variation in the composition of this short region (47-48 amino acids). Mutational analyses coupled with X-ray crystallography of ligand/receptor complexes should provide meaningful information on the ligand binding domaints) of the FGF receptor. The recent publication of the threedimensional structures of aFGF and bFGF also should provide valuable information for these studies (Zhu et al., 1991). The long-range goal of designing effective agonist and antagonists of FGF action has considerable therapeutic value. Agonists of FGF might be useful for accelerating wound healing and neovascularization, and maintaining viability of certain neuronal populations. Antagonists of FGF, on the other hand, might be useful for blocking angiogenesis in pathological conditions such as diabetic retinopathy and tumor neovascularization. ACKNOWLEDGMENTS We are deeply indebted to many colleagues for helpful insights and suggestions, and for providing data prior to publication. Without their cooperation and generosity this review would not have been possible. We thank Kevin Peters, Dah-Shuhn R. Duan, Sabine Werner, Carlie de Vries, Pauline Lee, Hikaru Ueno, Khoi Le, Dan Mirda, and Michael Jaye. This work was supported by the National Institutes of Health Program of Excellence in Molecular Biology (HL43821). D.E.J. was supported by American Heart Association Fellowship 94-1219116.
REFERENCES Abraham, J. A., Mergia, A., Whang, J. L., Tumolo, A., Friedman, J.. Hjerrild, K. A., Gospodarowicz, D., and Fiddes, J. C. (1986a). Science 438, 545-548. Abraham, J. A., Whang, J. L., Tumolo, A., Mergia, A., Friedman, J., Gospodarowicz, D., and Fiddes, J. (1986b). EMBOJ. 5, 2523-2528. Amaya, E., Musci, T. J., and Kirschner, M. W. (1991). Cell (Cambridge, Marc.)66,257-270. Anderson, K. J., Dam, D., Lee, S., and Cotman, C. W. (1988). Nature (London) 334, 360361.
36
DANIEL E. JOHNSON A N D LEWIS T. WILLIAMS
Armelin, H. A. (I973). Proc. Natl. Acad. Sci. U.S . A, 70,2702-2706. Baird, A., Esch, F., Ling, N., and Gospodarowicz, D. (1985a). Regul. Pept. 12, 201-213. Baird, A., Esch, F., Gospodarowicz, D., and Guillemin, R. (1985b).B i o c h i r t l y 24,78557859. Baird, A., Esch, F., Mormede, P., Ueno, N., Ling, N., Bohlen, P., Ying, S.-Y., Wehrenberg, W. B., and Guillemin, R. (1986). Recent Prog. H u m . Res. 42, 143-205. Bashkin, P., Doctrow, S., Klagsbrun, M., Svahn, C. M., Folkman, J., and Vlodavsky, I. S t 1737-1 ~ 743. (1989). B i ~ ~ h i 28, Bellot, F., Crumley, G., Kaplow,J. M., Schlessinger, J.. Jaye, M., and Dionne, C. A. (1991). EMBO J. 10,2849-2854. Bjorge, J. D., Chan, T.-O., Antczak, M., Kung, H.-J., and Fujita, D. J. (1990). Proc. Natl. Acid. Sn'. U . S.A . 87,3816-3820. Bottaro, D. P., Rubin, J. S., Ron, D., Finch, P. W., Florio, C., and Aaronson, S. A. (199O).J. Biol. C h . 465, 12767-12770. Bovi, P. D., Curatola, A. M., Kern, F. G., Greco, A., Ittmann, M., and Basilico, C. (1987). Cell (Canbridge, Mass.) 50, 729-737. Broad, T. E., and Ham, R. G. (1983). Eur. J . Biochem. 135,33-39. Brown, K. D., Blakeley, D. M., and Brigstock, D. R. (1989). FEES Lett. 247,227-231. Burgess, W. H., and Maciag, T. (1989). Annu. Rev. Biochem. 58, 575-606. Burgess, W. H., Dionne, C. A., Kaplow, J.. Mudd, R., Friesel, R., Zilbertstein, A,, Schlessinger, J., and Jaye, M. (1990). Mol. CeU. Biol. 10, 4770-4777. Burrus, L. W., and Olwin, B. B. (1989).J. Biol. Chem. 264, 18647-18653. Champion-Arnaud, P., Ronsin, C., Gilbert, E., Gesnes, M. C., Houssaint, E., and Breathnach, R. (1991). Oncogene 6, 979-987. Clegg, C. H., Linkhart, T. A., Olwin, B. B., and Hauschka, S. D. (1987).J. Cell Biol. 105, 949-956. Coughlin, S. R., Barr, P. J., Cousens, L. S., Fretto, L. J., and Williams, L. T. (1988).J. Biol. C h . 263,988-993. Coughlin, S. R., Escobedo, J. A., and Williams, L. T. (1989). Science 243, 1191-1 194. Courty, J., Dauchel, M. C., Mereau, A., Badet, J., and Barritault, D. (1988).J. Biol. C h a . 263, 11217-11220. Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. (1985). Science 230, 1 132-1 139. Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R. L., Isacke, C., Verma, I. M.,and Ullrich, A. (1986). Nature (London) 340,277-280. Crumley, G., Bellot, F., Kaplow, J. M., Schlessinger, J., Jaye, M.,and Dionne, C. A. (1991). OnCogm 6,2255-2262. Cunningham, B. A., Hemperly, J. J., Murray, B. A., Prediger, E. A., Brackenbury, R.,and Edelman, G. M. (1987). Nature (London) 236, 799-806. Dell, K. R., and Williams, L. T. (1992). Submitted for publication. de Vries, C., and Williams, L. T. (1992). In preparation. Dickson, C., Smith, R., Brookes, S., and Peters, G. (1984). Cell (Cambridge, Mass.)37, 529536. Dionne, C. A., Crumley, G., Bellot, F., Kaplow, J. M., Searfross, G., Rum, M., Burgess, W. H., Jaye, M., and Schlessinger, J. (1990). EMBOJ. 9, 2685-2692. Duan, D.-S. R., Werner, S., and Williams, L. T. (1992).J. Biol. Chem. In press. Eisemann, A., Ahn, J. A., Graziani, G., Tronick, S. R., and Ron, D. (1991). Oncogene 6, 1195-1202. Ellis, C., Moran, M., McCormick, F., and Pawson, T. (1990). Nature (London) 343,377-381.
FGF RECEPTOR MULTIGENE FAMILY
37
Esch, F., Baird, A., Ling, N., Ueno, N., Hill, F., Denoroy, L., Klepper, R., Gospodarowicz, D., Bohlen, P., and Guillemin, R. (1985).Proc. Natl. Acad. Sci. U.S.A. 82,6507-651 1. Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfay, D., Fried, V. A., and Williams, L. T. (1991).Cell (Cambridge, Mass.)65, 75-82. Finch, P. W., Rubin, J. S., Miki, T., Ron, D., and Aaronson, S. A. (1989).Science 245,752-
755. Folkman, J., and Klagsbrun, M. (1987).Science 235, 442-447. Friesel, R., Burgess, W. H., Mehlman, T., and Maciag, T. (1986).J.Biol. C h . 261, 7581-
7584. Gimenez-Gallego, G., Rodkey, J.. Bennett, C., Rios-Candelore, M., DiSalvo, J., and Thomas, K. A. (1985).Science 230, 1385-1388. Glazer, L., and Shilo, B.-Z. (1991).Genes Den 5, 697-705. Gospodarowicz, D. (1974).Nature (London) 249, 123-127. Gospodarowicz, D.(1975).J. Biol. Chem. 250, 2515-2520. Gospodarowic, D., Jones, K. L., and Sato, G. (1974).Proc. Natl. Acad. Sci. U . S.A. 71,2295-
2299.
Gospodarowicz, D., Bialicki, H., and Greenberg, G. (197QJ.Biol. Chem. 253,3736-3743. Gospodarowicz, D., Cheng, J., Lui, G.-M., Baird, A., Esch, F., and Bohlen, P. (1985a). Endocrinology, (Baltimore) 117,2283-2291. Gospodarowicz, D., Cheng, J., Lui, G.-M., Fujii, D. K., Baird, A., and Bohlen, P. (1985b). Biochem. Biophys. Res. C a m u n . 30, 554-562. Gospodarowicz, D.,Baird, A., Cheng, J., Lui, G.-M., Esch, F., and Bohlen, P. (1986a). Endocrinology (Baltimore) 118, 82-90. Gospodarowicz, D., Neufeld, G., and Schweigerer, L. (1986b).Cell Dzffm. 19, 1-17. Gross, J. L., Moscatelli, D., Jaffe, E. A., and Rifkin, D. B. (1982).J.Cell Bid. 94,974-981. Gross, J. L., Moscatelli, D., and Rifkin, D. B. (1983).Proc. Natl. Acad. Sci. U . S. A. 80,2623-
2627.
Halaban, R., Ghosh, S., and Baird, A. (1987).In Vitro Cell. Den B i d . 23,47-52. Halperin, J. A., and Lobb, R. R. (1987).B i o c h . Biophy. Res. Commun. 144, 115-122. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988).Science 241, 42-52. Hattori, Y.,Odagiri, H., Nakatani, H., Miyagawa, K., Naito, K., Sakamoto, H., Katoh, O., Yoshida, T., Sugimura, T., and Terada, M. (1990).Proc. Natl. Acad. Sci. U . S. A. 87,
5983-5987.
Hauschka, P.V., Mavrakos, A. E., Iafrati, M. D., Doleman, S. E., and Klagsbrun, M. (1986). J . Biol. C h a . 261, 12665-12674. Heuer, J.,von Bartheld, C., Kinoshita, Y., Evers, P., and Bothwell, M. A. (1990).Neuron 5,
283-296. Hoffman, R. S. (1940).Growth 4,361-376. Hou, J., Kan, M., McKeehan, K., McBride, G., Adam, P., and McKeehan, W. L. (1991). Scierue 251,665-668. Houssaint, E., Blanquet, P. R., Champion-Arnaud, P., Gesnel, M. C., Torriglia, A., Courtois, Y., and Breathnach, R. (1990).Proc. Natl. Acad. Sci. U . S.A. 87,8180-8184. Huang, S. S., and Huang, J. S. (1986).J.Biol. C h a . 261, 9568-9571. Imamura, T., Tokita, Y., and Mitsui, Y. (1988).Biochem. Bwphys. Res. Commun. 155,583-
590.
Jaye, M.,Howk, R.,Burgess, W. H., Ricca, G. A., Chiu, I.-M., Ravera, M. W., OBrien, S. J., Modi, W. S., Maciag, T., and Drohan, W. N. (1986).S a k e 233, 543-545. Jaye, M., Lyall, R. M., Mudd, R., Schlessinger, J,, and Sarver, N. (1988).EMBOJ. 7,963-
969.
Johnson, D. E., Lee, P. L., Lu, J., and Williams, L. T. (1990).Mol. Cell. Biol. 10,4728-4736.
38
DANIEL E. JOHNSON AND LEWIS T. WILLIAMS
Johnson, D. E., Lu, J., Chen, H., Werner, S., and Williams, L. T. (1991).Mol. Cell. Biol. 11, 4627-4634. Kaplan, D. R., Morrison, D. K., Wong, G., McCormick, F., and Williams, L. T. (1990). Cell (Cambndge, Mars.) 61, 125-133. Kazlauskas, A., and Cooper, J. A. (1990). E M B O J . 9,3279-3286. Kazlauskas, A,, Ellis, C., Pawson, T., and Cooper, J. A. (1990). Science 247, 1578-1581. Keegan, K., Johnson, D. E., Williams, L. T., and Hayman, M. J. (1991).Proc. Natl. Acad. Sci. C'. S . A. 88, 1095-1099. Kiefer, M. C., Stephans, J. C., Crawford, K., Okino, K., and Barr, P. J. (1990). Proc. Nutl. Acad. Sci. 1'. S. A. 87,6985-6989. Kimelman, D., and Kirschner, M. (1987). Cell (Cambndge, Mass.)51, 869-877. Kimelman, D., Abraham, J. A., Haaparanta, T., Palisi, T. M., and Kirschner, M. W. (1988). S c k u e 242, 1053-1056. Klagsbrun, M., and Baird, A. (1991). Cell (Cambrulge, Mass.) 67,229-231. Klagsbrun, M., and Shing, Y. (1985). Proc. Natl. Acad. Sci. U . S. A. 82, 805-809. Kornbluth, S., Paulson, K. E., and Hanafusa, H. (1988). Mol. Cell. Biol. 8, 5541-5544. Kruijer, W., Cooper, J. A., Hunter, T., and Verma, I. M. (1984). Nature(London) 312,711716. Krypra, R. M., Goldberg, Y., Uiug, E. T., and Coutneidge, S. A. (1990). Cell (Cambridge, Mass.) 62, 481-492. Kumijan, D. A., Wahl, M. I . , Rhee, S. G., and Daniel, T. 0.(1989).Proc. Natl. Acad. Sci. U . S . A. 86, 8232-8239. Kurokawa, T., Sasada. R., Iwane, M., and lgarashi, K. (1987). FEBS Lett. 213, 189-194. Larhrop, B., Olson, E., and Glaser, L. (1985).J. Cell. Biol. 100, 1540-1547. Lee, P. L., Johnson, D. E., Cousens, L. S., Fried, V. A., and Williams, L. T. (1989). Science 245, 57-60. Libermann, T. A., Friesel, R., Jaye, M., Lyall, R., Westermark, B., Drohan, W., Schmidt, A,, Maciag, T., and Schlessinger, J. (1987). E M B O J . 6, 1627-1632. Linkhart, T. A., Clegg, C. H., and Hauschka, S. D. (1981). Deu. Biol. 86, 19-30. Lobb, R. R., Harper, J. W., and Fett, J. W. (1986). Anal. B i o c h . 154, 1-14. Maciag, T., Mehlman, T., Friesel, R., and Schreiber, A. B. (1984). Science 225, 932-934. Magnaldo, I., L'Allemain, G., Chambard, J. C., Moenner, M., Barritault, D., and Pouyssegur, J. (1986).J. Bwl. C h . 261, 16916-16922. Mansukhani, A., Moscatelli, D., Talarico, D., Levytska, V., and Basilico, C. (1990). Proc. N d l . A d . Sci. U . S. A. 87,4378-4382. Margolis, B., Rhee, S. G., Felder, S., Mervic, M., Lyall, R., Levitzki, A., Ullrich, A,, Zilbertstein, A,, and Schlessinger, J. (1989). Cell (Cambridge, Mass.) 57, 1101-1107. Marics, I., Adelaide, J., Raybaud, F., Mattei, M., Coulier, F., Planche, J., Lapeyriere, O., and Birnbaum, D. (1989). Oncogene 4, 335-340. Matsuda, M., Mayer, B. J., Fukui, Y., and Hanafusa, H. (1990). Science 248, 1537-1539. Mayer, B. J., and Hanafusa, H. (1990). Proc. Natl. Acad. Sci. U . S . A. 87, 2638-2642. Meisenhelder, J., Suh, P.-G., Rhee, S. G., and Hunter, T. (1989). Cell (Cambridge, Mass.) 57, 1109-1122. Mergia, A., Eddy, R., Abraham, J. A., Fiddes, J. C., and Shows, T. B. (1986). Biochem. Biophys. Res. Commun. 138, 644-65 1 . Mignatti, P., Tsuboi, R., Robbins, E., and Rifkin, D. B. (1989).J.Cell Biol. 108, 671-682. Miki, T., Fleming, T. P., Bottaro, D. P., Rubin, J. S., Ron, D., and Aaronson, S. A. (1991). Science 251,72-75. Moenner, M., Chevallier, B., Badet, J., and Barritault, D. (1986).Proc. Natl. Acad. Sci. U . S . A . 83, 5024-5028.
FGF RECEPTOR MULTIGENE FAMILY
39
Mohammadi, M., Honegger, A. M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C. A,, Jaye, M., Rubinstein, M., and Schlessinger, J. (1991). Mol. Cell. Biol. 11, 5068-5078. Molloy, C. J., Bottaro, D. P., Fleming, T. P., Marshal, M. S., Gibbs, J. B., and Aaronson, S. A. (1989). Nature (London) 342, 711-714. Moore, R., Casey, G., Brookes, S., Dixon, M., Peters, G., and Dickson, C. (1986).EMBOJ. 5, 919-924. Morrison, D. K., Kaplan, D. R., Rapp, U., and Roberts, T. M. (1988).Proc. Nutl. Acad. Sci. U. S. A. 85,8855-8859. Morrison, D. K., Kaplan, D. R., Escobedo, J. A., Rapp, U. R., Roberts, T. M., and Williams, L. T. (1989). Cell (Cambridge, Mass.) 58,649-657. Morrison, D. K., Kaplan, D. R., Rhee, S. G., and Williams, L. T. (1990).Mol. Cell. Biol. 10, 2359-2366. Morrison, R. S., Sharma, A., De Vellis, J., and Bradshaw, R. A. (1986).Proc. Nutl. Acad. Sci. U . S. A. 83, 7537-7541. Moscatelli, D. (1987).J. Cell. Physiol. 131, 123-130. Moscatelli, D. (1988).J. Cell Biol. 107, 753-759. Moscatelli, D., and Quarto, N. (1989).J. Cell Biol. 109, 2519-2527. Moscatelli, D., Presta, M., and Rifkin, D. B. (1986).Proc. Nutl. Acad. Sci. U. S. A. 83,20912095. Muller, R., Bravo, R., Burckhardt, J., and Curran, T. (1984). Nature (London) 312, 716720. Musci, T. J., Amaya, E., and Kirschner, M. W. (1990). Proc. Nutl. Acad. Sci. U. S. A. 87, 8365-8369. Neufeld, G., and Gospodarowicz, D. (1985).J. Biol. Chem. 260, 13860-13868. Neufeld, G., and Gospodarowicz, D. (1986).J. Biol. Chem. 261, 5631-5637. Neufeld, G., Mitchell, R., Ponte, P., and Gospodarowicz, D. (1988).J. CellBiol. 106, 13851394. Nishi, N., Matuo, Y., Mugurama, Y., Yoshitake, Y., Nishikawa, K.,and Wada, F. (1985). Biochem. Biophys. Res. Commun. 132, 1103-1 109. Olwin, B. B., and Hauschka, S. D. (1986).Biochemistly 25, 3487-3495. Olwin, B. B., and Hauschka, S. D. (1989).J. Cell. Biochem. 39,443-454. Otsu, M., Hiles, I., Gout, I., Fry, M. J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., Smith, A. D., Moryan, S. J., Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1991). Cell (Cambridge, Mars.) 65, 91-104. Partanen, J., Makela, T. P., Eerola, E., Korhonen, J., Hirvonen, H., Claesson-Welsh, L., and Alitalo, K. (1991). EMBOJ. 10, 1347-1354. Pasquale, E. B. (1990). Proc. Natl. Acad. Sci. U. S. A. 87, 5812-5816. Pasquale, E. B., and Singer, S. J. (1989). Proc. Natl. Acad. Sci. U . S. A. 86, 5449-5453. Pelech, S. L., Olwin, B. B., and Krebs, E. G. (1986).Proc. Natl. Acad. Sci. U . S. A. 83,59685972. Peters, G., Brookes, S., Smith, R., and Dickson, C. (1983). Cell (Cambridge, Mas.) 33,369377. Peters, K. G., Werner, S., Chen, G., and Williams, L. T. (1992a). Development (Cambridge, UK) 114,233-243. Peters, K. G., Basbaum, A., Williams, L. T., and Wilcox, J. (1992b).In preparation. Peters, K. G., Ornitz, D., Werner, S., and Williams, L. T. (1992~).In preparation. Peters, K. G., Marie, J., Escobedo, J., Del Rosario, M., Mirda, D., and Williams, L. T. (1992d). Submitted for publication. Presta, M., Mignatti, P., Mullins, D. E., and Moscatelli, D. (1985). Biosci. h p . 5, 783-788. Rapraeger, A. C., Krufka, A., and Olwin, B. B. (1991). Science 252, 1705-1708.
40
DANIEL E. JOHNSON A N D LEWIS T. WILLIAMS
Raz, V., Kelman, Z., Avivi, A., Neufeld. G.. Givol, D., and Yarden. Y. (1991). Oncogene 6, 753-760. Reid, H. H., Wilks, A. F., and Bernard, 0. (1990). Proc. Natl. Acad. Sci. U . S . A. 87, 15961600. Rogelj, S., Weinberg, R. A., Fanning, P., and Klagsbrun, M. (1988). Nature (London) 331, 173-1 75. Rubin, J. S., Osada, H., Finch, P. W., Taylor, W.G., Rudikoff, S., and Aaronson, S. A. (1989).Proc. Natl. Acad. Sci. U . S . A. 86,802-806. Ruta, M., Howk, R., Ricca, G., Drohan, W.. Zabelshansky, M., Laureys, G., Barton, D. E., Francke, U., Schlessinger, J., and Givol, D. (1988). Oncogene 3, 9-15. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., and Erlich, H. A. (1988). Science 239, 487-491. Sasada, R., Kurokawa, T., Iwane, M., and Igarashi, K. (1988). Mol. Cell. Biol. 8, 588-594. Sato, M., Kitazawa, T., Iwai, T., Seki, J., Sakato, N., Kato, J., and Takeya, T. (1991). Oncogent 6, 1279-1283. Schreiber, A. B., Kenney, J.. Kowalski, W. J., Friesel, R., Mehlman, T., and Maciag. T. (1985). PYOC.Natl. A d . Sn. U . S . A. 84,6138-6142. Serrero, G., and Khoo, J. C. (1982). Anal. B i o c h . 120, 351-359. Shing, Y.. Folkman, J.. Murray, M., and Klagsbrun, M. (1983).J. Cell B i d . 97, 395a. Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., and Klagsbrun, M. (1984). Science 423, 1296- 1299. ~P 326, Slack,J. M., Darlington, B. G., Heath, J. K., and Godsave, S. F. (1987). N Q ~ U(London) 197-200. Stark, K. L., McMahon, J. A., and McMahon, A. P. (1991). Deuelopment (Cambrtdge, UK) 113, 64 1-65 1. S t u m p , D. J., and Blackshear, P. J. (1986). Proc. N o d Acad. Sci. Lr. S . A . 83, 9453-9457. Sullivan, R.,and Klagsbrun, M. (1985).J. Biol. C h . 260, 2399-2403. Taira, M., Yoshida, T., Miyagawa, K., Sakamoto, H., Terada, M., and Sugimura, T. (1987). Proc. Natl. Acad. Sci. U.S . A . 84,2980-2984. Thomas, K. A. (1987). FASEB 1. 1,434-440. Thomas, K. A., Rios-Candelore, M., Gimenez-Gallego, G., DiSalvo,J., Bennet, C., Rodkey, J., and Fitzpatrick, S. (1985). Proc. Natl. Acad. Sci. U . S . A. 82, 6409-6413. Togari, A., Dickens, G., Kuzuya, H., and Guroff, G. (1985).J. Neurosci. 5, 307-3 16. Trowell, 0. A., Chir, B., and Willmer, E. N. (1939).J. Exp. Biol. 16, 60-70. Tsuda, T., Kaibuchi, K., Kawahara, Y.,Fukuzaki, H., and Takai, Y. (1985). FEBS Lett. 187, 43-46. Ueno, N., Baird, A., E x h , F., Shirnasaki, S., Ling, N., and Guillemin, R. (1986). Regul. Pept. 16, 135-145. Ueno, N., Baird, A., Esch, F., Ling, N., and Guillemin, R. (1987). Mol. Cell. Endocrinol. 49, 189- 194. Ueno, H., Gunn, M., Dell, K., Tseng, A., Jr., and Williams, L. T. (1992).J. Bzol. Chem 267, 1470-1476. Ullrich, A.. and Schlessinger, J. (1990). Cell (Cambridge, Mass.) 61, 203-212. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. (1984). Nature (London)309,418-425. Ullrich, A., Bell, J. R., Chen, E. Y., Herrera. R., Petruzzelli. L. M., Dull, T. J., Gray, A,, Coussens, L., Liao, Y. C., Tsubokawa, M., Mason, A., Seeburg, P. H., Grunfeld, C., Rosen, 0. M., and Ramachandran, J. (1985). Nature (London) 313, 756-761. Ullrich, A.. Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa. M.,Collins, C., Henzel, W.,
FGF RECEPTOR MULTIGENE FAMILY
41
Le Bon, T., Kathuria, S., Chen, E., Jacobs, S., Francke, U., Ramachandran, J., and Fugita-Yamaguchi, F. (1986). EMBO J. 5,2503-2512. Wagner, J. A., and DAmore, P. A. (1986).J. Cell Biol. 103, 1363-1367. Wahl, M. I., Daniel, T. O., and Carpenter, G. (1988). Science 241, 968-970. Wahl, M. I., Olashaw, N. E., Nishibe, S., Rhee, S. G., Pledger, W. J., and Carpenter, G. (1989). Mol. Cell. Biol. 9, 2934-2943. Walicke, P., Cowan, W. M., Ueno, N., Baird, A., and Guillemin, R. (1986).Proc. Natl. Acad. S C ~U . . S. A. 83, 3012-3016. Wanaka, A., Johnson, E. M., Jr., and Milbrandt, J. (1990). Neuron 5,267-281. Wanaka, A., Milbrandt, J., and Johnson, E. M., J . (1991).Deuelmt(Cambridge, UK) 111, 455-468. Werner, S., Duan, D.3. R., de Vries, C., Peters, K. G., Johnson, D. E., and Williams, L. T. (1992a). Mol. Cell. Biol. 12, 82-88. Werner, S., Peters, K. G., and Williams, L. T. (1992b). In preparation. Williams, A. F., and Barclay, N. A. (1988). Annu. Rev. Immunol. 6 , 381-408. Williams, L. T. (1989). Science 243, 1564-1570. Yarden, Y., Escobedo, J. A., Kuang, W.-J., Yang-Feng, T. L., Daniel, T. O., Tremble, P. M., Chen, E. Y., Ando, M. E., Harkins, R. N., Francke, U., Friend, V. A., Ullrich, A,, and Williams, L. T. (1986). Nature (London) 323, 226-232. Yayon, A., Klagsbrun, M., Esko,J. D., Leder, P., and Ornitz, D. M. (1991). Cell (Cambridge, MOSS.)64,841-848. Zhan, X., Bates, B., Hu, X., and Goldfarb, M. (1988). Mot. Cell. Biol. 8, 3487-3495. Zhu, X., Komiya, H., Chirino, A., Faham, S., Fox, G. M., Arakawa, T., Hsu, B. T., and Rees, D. C. (1991). Science 251, 90-93.
This Page Intentionally Left Blank
PROTEIN TYROSINE KINASE GROWTH FACTOR RECEPTORS AND THEIR LIGANDS IN DEVELOPMENT, DIFFERENTIATION, AND CANCER Andrew F. Wilks Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Victoria 3050, Australia
I. Introduction 11. Structure of Receptor Protein Tyrosine Kinases 111. RTKs in Development
A. Developmental Mutants of the Mouse B. Developmental Mutants of Drosophikz melanagaster 1V. RTKs and Tumorigenesis A. RTKs as Retroviral Oncogenes B. RTKs as Cellular Oncogenes V. Genetics and Cancer References
I. Introduction The protein tyrosine kinases (PTKs) are a thematic protein family (comprising at least seven structural variants), built around a highly conserved domain capable of phosphorylating protein substrates on tyrosine residues. The physiologically powerful catalytic activity of this domain has been harnessed to a wide range of metabolic demands, from transduction of extracellular growth stimuli (Yarden and Ullrich, 1988; Ullrich and Schlessinger, 1990) to responding to changes in intracellular REDOX potential (Bauskin et al., 1991).Members of this family are thus made up as a mosaic of sensory, regulatory, and effector domains, a composition best understood in one structural variant of the family: the growth factor receptor PTKs (receptor tyrosine kinases or RTKs). Members of this class of protein each share a common transmembrane topology, with an often highly glycosylated N-terminal ligand binding domain presented to the extracellular milieu, and an intracellular protein tyrosine kinase domain toward the C-terminus of the protein. A single hydrophobic “transmembrane” region lies between these two domains (Fig. 1). The structure of signal transduction molecules such as these facilitates a directional flow of information from the exterior of the cell to the interior of the cell. This process is specific for the correct recep43 ADVANCES IN CANCER RESEARCH, VOL. 60
Copyright 8 1993 by Academic Press, Inc. All rights of reproduction in any form reserved.
44
ANDREW F. WILKS
Class f Class III
LEU
EGF R MU ErbB3 Xmrk DER let23
#
PDGFa-R PDGFfi-R CSFl-R c-kt FLT
Class 11
Class IV Class V
u
-I
INSULIN-R IGH-R IRR3
FGF R BEK CEK2 FGFR4
FLT3 NEwFLkl
EPH ELK ERK EEK ECK HEK
= Fibronectin type III repeat
= Trans-membrane Domain
= Cysteine Rich Domain I
= Qrosine Kinase Domain
= Cysteine Rich Domain 11 = Cysteine Rich Domain In
= Ig-like Domain
= Insert Domain 4
= Liganddependent Autophosphorylation Sites
FIG. 1. RTK families. Five of the six classes of RTK are shown, displaying structural features which define each class. T h e nature of each of these structural features is shown at the right. Classes I, 11, and I l l are as defined by Yarden and Ullrich (1988); the remaining classifications are discussed in the text. References describing each of the RTKs listed below their prototypical structure are found in the text.
PROTEIN TYROSINE KINASE GFR
45
torlligand interaction and results in significant amplification (or “gain”) as the signal (phosphorylation of substrates upon tyrosine residues) is transmitted within the cell. Under the strictest control, this combination of specificity and thematic signal transduction has been frequently used in building the repertoire of possible differentiation processes that are presumably available to the totipotent cells of a preimplantation embryo. Unconstrained, it is also, by virtue of its pivotal position in most widely accepted schemes of signal transduction processes, a likely mechanism by which cancer cells acquire some of the features of their tumorigenic phenotype, such as their apparent independence of extracellular growth stimulation (Aaronson, 1991; Bishop, 1991; Hunter, 1991; Cross and Dexter, 1991). Both of these aspects of the biochemistry of RTKs will be addressed in this review.
II. Structure of Receptor Protein Tyrosine Kinases Members of the RTK family hold a number of structural features in common. These are an extracellular ligand-binding domain; a single transmembrane domain [in contradistinction to the seven transmembrane receptor family (e.g., Noda et al., 1984)]; a single protein tyrosine kinase domain; and at least one regulatory domain, which serves to reign in the catalytic activity of the PTK domain. Within the rather loose constraints of the foregoing description there are at least seven distinct morphotypes of RTK, some of which have become evolutionarily successful combinations of structural elements, and upon which structures family clusters of RTKs have been elaborated (Hanks et al., 1988; Hanks and Quinn, 1991). These structures are shown in Fig. 1. Yarden and Ullrich (1988) described three classes of RTK based on structural features. Class I included the EGF receptor (Ullrich et al., 1984)and its siblingNEUlerbB2 (Bargmann et al., 1986a),erbB3 (Kraus et al., 1989),and Xmrk (see Section IV,A and B) (Wittbrodt et al., 1989).The Drosophilu EGF receptor-related protein (Livneh et al., 1985) and the let23 gene of Caenmhabditis elegans (Aroian et al., 1990) were discovered subsequently, and each RTK clearly exhibited an overall structural similarity to the prototypical members of this class. Class I11 RTKs included the platelet-derived growth factor p (PDGFP) receptor (Yarden et al., 1986), c-kit (subsequently discovered to be allelic to the W locus, see Section II1,A) (Yarden et al., 1987), and the colony-stimulating factor 1 (CSFI) receptor (Coussens et al., 1986; Rothwell and Rohrschneider, 1987). More recently RTKs with a related structure have been uncovered, such as the PDGFa receptor (Claesson-Welsh et al., 1989),jlt
46
ANDREW F. WlLKS
(Shibuya et al., 1990),flt3/flk-2(Matthewset al., 1991a; Rosnet et al., 1991) and fEk-1 (Matthews et al., 1991b). Class I1 RTKs included the homodimer receptors for insulin (Ebina et al., 1985),and IGFl (Ullrich et al., 1986), to which has recently been added a third family member, IRR (insulin-related receptor) (Shier and Watt, 1989). The recent explosion of reports of the discovery of P T K related sequences wrought by the advent of screening protocols based around the high degree of sequence similarity within the catalytic domain of members of this family of proteins [including low-stringency cDNA library screening (e.g., Kraus and Aaronson, 1991),or the polymerase chain reaction (PCR) (Wilks, 1989, 1991), or upon the catalytic activity of the PTK domain itself (Letwin et al., 1988; Lindberg et al., 1988; Lindberg and Pasquale, 1991)] has rendered the original classification of the RTKs obsolete. Among the newly discovered RTKs novel structural formats have been discovered. Highly populated familial clusters have been described; for example, the fibroblast growth factor (FGF) receptor class of RTKs accommodates four mammalian-derived RTKs (Reid et al., 1990; Kornbluth et al., 1988; Keegan et al., 1991; Partanen et al., 1991; Stark et al., 1991) and additional representatives from Xmopus htwis (Musci et al., 1990) Drosophila melanogaster (Glazer and Shilo, 1991), and chicken (Lee et al., 1989; Pasquale, 1990). The cluster of related RTKs based around the structure of EPH (Hirai et al., 1987) at present includes six members [EPH (Hirai et al., 1987);ECK (Lindberg and Hunter, 1990);ELK (Letwin et al., 1988; Lhotak et al., 1991); ERK (Chan and Watt, 1991);EEK (Chan and Watt, 1991);HEK (Boyd et al., 1992)]. A third cluster of related sequences is centred around the trk protooncogene (Martin-Zancaet al., 1986,1990a) and, to date, includes three members [trk (Martin-Zanca et al., 1986); t d B (Klein et al., 1989); trkC (Lamballe et al., 1991)l. In order to extend the original nomenclature devised by Yarden and Ullrich (1988), it is proposed that these three families of RTK be denominated the Class IV, Class V, and Class VI RTKs, respectively, in acknowledgment of the frequency with which their structure reoccurs. Finally, a host of “orphan” receptors have also been uncovered, whose structures are, at present, unique (see Fig. 2). Presumably other family members for each of these receptors will be discovered in time. At present, the number of putative RTKs far exceeds the number of ligands available for assignment. The process of marrying ligand to receptor is thus still at an early stage. However, some degree of success has been achieved. For example, putative ligands for the MET receptor (Bottaro et al., 1991; Naldini et al., 1991), c-kit (Williams et al., 1990; Copeland et al., 1990; Zsebo et al., 1990a,b; Martin et al., 1990; Huang et al., 1990; Flanagan and Leder, 1990; Anderson et al., 1990), and NEU
PROTEIN TYROSINE KINASE GFR
47
ORPHAN RECEPTORS
!I!
LTK
MET
SEA
= Fibronectin type
a
SEVENESSIROS
III repeat
= Trans-membrane Domain
DI
= Tyrosine b a s e Domain
= Cysteine Rich Domain = Ig-like Domain
34 4
= Ligand-dependent Autophosphorylation Sites
FJG.2. Orphan receptors. RTKs unrelated to other known classes of RTK (see Fig. 1) are shown. The structural motifs encountered in these proteins are defined at the right. The references describing these receptors are cited in the manuscript, with the exception of RYK (Hovens, S. Stacker, and A. F. Wilks, unpublished results).
(Lupu et al., 1990; Tarakhovsky et al., 1991) have been described. Recently, each member of the trk family of RTKs (see Fig. 3) has been paired with its respective ligand. Members of this family of RTKs are expressed predominantly in tissues of neural origin. trk was originally discovered as an oncogenic fusion protein combining the catalytic domain of trk and a portion of the nonmuscle tropomyosin gene (MartinZanca et al., 1986) (see Section IV). More recently other members of this family of RTKs have been uncovered using low-stringency cDNA library screening techniques. These include trkB (Klein et d.,1989) and trkC (Lamballe et al., 1991). A major advance was made when it was discovered that trk was the receptor for nerve growth factor (NGF)
48
ANDREW F. WILKS
NGF
NT-3
BDNF
m
= Cysteine Rich Domain I = Cysteine Rich Domain 11 = Ig-like DO= Trans-membraneDomain = Leucine Rich Domain = Tyrosine Kinase Domain
trk
trkC
trk B
gp140
gp145
gp145
FIG.3. The trk family of RTKs and their ligands. The three members of the trk family (Class VI) of RTKs, trk, trkB, and trkC, are shown displaying the structural motifs that have been encountered in their sequence. The extracellular domains of trk and trkC are 54% identical, and the extracellular domains of trkB and trkC are 53% identical. The PTK domains of trk and trkC are 76% identical, and the PTK domains of trkB and trkC are 83% identical. The ligands for each of these RTKs are shown above their respective receptor. The trkC ligand, NT3, appears to be able to bind to the other two members of the trk family, albeit with lower affinity.
PROTEIN TYROSINE KINASE GFR
49
(Cordon-Cardo et al., 1991; Kaplan et al., 1991a,b; Klein et al., 1991a), and that trkB and trkC were the cellular receptors for two related growth factors, namely brain-derived neurotrophic factor (BNDF) (Klein et al., 1991b; Soppet et al., 1991; Squint0 et al., 1991) and neurotrophin-3 (Lamballe et al., 1991),respectively. Each of these growth factors is capable of binding with low affinity to other members of the trk family (Lamballe et al., 1991)and the complex interrelationship between these receptors and their ligands remains to be elucidated. Although it is not within the purview of this article to consider the nature of the signal transmitted within the cell by the PTK domain of members of the RTK family (for a review of this aspect of the biochemistry of PTKs, see Ullrich and Schlessinger, 1990),it is appropriate at this point to reflect on the multiplicity of cellular responses that appear to be mediated by members of this family. Thus, the specific inductive events mediated by the D. melanoguster sevenless gene product (detailed elsewhere in this review) may well involve the production of intracellular signals distinct from those induced by, for example, the murine RTK, c-kit. While acknowledging this fact, for the purposes of this review, the function of each of these RTKs is considered to be broadly equivalent: in both cases intracellular processes that affect the developmental fate of cells bearing these RTKs are triggered. Thus RTKs will be considered tools with which various developmental programs are established, and the question of mechanism will not be approached. With this caveat in mind, it is nonetheless evident that RTKs feature in developmental processes in several distinct modes. Examples of a number of diverse developmental roles are presented below. Ill. RTKs in Development
The expression patterns of many human, murine, and Drosophila RTKs have been determined by Northern analysis of mRNAs from adult tissues. For some murine and Drosophila RTKs in situ hybridization analysis has also been performed. Using this latter approach, the expression patterns of these mRNAs appear to range from widespread [e.g., the D. melanoguster EGF receptor homolog DER (Katzen et al., 1991)] to exquisitely highly localized [e.g., members of the trk family of RTKs (Klein et al., 1989; Martin-Zanca et al., 1990b; Lamballe et al., 1991)JMoreover, analyses of expression of RTKs during embryogenesis have provided insight into the possible developmental role played by certain members of this family. Thus, in situ hybridization analyses of CSFl and its receptor (Regenstreif and Rossant, 1989) firmly place both ligand and receptor in the region of the developing trophoblast during the development
50
ANDREW F. WILKS
of the placenta. Similarly, angiogenesis during human extraembryonic development has been demonstrated by the same technique to involve the spaciotemporal expression of PDGFP and its receptor (Holgren et al., 1991). Studies such as these strongly favor the interpretation that these receptor/ligand pairs have important roles to play in the induction events that mediate the developmental processes occurring at these locations. More definitive demonstration that members of these classes of molecules are involved has come from the investigation of a number of developmental mutants of both the mouse and the fruit fly D. melanogmter. These studies are outlined below.
A. DEVELOPMENTAL MUTANTSOF THE MOUSE A large number (> 1000) of mutant mouse strains have been described (Lyon and Searle, 1989), each exhibiting an unusual developmental phenotype that is the result of mutation at a single genetic locus. Three such mutants, dominant white (W) spotting (Little, 1915; Gruenberg, 1942; Russell, 1970), patch (Gruenberg and Truslove, 1960), and steel (Bennett, 1956), are of particular interest in the context of the role of RTKs in development. Each of these loci maps to a gene encoding a growth factor or an RTK growth factor receptor, and the profound developmental phenotypes associated with the loss of each of these genes are a testimony to the importance of molecules of each of these classes to the progress of normal murine development. The W, steel, and patch mutants are particularly informative of the types of processes in which these molecules are involved. In view of their importance, each of these mutants will be discussed separately.
I . The Dominant White Spotting (W) and Steel Loci The W locus has been the focus of genetic analysis for over 75 years (Little, 1915) and at least 25 distinct alleles of this locus have been described in the mouse (see references in Lyon and Searle, 1988) and one in the rat (Niwa et al., 1991; Tsujimura et al., 1991) The phenotypes of these alleles range from severe [e.g., W37, where heterozygotes are mostly white and homozygote embryos become inviable soon after implantation (Geissler et al., 19811 to mild [for example, W57 (Reith et al., 1990), where heterozygotes have a single white spot and homozygotes have white patches and are mildly anemic]. Overall, the W mutants appear to have common defects of differing severity in melanogenesis, hematopoeisis, and primordial germ cell production. Analysis of embryonic chimeras has shown that the W gene product itself is required to be produced by the afflicted cells themselves (Russell, 1979). In contrast,
PROTEIN TYROSINE KINASE GFR
51
the steel ( S I ) mutation (located on chromosome 10 in the mouse and represented by at least 10 alleles), whose phenotype shares deficiencies in pigment cells, blood cells, and germ cells with that of the W mutant, appeared to perturb some aspect of the microenvironment of these cells (Russell, 1979). This led to the suggestion that these two loci were intimately involved with the transmission of a common developmental signal to these cells and were most likely a growth factor receptor and its cognate ligand. Recently, the S I gene has been shown to encode stem cell factor (SCF) (Zsebo et al., 1990a,b)[also known as mast cell growth factor (MCGF) (Williams et al., 1990; Anderson et al., 1990; Copeland et al., 1990)], the ligand for the growth factor receptor encoded by the W locus. SCF is a membrane-bound glycoprotein of 36 kDa, with a 31- to 33-kDa processed form that is secreted (Anderson et al., 1990; Zsebo et al., 1990a; Nocka et al., 1990; Flanagan et al., 1991). The W locus was mapped to chromosome 5 in the mouse (Yarden et al., 1987) and has subsequently been demonstrated to be allelic to the gene for the RTK c-kit (Chabot et al., 1988; Geissler et al., 1988) and the protooncogene borne by the feline retrovirus HZ4-FeSV (Besmer et al., 1986a).The same RTK gene was demonstrated to be mutated in the Ws allele of the rat (Niwa et al., 1991; Tsujimura et al., 1991). Intriguingly, this same locus has emerged as the mutant allele in the human autosoma1 genetic disorder piebaldism (Morgan, 1786; Rizzoli, 1877, 1878), which is characterized by congenital patches of skin and hair that are completely devoid of melanocytes. In this mutant human allele, a single point mutation in the PTK domain of the c-kit gene appears to be the genetic basis of this disorder (Giebel and Spritz, 1991; Fleischman et al., 1991).Thus mutation in the c-kit gene in mouse (Reith et al., 1990; Tan et al., 1990), rat (Niwa et al., 1991; Tsujimura et al., 1991), and human (Giebel and Spritz, 1991; Fleischman et al., 1991) appears to be the basis for similar developmental defects in all three species. A particularly elegant study (Kishet et al., 1991) examining, by in situ hybridization, the expression pattern of c-kit and its cognate ligand SCF, during the development of the postimplantation mouse embryo, has shed light on the mechanism of action of these two molecules, and laid a biochemical basis for the genetic studies performed on these loci. A particular focus of this study was the migrating stem cell populations known to be affected in W and S I mutant mice. In these two mutant phenotypes three populations of migratory cells are affected. The migration of the primordial germ cells from their site of origin, in the allantois, through the mesentery and hindgut, to the forming genital ridges occurs between Embryonic Days 9.5 and 11.5 (Donovan et al., 1986; Bennett, 1956; Mintz and Russell, 1957). At the time of onset of
52
ANDREW F. WILKS
the primordial germ cell migration, SCF mRNA appears to be expressed at its highest level in the developing genital ridge, whereas, the c-kit mRNA is found associated with cells in the mesentery in the vicinity of the dorsal aorta, the location of the migrating primordial stem cells. Similarly, melanoblasts derived from neural crest cells begin to migrate around at Day 8.5 of embryonic life and are fully dispersed in the trunk endoderm by Day 11.5. Again, SCF appears to be expressed in the precursor of the skin (dermamyotome), whereas c-kit expression appears to be expressed only in migrating melanoblasts. At Embryonic Day 15.5, the patterns of SCF and c-kit established earlier in the proceedings remain, even though essentially all of the migration of the melanoblasts is complete. During this phase, however, there is a considerable expansion of the numbers of melanocytes at this location. Each of these patterns of expression fit well with the phenotype of the W and S l mutants described above. Nonetheless, c-kit and SCF expression was also detected at sites in the neural tube and developing brain, tissues which are not affected by the loss of these genes in the W and S 1 mutant strains. Accordingly, there remain elements of uncertainty in combining the data emerging from the analysis of the developmental mutants with that derived from the studies of the expression patterns of these proteins during embryogenesis. Several plausible interpretations are possible. First, the embryonic lethality characteristic of homozygotes with the more severe W and SZ alleles has been attributed to the consequences of the severe anemia that results from these mutations. It may well be that the actual cause of the lethality resulting from these mutant alleles lies with the neurological defects caused by the absence of their gene products from normal sites of expression in the neural tube and developing brain. A possible alternative explanation of these data may lie in a builtin redundancy of the molecules required for the induction of the neurological development of the embryo. The steel-Dickie ( s l d ) mutant is a semidominant mutant that arose spontaneously in the DBA/2J inbred strain (Bernstein, 1960). s l d l s l d homozygotes are viable, although they are severely anemic and sterile. The s l d mutation lies within the SCF (MCGF) gene and consists of a 4-kb intragenic deletion that removes sequences encoding the normal C-terminus of the SCF protein (Flanagan et al., 1991; Brannan et al., 1991). The new C-terminus of the mutant protein is taken from adjacent intron sequences, and the sld-allele-derived SCF no longer bears a transmembrane domain. The truncated SCF appeared to be fully biologically active, when measured as a mitogen on a murine mast cell line. Further, injection of sld/sldmice with pharmacological doses of a soluble form of SCF was able to partially rescue the hematopoietic defects in these mice
PROTEIN TYROSINE KINASE GFR
53
(Zsebo et al., 1990b).Thus, if there is biologically active SCF produced in the SId mutant mouse, why is the phenotype so severe? Although the answer to this question remains unknown, it is probable that the membrane-bound form of SCF is required during embryonic development, when the three classes of migratory cells are “in transit.” In this way, the location of the primordial germ cells and melanoblasts could be accurately defined so that their subsequent development proceeds properly. This sort of function could not be carried out by the soluble sId-derived SCF. After birth, however, the alleviation of the usually fatal macrocytic anemia that is characteristic of this mutant phenotype can be achieved by the soluble SCF, and the sId mutant therefore remains viable. Thus SCF may have multiple functions, both as a soluble growth factor and as a membrane-anchored growth factor. What has the detailed analysis of the S I and W loci and their incumbent growth factor and growth factor receptor genes taught us about the roles played by these classes of molecules in embryonic development? First, the impact of these mutations on developmental fate appears to differ with the cell type under consideration. Thus, W alleles can demonstrate severe defects in melanoblast migration and exhibit the macrocytic anemia characteristic of this mutant, but nonetheless remain fertile (Lyon and Searle, 1989). Whether this is a product of a combination of the reduced capacity of the mutant c-kit gene to transduce the appropriate signal coupled with a lack of availability of sufficient ligand in particular locations in the developing embryo, or is the result of a differential sensitivity of each of these classes of cells to the type of signal transmitted by the c-kit RTK, is at present unresolved. A third possibility would be the presence of an overlapping induction system (for example, in the migrating germ cell population) that could compensate, at least in part, for the reduced signaling capacity of the mutant c-kit protein. These issues remain to be resolved. Second, although the nature of the inductive event remains enigmatic, it appears likely that there exists a “gradient” of SCF ligand along which the migratory melanoblasts, germ cells, and hemopoeietic stem cells move. These cells appear to stop their migratory phase at locations of highest SCF levels, and begin to divide in these sites. Thus the c-kitlSCF interaction appears to have the effect of permitting the movement of these migratory cells, and ultimately fixing their correct position for an expansionary phase later in embryonic development. Although clearly present at the time of this expansionary phase, it is at present unknown whether c-kit and its ligand have a role to play in this process. Further, whether the apparent dependence of these cell migrations upon c-kit signaling is wrought as a consequence of a mitogenic effect of
54
ANDREW F. WILKS
this RTK or flows from a chemotactic response to the presence of SCF is equally mysterious. Third, the lack of an obvious neurological defect in W mice, despite strong evidence that both this RTK and its cognate ligand are expressed in the developing neural tube, appears to be at odds with the otherwise good correlation of the W phenotype with the expression pattern of the c-kit gene (Kishet et al., 1991). Although it is possible that such a defect would only manifest itself in the Wl W homozygote, and on this account may in fact be the cause of the lethality of such a genotype, it is equally plausible that the development of this particular tissue has a built-in level of redundancy, which secures its development even in the absence of the developmental cues usually transmitted by the c-kit gene product. Clearly, much work remains to be done to resolve these issues. 2. Patch (Ph) Patch (Ph) is a semidominant mutant of the mouse that arose spontaneously in the C57/BL strain. Mice heterozygous for the mutant patch allele have sharply defined white spots in the belt region, due to an absence of functional melanocytes in the torso and a somewhat deformed face, due to a wider prefrontal bone (Gruenberg and Truslove, 1960). Homozygous PhlPh mice do not survive to birth and usually die in utero sometime after Day 10 of embryonic life. Embryos that survive beyond Day 10 have profound deformities in the region of their snout and palate. T h e P h locus is on mouse chromosome 5 and is allelic to the receptor for platelet derived growth factor a (PDGFa-R) (Stevenson et al., 1991; Smith et al., 1991), which lies very close to the c-kit locus in both mouse and humans (Yarden et al., 1987; Lalley et al., 1989). Although the precise boundaries of the regions lost have not yet been mapped (D. Bowen-Pope, personal communication), the PDGFa-R is clearly absent, and the nearby c-kit gene remains unaffected. It nonetheless remains a formal possibility that there are other genes in addition to the PDGFa-R gene that are lost at the mutant locus, and whose loss may play a part in the establishment of the phenotype. PDGFa-R expression in the embryo follows a distinctive course, which to a greater or lesser extent is predictive of the phenotype of these mutants. For example, on the basis of in situ hybridization studies performed on the developing mouse embryo (D. Bowen-Pope, personal communication), most mesoderm-derived tissues appear to express the PDGFa-R. Rarely, tissues that are derived from the ectoderm, such as the lens of the eye and the choroid plexus, also express significant levels of PDGFa-R. Thus, PhlPh homozygotes reach several critical developmental stages beyond which only a proportion of them are able to proceed. By Embryonic Day 9, many of the
PROTEIN TYROSINE KINASE GFR
55
tissues derived from the mesoderm that express PDGFa-R in normal embryos have failed to develop appropriately. Approximately two-thirds of these PhlPh embryos die around this time. Surviving embryos manifest defects in many tissues derived from the mesoderm, including the heart, dermis of the skin, and tissues derived from the nonneurogenic cells of the neural crest. Defects in the ectodermally derived tissues normally expressing PDGFa-R, such as the lens and the choroid plexus, are also evident (D. Bowen-Pope, personal communication). The foregoing discussion of the patch phenotype, and its purported provenance as a null mutation in the PDGFa receptor gene, raises the question of functional redundancy of molecules such as these in development. The mere fact that one-third of PhlPh survive beyond Day 9 of embryogenesis in the complete absence of the PDGFol receptor suggests that the absence of a functional PDGFa receptor can be compensated for, to some extent, by other mechanisms. The further observation that only rarely do surviving embryos reach term, and that there is a progressive and continued loss of viability between Day 9 and term, suggests that there is no single crisis point reached by these embryos, but rather a gradual reduction in viability of their tissues. Thus, although functional redundancy is a strong candidate for the basis of the survival of these embryos, this process is highly inefficient and ultimately ineffective in reestablishing a normal developmental program in the PhlPh embryo. The semidominant nature of the W and patch mutants is particularly revealing of the biochemistry of RTK activity. Three alleles of W, namely W, Wx, and WlgH, are essentially null mutations of the c-kit locus (Geissler et al., 1988). Their dominant phenotype extends only to their effects on melanocyte migration and is due to haploinsufficiency of the remaining normal c-kit allele. Other alleles of W 1e.g. W4*, W3’, Wv, and W41 (Nocka et al., 1990)] have a more severe phenotype than the presumed null alleles mentioned above. The implication here is that the presence of a mutant version of the c-kit receptor suppresses even the reduced signal emanating from the normal gene product. In a functional sense this indicates that the normal and mutant proteins must interact with each other, either as dimers or as larger oligomers. This type of suppressive mutant gene product was termed an “antimorph” by Muller (1932), although in more current parlance the term “dominant negative mutant” (Herskovitz, 1987) seems to have replaced this original term. Recent work has demonstrated that many of the dominant W mutants are the product of point mutations in the coding sequence of the c-kit gene (Reith et al., 1990; Nocka et al., 1990; Tan et al., 1990).The molecular basis of their dominant effect appears to lie in the fact that each of these point mutations lies in an important segment of the PTK
56
ANDREW F. WILKS
catalytic domain of c-kit and results in the (usually) complete abrogation of the intrinsic kinase activity of the mutant proteins (Reith et al., 1990; Nocka et al., 1990). Upon mutual contact of the receptor and its ligand, a process of dimerization occurs, whereupon a process of cross-phosphorylation is initiated (Ullrich and Schlessinger, 1990). Failure to enact this cross-phosphorylation event results in failure to transmit an appropriate intracellular signal. Thus, equimolar quantities of mutant and normal c-kit receptor on the surface of a cell will produce only 25% functional dimers upon ligand activation, the remaining 75% being nonfunctional heterodimers o r mutant homodimers. Thus a greater severity of the W phenotype is observed in heterozygotes bearing antimorph alleles of c-kit than with null mutant heterozygotes. These data have been used to strengthen the case for ligand-induced receptor dimerization developed from purely biochemical studies in other systems (Ullrich and Schlessinger, 1990). MUTANTSOF B. DEVELOPMENTAL Drosophila Melanogaster
Our understanding of the genetics of D . melanogaster is more detailed than that of any other multicellular organism. T h e utility of D . wlanogaster as a system for the analysis of developmental programs stems from this fact coupled with the availability of sophisticated protocols capable of screening and propagating homeotic mutants and maternal effect zygotic mutants (Nusslein-Volhard and Wieschaus, 1980) and enhancers o r suppressors of these mutant loci (Strecker et al., 1991; Simon et al., 1991). In the light of the power of D . melanogaster as a tool for seeking genetic events that perturb development, it is not surprising that a proportion of these mutants are allelic to genes encoding RTKs. Drosophila RTK mutants include loss-of-function mutants such as jib (Nusslein-Volhard et al., 1984), torpedo (Schuepbach, 1987), and sevenless (Harris et al., 1976; Campos-Ortega et al., 1979) and gainof-function mutants, such as torso-D4021 (Sprenger et al., 1989) and ellipse (Baker and Rubin, 1989). Each mutant has been informative in framing our current notions of how members of the RTK family contribute to the process of embryogenesis, and are worth examination in some depth.
I . jlb, ellipse, and torpedo The D. melanogaster EGF receptor homolog (DER) (Livneh et al., 1985) is allelic to genetic loci of three Drosophila developmental mutants. These are faint little ball cflb) (Schejter and Shilo, 1989), torpedo (Price et al.,
PROTEIN TYROSINE KINASE GFR
57
1989),and ellipse (Baker and Rubin, 1989).jb is a loss-of-functionzygotic mutant whose complex phenotype affects all germ layers of the embryo. In severe alleles ofjb, anterior head structures fail to develop properly, most probably as a result of cell death rather than a defect in cell determination (Schejter and Shilo, 1989). Further, the germ band does not retract and the embryonic central nervous system does not develop appropriately. torpedo is a recessive female-sterile mutation (Schuepbach, 1987) that affects the pattern of the eggshells of homozygous females. Although demonstrably allelic to each other (Price et al., 1989), torpedo alleles are weaker than jlb alleles, and homozygous mutant flies survive to reproductive age. Female homozygous torpedo flies are nonetheless sterile due to their failure to establish the dorsoventral pattern of the eggshell and embryo. Thus DER appears to be involved in the establishment of this positional patterning, the loss of which is lethal to the developing embryo. These mutational analyses have been correlated with the expression pattern of DER (Katzen et al., 1991), wherein the differential regulation of the DER transcript during embryogenesis appears to explain the susceptibility of certain tissues to the pleiotropic effects of the mutant alleles. Similar studies on the expression pattern of the DER protein (Zak et al., 1990) underscore these findings. Thus, not surprisingly, widespread and pleiotropic effects appear to be the consequence of mutation at a widely expressed RTK locus.
2. sevenless In the developing compound eye of D. melanogaster, multipotent precursor cells undergo a timed series of inductive events, during which the coordinate production of 8 neuronal photoreceptor cells (six outer cells, Rl-R6, and two inner cells, R7 and R8) and 12 to 14 accessory cells, each held in a precise array, are produced in each ommatidium (Tomlinson, 1988; Ready et al., 1976) (see Fig. 4). Each eye bears around 800 such units. The retinal primordium is derived from the eye imaginal disc (Garcia-Bellidoand Merriam, 1969) and during the third-instar of larval development a wave of differentiation (called the morphogenic furrow) sweeps across the disc epithelium from posterior to anterior. Ahead of this furrow, the cells are undifferentiated and behind it the photoreceptor neurons Rl-R8 have already formed into the highly organized structure of the adult compound eye. The sequence of inductive events at the morphogenic furrow is as follows: The central R8 cell differentiates first, followed by the pairwise differentiation of the R2 and R5 cells, the R3 and R4 cells, and the R1 and R6 cells. The R7 cell, which lies touching the R8, R6, and R1 cells at the apex of the cluster of neuronal cells, is the last to undergo differentiation. As a developmental system,
58
ANDREW F. WILKS
time
1 I
I
I
I
I
3hr
6hr
9hr
12hr
15hr
I
I
*
FIG.4. Ommatidial development in Drosophzla melanogaster. A single ommatidium is shown. The initiation of each array begins with the determination of the R8 photoreceptor cell. This is followed after 5-6 hr by the R5 and R2 cells, and between 8 and 10 hr by the R4 and RS cells. The R1 and R 6 cells are determined 12 hr after the R8 cell, and finally the R7 cell after 15 hr. The sevenless phenotype occurs after failure of the R8 cell to induce photoreceptor differentiation in the R7 cell.
the fate of the R7 cell has been the focus of various elegant studies which have identified several genes that have a role to play in the induction of the appropriate developmental program in this cell. Two proteins in particular are central to the theme of this review; they are the product of the homeotic gene sevenless, an RTK, and its ligand, bride ofsevenless (also known as boss). T h e elegant studies performed in this system have shed light on some of the processes of embryonic induction, and in particular the role that the RTKs play in them. In the homeotic mutant sevenless the R7 cell fails to respond to its developmental cue and instead becomes a cone cell (Tomlinson and Ready, 1986). T h e sevenless protein bears all of the hallmarks of an RTK (Hafen et al., 1987; Bowtell et ul., 1988), albeit with an uncommon structure (Fig. 1). T h e sevenless gene encodes a protein of 2559 amino acids (290 kDa), with two putative transmembrane domains, one at the Nterminus of the protein, and a second located approximately 400 amino acids from the C-terminus of the protein (Bowtell et al., 1988). The PTK domain is situated within the intracellular C-terminal portion of the protein. T h e extracellular domain is more than 2100 amino acids (290 kDa) in length and is post-translationaly cleaved to two chains of 220 and 58 kDa after synthesis (Simon et ul., 1989).T h e mammalian RTK, ROS (Birchmeier et al., 1990; Matsushime and Shibuya, 1990), is structurally related to sevenless, although it appears to be functionally quite distinct and does not play an equivalent role in mammalian eye development.
PROTEIN TYROSINE KINASE GFR
59
Genetic mosaic analyses of the boss gene provided the first evidence that the R8 cell delivered an inductive cue for the R7 cell (Reinke and Zipursky, 1988). An immediate inference made from this observation was that the boss gene product was the ligand for the sevenless RTK. The molecular cloning of the boss gene (Hart et al., 1990) drew the surprising conclusion that the boss gene encoded a protein with seven putative membrane spanning domains and a large (498 amino acids) extracellular domain. Further work by the same group (Kraemer et al., 1991) elegantly demonstrated that the 120-kDa boss glycoprotein, when expressed in vitro on the surface of S2 cells, was able to mediate the homotypic aggregation of other S2 cells bearing the sevenless gene product. Further, the physical proximity of the two proteins on the adjacent surfaces of the R8 (boss-bearing) and the R7 (sevenless-bearing) cells (Kraemer et al., 1991) provided compelling evidence that these two proteins have the opportunity to interact with each other during the induction of R7 cells by their R8 neighbors. Thus, superficially,the induction of the R7 cell by the R8 cell appears to be a simple process requiring the expression of the sevenless receptor on the R7 cell and its inductive ligand, boss, on the R8 cell. However, several additional layers of complexity have been added to the picture, and some anomalies remain to be resdved. For example, at one time or another, all of the cells R1 through R6 express the sevenless gene, but these cells are unable to respond to the same inductive stimulus provided by the R8 cell in their midst. Second, expression of a ligandindependent activated sevenless protein in flies under the control of the sevenless promoter (Basler et al., 1991) results in the recruitment of many of the surrounding cone cells to an R7 fate; meanwhile, the R3 and R4 cells, which clearly express the activated sevenless protein, do not alter their fate. Further, the expression in flies of boss under a heat shock promoter is capable of recruiting cone cells, which surround the neuronal Rl-R8 cells, to adopt an R7 neuronal phenotype, although again, the Rl-R6 cells, which express the sevenless receptor, fail to change their own developmental fate (Van Vactor et al., 1991). It has therefore been postulated that although the sevenless receptor is sufficient to determine the fate of the R7 cell, this program is overridden in the Rl-R6 cells by a mechanism, or mechanisms, as yet unknown. These observations serve to underline the complexity of the inductive process, and demonstrate the importance of the hierarchical influences that impinge upon the ultimate fates of cells during organogenesis. Whether the bosslsevenless interaction is typical of a wider range of embryonic inductions is not known at present. Indeed whether this process can be said to be representative of growth factorlgrowth factor
60
ANDREW F. WILKS
receptor interactions in general is moot. Neither protein is typical of either of these two classes of molecule, nor is their interaction at the interface of the R8 and R7 cells mechanistically similar to, for example, the EGF/EGF receptor interaction, upon which biochemical basis many of our notions of this type of system have been developed. Moreover, whether the inductive event is a promotion of cellular growth at all (and therefore the act of a “growth factor”) is unlikely, since the presumptive R7 cell does not become extinct in the absence of the inductive event, but simply alters its developmental fate and becomes a cone cell. Thus, the activation of the sevenless PTK domain has a measurable impact on the fate of the R7 cell, an observation in apparent counterpoint to the role that the c-kit P T K domain presumably plays in the migration of melanoblasts in midgestation mouse embryos (see Section 111, A). Thus a wide range of apparently distinct cellular processes appear to be responsive to the catalytic activity wrought by the P T K domain of RTK family members.
IV. RTKs and Tumorigenesis Tumorigenesis is a complex multistep process, resulting from the accumulation of gain-of-function (or loss-of-function) mutations in genes whose gene products regulate cell growth and/or differentiation. Among the many protooncogenes described to date, a significant number of them encode either growth factors or growth factor receptors (Hunter, 1991). This is, perhaps, not surprising considering the pivotal role members of these two families play in signal transduction processes. The oncogenic capabilities of RTKs have generally been uncovered through one of two mechanisms: capture by an acutely transforming retrovirus (often coupled with subsequent mutation) or as a transforming gene in a 3T3-based transformation assay. In addition, RTKs have been detected at elevated levels in particular types of tumor [e.g., NEU (Slamon et al., 1987, 1989; Hung, 1988; Zhang et al., 1989). Table I lists the RTKs implicated in the etiology of various tumors and the presumed molecular basis for their activation. In summary, in order to transform cells, RTKs may be overexpressed (Slamon et al., 1987, 1989; Hung, 1988; Zhang et al., 1989) and/or inappropriately expressed (Janssen et al., 1991; O’Bryan et al., 1991) or be expressed in a ligand-independent activated form (Martin-Zanca et al., 1986). In this review, several aspects of the oncogenicity of members of the RTK family will be considered. Discussion of the signal transduction pathways downstream of the activated receptor are expressly absent
61
PROTEIN TYROSINE KINASE GFR
TABLE I IMPLICATED IN TUMORICENESIS RTK ONCOGENES Type of tumor
Oncogene EGF receptor NeU
trk
i. Squamous cell carcinoma
Amplification (1)
ii. Astrocytoma
Amplification (2)
i. Neuroblastoma (carcinogen induced) ii. Breast carcinoma i. Colon carcinoma ii. Breast carcinoma
RET ROS K-sam arllUF0
Mode of activation
iii. Breast carcinoma iv. Papillary thyroid carcinoma Papillary thyroid carcinoma Astrocytoma Carcinoma of the stomach Chronic myeloid leukemia
Point mutation in
T M domain (3) Amplification (4) Rearrangement (5) Rearrangement (6)* Rearrangement (7)* Rearrangement (8) Rearrangement (8,9) Rearrangement ( 10) Amplification ( 1 1) Overexpression (12)
Note. The involvement of certain RTKs, and their apparent mode of activation, for a number of different tumors is shown. References for each of these relationships are as follows: 1. Ishitoya et al. (1989); 2. Burgart el al. (1991); 3. Bargmann elal. (1986); 4. Slamon et al. (1989); 5. Martin-Zanca et al. (1986); 6. Kozma et al. (1988); 7. Ziemiecki el al. (1990); 8. Bongarzone et al. (1989); 9. Grieco et al. (1990); 10. Fasanoetal. (1984); 11. Nakatanietal. (1990); 12. OBryanetal. (1991);Janssenetal. (1991). The asterisks denote RTKs rearranged as part of the transformation process.
from the material presented here. These important aspects of the subject have been well reviewed in other articles (e.g., Cantley et al., 1991). Instead, this section will focus on the structural alterations associated with the acquisition of oncogenicity by members of this class of proteins. A. RTKs
AS RETROVIRAL ONCOGENES
The capture of RTK sequences into the genomes of acutely transforming retroviruses has been one of the predominant mechanisms by which these molecules become overexpressed or inappropriately expressed. For example, the RTKs erbB (chicken) (Ullrich et al., 1984),sea (chicken) (Smith et al., 1989), kit (feline) (Besmer et al., 1986a), and fm (feline) (Hampe et al., 1982) were first uncovered in this fashion. Both overexpression and mutation appear to be features of the RTK sequences captured by retroviruses. N-terminal truncations, which usually remove a significant portion of the extracellular ligand-binding domain
62
ANDREW F. WILKS
are found in v-kit (Besmer et al., 1986a), v-erbB (Ullrich et al., 1984), and v-sea (Smith et al., 1989). This is presumably part of the mechanism whereby the RTK is rendered free of the requirement for its ligand to activate it. T h e absence of a ligand-binding domain is often accompanied by its replacement with viral sequences, such as the gag protein [e.g., ROS (Neckamayer and Wang, 19851 and the e m protein [e.g., sea (Smith et al., 1989)l. There is some limited evidence that mere truncation may be insufficient to render certain RTKs tumorigenic. For example, deletion of the extracellular domain of the insulin receptor was unable to ftransform chicken embryo fibroblasts (Poon et a!., 1991). In contrast, the same deletion with an added N-terminal gag sequence was able to render these cells fully transformed, suggesting that the viral gag component had a role other than the mere provision of a translation start codon (Poon et al., 1991). The C-terminus of an RTK often bears regulatory elements, such as tyrosine autophosphorylation sites (Ellis et al., 1986; Margolis et al., 1989; reviewed in Ullrich and Schlessinger, 1990). Truncation of the Cterminus is thus, not surprisingly, a feature of several retroviral transduction events. For example, the v f m proteins borne by the feline acutely transforming retroviruses SM-FeSV (McDonough et al., 197 1; Donner et al., 1982) and HZ-5 (Besmer et al., 1986b) each bear deletions at their C-termini, compared with the cfm protein. Although these deletions remove negative regulatory elements (Browning et al., 1986; Roussel et al., 1987), they were unable to unleash the transformation potential of c-fms (Roussel et al., 1990), suggesting that the trigger of the ligand-independent signal transmitted by the oncogenic forms of this protein lay elsewhere in the protein. Intriguingly, a single point mutation, in the region of the v-fms gene that codes for the extracellular domain of this protein, was able to confer transforming ability to an otherwise wild-type cfm protein (Roussel et al., 1990). T h e conversion of the wild-type leucine residue, located at position 301 in the extracellular domain of this protein, to a serine, threonine, glutamic acid, or proline rendered the human CSF 1 receptor capable of transforming murine 3T3 cells. Thus, the oncogenic potential of the cfm gene was unmasked by the combination of an N-terminal point mutation, probably coupled with a C-terminal deletion. T h e rigors of capture by a retroviral genome are highly likely to lead to point mutation and deletion in any gene so transduced, and the selection procedure for oncogenic transformations is very sensitive. In the light of such highly mutagenic mechanisms, whether there is a role for RTKs in nonviral tumorigenesis is a legitimate question.
PROTEIN TYROSINE KINASE GFR
63
B. RTKs AS CELLULAR ONCOGENES 1 . Rearrangement of RTK Genes The development of DNA transfection techniques (Graham and Van der Eb, 1973; Shih et al., 1979; Krontiris and Cooper, 1981; Murray et al., 1981; Perucho et al., 1981)provided a significant leap forward in the isolation of many of the genes capable of transforming cells. Several loci encoding proteins with all of features of growth factor receptors were isolated from the DNA of tumors in this way. These include MET (Cooper et al., 1984), NEU (Schechter et al., 1984, 1985; Hung et al., 1986; Bargmann et al., 1986a), trk (Martin-Zanca et al., 1986; Kozma et al., 1988), RET (Takahashi et al., 1985; Takahashi and Cooper, 1987), ROS (Fasano et al., 1984; Birchmeier et al., 1986)and ajcllUF0 (O’Bryan et al., 1991; Janssen et al., 1991) (see Table I). Some RTK loci seem to be, in some degree, intrinsically unstable. Both trk (Oskam et al., 1988; Kozma st al., 1988) and RET (Ishizaka et al., 1989; Koda, 1988) have been demonstrated to undergo an oncogenic rearrangement during the process of transfection into the recipient 3T3 cells. The original trk oncogene (trk-lh)was generated by rearrangement of the trk locus with the gene for nonmuscle tropomyosin (Martin-Zanca et al., 1986). Subsequently, fusion proteins of trk with a portion of the ribosomal protein L7a (trk-2h) (Kozma et al., 1988) and a second unknown protein (Kozma et al., 1988) were also isolated after transfection of NIH/3T3 cells. In the case of the activation of RET, there also appears to be some degree of instability intrinsic to the locus encoding this RTK gene. Initial studies demonstrated that the gene became truncated and activated after, and possibly as a consequence of, the transfection process. In one case, in a human T-cell lymphoma, the RET gene fused with a putative zinc finger protein, fp, to form a fusion protein with PTK activity (Takahashi et al., 1988). Subsequently, the RET gene was found to be rearranged following, but not preceding, transfection of DNAs from a human gastric carcinoma (Ishizaka et al., 1989) and a human colon carcinoma (Koda, 1988). In papillary thyroid carcinoma, however, the bona fide oncogenic potential of the human RET locus was uncovered after transfection into 3T3 cells (Grieco et al., 1990). In this case, whether a truncated RET gene product is formed, or a fusion protein with an as yet uncharacterized 5’ partner, is not known. It is intriguing to note that the location of the most extreme portion of the RET protein that remains in the oncogenic version of this protein is only 13 amino acids N-terminal of the ATP binding site of the catalytic domain and corresponds to the location of a splicejunction (Ishizaka et al.,
64
ANDREW F. WILKS
1989). No suitable AUG start codon appears to be present in the portion of the RET protein remaining at the mutated locus, suggesting that this may come from the upstream fusion partner and be spliced into place after transcription. In all cases where a fusion protein is formed from the junction of a RTK and another cellular sequence, the P T K domain is always located at the C-terminus of the protein and never at the Nterminus. 2 . Amplification of RTK Genes Amplification of RTK genes appears to be another mechanism whereby these genes can be rendered oncogenic. T h e oncogene K-sum, for example, was discovered as a component of a highly amplified region of the genome of a stomach-cancer-derived cell line KATO-I11 (Hattori et al., 1990). This gene bears considerable similarity to members of the FGF receptor family (see Section 11). Although highly tentative, the murine gene bek (Kornbluth et al., 1988) appears to be the most similar to the K-sum sequence. Amplification of the K-sum gene appears to be restricted to poorly differentiated types of stomach cancer (Nakatani et al., 1990). T h e normal K-sum transcripts are 4.5-kb mRNA with a minor component at 3.5 kb. Amplification of the K-sum gene results in the highly abundant expression of the 3.5-kb transcript. There does not appear to be any mutation present in the K-sum mRNA that could explain its oncogenicity, and it is presumed that overexpression of this gene is all that is required. Reports of amplification of other members of the FGF receptor family in breast carcinoma (Adnane et al., 1991) confirm the possible importance of this type of event in the etiology of a significant proportion of tumors. In this study, bek andflg were found to be amplified in 11.5 and 12.5% of breast tumors, respectively. In this case, correlation with prognosis had not been accomplished. T h e NEU (c-erbB2 or HER-2) protooncogene was first identified (Schechter et al., 1984, 1985; Hung et al., 1986; Bargmann et al., 1986a) by transfection of DNA from chemically induced neuroglioblastomas in a 3T3 transformation assay similar to that described above. The NEU protein is a member of the EGF receptor family (Class I RTK), and several candidate ligands have been detected for it (Lupu et al., 1990; Tarakhovsky et al., 1991). Remarkably, the mutated, and oncogenic, version of the rat NEU gene differs by only a single point mutation (a valine to glutamic acid alteration in the transmembrane domain) from the normal allele (Bargmann et al., 1986b). In one study, four independent cell lines containing activated rat NEU alleles bore exactly the same activating point mutation (Bargmann et al., 1986b), suggesting that there
PROTEIN TYROSINE KINASE GFR
65
are only a limited number of mutagenic events capable of oncogenically activating this RTK. The human NEU gene also has oncogenic potential. In one particular study, amplification of the NEU gene was detected in 28% of 189 primary breast cancers (Slamon et al., 1987) and a correlation between NEU amplification and poor prognosis was observed. An extended study by the same authors examined the status of the NEU gene in patients with breast cancer or ovarian cancer (Slamon et al., 1989). The amplification of NEU was demonstrated to be a strong indicator of both future relapse and/or survival in these patients. The absence of any alteration in the coding sequence of NEU transcripts isolated from tumors, most notably the activating point mutation detected in the rat system, suggested that the oncogenic potential of the NEU gene product was a function of its overexpression. Moreover, the raised levels of NEU protein detected in these tumors were often not accompanied by amplification of the NE U gene. The demonstration that overexpression of the normal NEU gene could transform 3T3 cells to tumorigenicity provides an in vitro correlate of the in vivo situation (Bargmann et al., 1986b). Overexpression of an otherwise normal receptor thus appears to be the mode of activation of several RTKs. The protooncogene axllUF0 (Janssen et al., 1991; OBryan et al., 1991) is a growth factor receptor uncovered as the transforming gene of two (of eight) (O'Bryan et al., 1991) or a single (Janssen et al., 1991) primary human chronic myeloid leukemias. Overexpression of this gene in murine 3T3 cells appears to be sufficient to transform these cells to a tumorigenic phenotype. In other studies, overexpression of other RTKs results in neoplastic transformation of recipient cells [e.g., EPH (Maru et al., 19901. Although the cognate ligand of the axl or the EPH receptors are unknown it may be that an autocrine loop is established, indeed in the case of the ax1 gene, the overexpression of this gene appears only to be a feature of CML and no other tumors (OBryan et al., 1991), suggesting that a downstream (i.e., intracellular signal transduction event) or an upstream (i.e., ligand binding) event is a feature of this type of cell alone. It may be that coexpression of the ligand for this receptor is thus required before the transforming capacity of the ax1 protooncogene reveals itself. V. Genetics and Cancer
One fascinating example of the transformation potential of RTKs is demonstrated by the Tu locus in Xiphophow hybrids (Wittbrodt et al., 1989). The platyfish X . maculatus and the swordtail X . helleri are related
66
ANDREW F. WILKS
species, each of which are normally uniformly gray in coloration. Certain varieties of X . muculatus, however, bear spot patterns (macromeianophores) arising from large accumulations of the melanocytic pigment cells from which they derive their normal grey body colouration. In cross-breeding experiments between grey X . hellerz and spotted X . maculatus, these macromelanophores develop into malignant melanoma. The genetic locus encoding the dominant oncogene Tu, whose activity becomes derepressed in these hybrids, has been demonstrated to be an RTK similar in structure to the EGF receptor. This protooncogene has been designated Xmrk, for X i p h o p h o m melanoma receptor tyrosine kinase (Wittbrodt et al., 1989). The precise genetics of the melanoma produced as a result of the unmasked expression of the Xmrk remain to be elucidated; however, genetic analyses suggest that the oncogenic potential of the Xmrk gene is suppressed in the X . muculatus background by a repressor, “R,” which is absent in the X . helleri background. The Xmrk locus thus encodes an activated RTK whose tumorigenic potential is suppressed in wild-type platyfish. The fine genetics of the Xmrk locus are complex and still remain to be fully resolved. The Xmrk genes are borne on the X and Y chromosome of the platyfish. A third copy is present on one of the autosomes. The oncogenic activation of Xmrk appears to be a consequence of the overexpression of the Xmrk gene, due to transcriptional activation (Adam et al., 1991). In tumor-prone animals, a 5.8-kb transcript from one of the Xmrk genes is accompanied by an apparently tumor-specific 4.7-kb transcript (Adam et al., 1991). The smaller mRNA may be derived from a tumor-specific promotor, or may be the product of premature termination/poIyadenylation of the Xmrk transcript. Thus, since the tumorigenic Xmrk protein is essentially identical to the protein produced in the non-tumor-prone genetic background, the transformation process appears to be dependent solely upon the unregulated expression of this RTK. In the Xzphophorus system, the genetic predisposition of certain strains to melanoma appears to be due to the absence of a protein that controls the expression of the oncogenic form of the Xmrk gene. However, overexpression of RTKs is a feature of several mammalian tumors. Thus, the overexpression of otherwise structurally normal RTKs, such as ax1 (Janssen et al., 1991; O’Bryan et al., 1991),NEU (Slamon et al., 1987, 1989), and EPH (Hirai et al., 1987), may be a product of the mutation of an erstwhile transcriptional regulator. These “indirect” events have yet to be described, but are likely to be a feature of turnongenesis involving RTKs and other protooncogenes.
PROTEIN TYROSINE KINASE GFR
67
ACKNOWLEDGMENTS I thank Dr. Helen Cooper and Dr. Steven Stacker for reading early drafts of this review, and for suggesting improvements.
REFERENCES
Aaronson, S. A. (1991). Science 254, 1146-1153. Adam, D., Maeueler, W., and Schartl, M. (1991). Oncogene 6,73-80. Adnane, J., Gaudray, P., Dionne, C. A., Crumley, G., Jaye, M., Schlessinger,J., Jeantuer, P., Birnbaum, D., and Theillet, C. (1991). Oncogene 6,659-663. Anderson, D. M., Lyman, S. D., Baird, A., Wignall, J. M., Eisenmann, J., Rauch, C., March, C. J., Boswell, H. S., Gimpel, S. D., Cosman, D., and Williams, D. E. (1990). Cell (Cambridge, Mars.) 63, 235-243. Aroian, R. V., Koga, M., Mendel, J. E., Oshima, Y.,and Sternberg, P. W. (1990). Nature (London) 348, 693-699. Baker, N. E., and Rubin, G. M. (1989). Nature (London) 340, 150-153. Bargmann, C. I., Hung, M.-C., and Weinberg, R. A. (1986a). Nature (London) 319, 226230. Bargmann, C. I., Hung, M.-C., and Weinberg, R. A. (1986b). Cell (Cambridge, Mass.) 45, 649-657. Basler, K., Christen, B., and Hafen, E. (1991). Cell (Cambridge, Mars.) 64, 1069-1081. Bauskin, A. R., Alkalay, I., and Ben-Neriah, Y. (1991). Cell (Cambridge, Mass.) 66,685-696. Bennett, D. (1956).J. Morphol. 98, 199-233. Bernstein, S. E. (1960). Mouse News Lett. 23, 33-34. Besmer, P., Murphy, J. E., George, P. C., Qui, F., Bergold, P. J., Lederman, L., Snyder, H. W., Jr., Brodeur, D., Zuckerman, E. E., and Hardy, W. D. (1986a).Nature (London) 320, 415-421. Besmer, P., Lader, E., George, P. C., Bergold, P. J., Qui, F.-H., Zuckerman, E. E., and Hardy, W. D., Jr. (1986b).J. Virol. 60, 194-203. Birchmeier, C., Birnbaum, D., Waitches, G., Fasano, O., and Wigler, M. (1986).Mol. Cell. Biol. 6, 3109-3116. Birchmeier, C., ONiell, K., Riggs, M., and Wigler, M. (1990).Proc. Natl. Acad. Scz. U . S . A. 87,4799-4803. Bishop, J. M. (1991). Cell (Cambndge, Mass.) 64,235-248. Bongarzone, I., Pierotti, M. A., Monzini, N., Mondellini, P., Manenti, G., Donghi, R., Pilotti, S., Grieco, M., Santoro, M., Fusco, A., Vecchio, G., and Della Porta, G. (1989). Oncogene 4, 1457-1462. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecick, T. E., Vande Woude, G. F., and Aaronson, S. A. (1991). Sczence 251, 802-804. Bowtell, D. D. L., Simon, M. A., and Rubin, G. M. (1988). Genes Dev. 119,620-634. Boyd, A. W., Ward, L. D., Wicks, I. P., Simpson, R. J., Salvaris, E., Wilks, A. F., Welch, K., Loudovaris, M., Rockman, S., and Busemanis, 1. (1992).J. Btol. Chem. 267,3262-3267. Brannan, C . I., Lyman, S. D., Williams, D. E., Eisenman, J., Anderson, D. M., Cosman, D., Bedell, M. A., Jenkins, N. A., and Copeland, N. G. (1991).Proc. Natl. Acad. Sci. U . S . A . 88,4671-4674. Browning, P. J., Bunn, H. F., Cline, A., Shuman, M., and Nienhius, A. W. (1986).Proc. Natl. Acad. SCZ.U . S.A. 83, 7800-7804.
68
ANDREW F. WILKS
Burgart, L. J., Robinson, R. A., Haddad, S. F., and Moore, S. A. (1991).Mod. Pathol. 4, 183186. Camps-Ortega, J. A., Juergens, G., and Hofbauer, A. (1979). Wilhelm Roux’s Arch. DEW. BWl. 186, 27-50. Cantley, L. C.. Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991). Cell (Cambndge, Mass.) 64, 281-302. Chabot, B., Stevenson, D. A., Chapman, V. M., Besmer, P., and Bernstein, A. (1988). Nature (London) 335, 88-89. Chan, J., and Watt, V. M. (1991). Oncogene 6, 1057-1061. Claesson-Welsh, L., Eriksson, A., Westermark, B., and Heldin, C.-H. (1989). Proc. Nutl. A c ~S.C ~U. . S . A. 86, 4917-4921. Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., and Vande Woude, G. F. (1984). Nature (London) 311, 29-33. Copeland, N. G., Gilbert, D. J., Cho, B. C., Donavon, P. J., Jenkins, N. A., Cosman, D., Anderson, D. M., Lyman, S. D., and Williams, D. E. (1990). Cell (Cambdge, Mass.}63, 175- 183. Cordon-Cardo, C., Tapely, P., Jing, S., Nanduri, V., ORourke, E., Lamballe, F., Kovary, K., Klein, R., Jones, K. R., Reichardt, L. F., and Barbacid, M. (1991). Cell(Cambndge, Mass.) 66, 173-183. Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R. L., Isacke, C. M., Verma, 1. M., and Ullrich, A. (1986). Nature (London} 320,277-280. Cross, M., and Dexter, T. M. (1991). Cell (Cambridge, Mass.) 64, 271-280. Donner, L., Fidele, L. A., Garon, C. F., Anderson, S. J., and Sherr, C. J. (1982).J. Virol. 41, 489-500. Donovan, P. D., Stott, D., Cairns, L. A., Heasman, J., and Wyhe, C. C. (1986). Cell (Cambridge, M a s . ) 44,831-838. Ebina, Y., Ellis, L., Jarnagin, K., Edery, M., Graf, L., Clauser, E., Ou, J.-H., Masiarz, F., Kan, Y. W., Godfine, I. D., Roth, R. A., and Rutter, W. J. (1985). Cell (Cambndge, Mass.) 40,747-758. Ellis, L., Clauser, E., Morgan, D. O., Edery, M., Roth, R. A., and Rutter, W. 1. (1986). Cell (Cambndge, Mass.)45, 721-732. Fasano, 0..Birnbaum, D., Edlund, L., Fogh, J., and Wigler, M. (1984). Mol. Cell. Biol. 4, 1695-1705. Flanagan, J. G.. and Leder, P. (1990). Cell (Cambridge, Mass.)63, 185-194. Flanagan,]. G., Chan, D. C., and Leder, P. (1991). Cell (Cambridge, Mass.)64, 1025-1035. Fleischman, R. A., Saltman, D. L., Stastny, V., and Zneimer, S. (1991). Proc. Nutl. Acad. Sci. L’. S . A. 88, 10885-10889. Garcia-Bellido, A., and Merriam, J. R. (1969).J. Exp. 2001.170, 61-76. Geissler, E. N., McFarland, E. C., and Russell, E. S. (1981). Genetics 97, 337-361. Ceissler, E. N., Ryan, M. A., and Houseman, D. E. (1988). Cell (Cambridge, Mass.) 55, 185192. Giebel, L. B., and Spritz, R. A. (1991). Proc. Natl. Acad. Sci. U.S . A. 88, 8696-8699. Glazer, L., and Shilo, B.-Z. (1991). Genes Dev. 5,697-705. Graham, F. L., and Van der Eb, A. J. (1973). Virology 52,456-463. Grieco, M., Santoro, M.,Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Porta, G., Fusco, A., and Vecchio, G. (1990). Cell (Cambridge, Mass.) 60,557-563. Gruenberg, H. (1942).J. Genet. 43,285-293. Gruenberg, H., and Truslove, G. M. (1960). Genet, Res. 1,69-90. Hafen, E., Basler, K., Edstrom, J. E., and Rubin, G. M. (1987). SCrence 236, 55-63.
PROTEIN TYROSINE KINASE GFR
69
Hampe, A., Laprevotte, I., Galibert, F., Fedele, L. A., and Sherr, C. J. (1982). Cell (Cambridge, Mars.) 30, 775-785. Hanks, S . K., and Quinn, A. M. (1991).In “Methods in Enzymology”(T. Hunter and B. M. Sefton, eds.), 200, 38-61. Academic Press, San Diego. Hanks, S. K., Quinn, A. M.,and Hunter, T. (1988). Science 441, 42-52. Harris, W. A., Stark, W. S., and Walker, J. A. (1976).J. Physiol. (London) 456, 415-439. Hart, A. C., Kraemer, H., Van Vactor, D. L., Jr., Paidhungat, M., and Zipursky, S. L. (1990). Genes Dev. 4, 1835-1847. Hattori, Y., Odigari, H., Nakatani, H., Miyagawa, K., Naito, K., Sakamoto, H., Katoh, O., Yoshida, T., Sugimora, T., and Terada, M. (1990). Proc. Natl. Acud. Sci. U . S . A. 87, 5983-5987. Herskovitz, I. (1987). Nature (London) 349, 219-222. Hirai, H., Maru, Y., Hagiwara, K., Nishida, J., and Takaku, F. (1987). Science 238, 17171720. Holgren, L., Glaser, A., Pfeifer-Ohlsson, S., and Ohlsson, R. (1991). Develqpment (Cambridge, U K ) 113,749-754. Huang, E., Nocka, K., Beier, D. R., Chu, T.-Y., Buck, J., Lahm, H.-W., Wellner, D., Leder, P., and Besmer, P. (1990). Cell (Cambridge, M m . ) 63, 225-233. Hung, H.-C. (1988). Cancer Bull. 40, 300-303. Hung, H.-C., Schecter, A. L., Chevray, P.-Y., Stern, D. F., and Weinberg, R. A. (1986).Proc. Natl. Acud. Sci. U.S . A . 83, 261-264. Hunter, T. (1991). Cell (Cambridge, Mars.) 64, 249-270. Ishitoya, J., Toriyama, M., Oguchi, N., Kitamura, K., Ohshima, M.,Asano, K., and Yamamoto, T. (1989). Br. J. Cancer 59, 559-562. Ishizaka, F., Takaku, F., Nagoa, M., and Sugimora, T. (1989). Ontogene 4, 789-794. Janssen, J. W. G., Schultz, A. S., Steenvoorden, A. C. M., Schmidtberger, M., Strehl, S., Ambros, P. F., and Batram, C. R. (1991). Oncogene 6, 2113-2120. Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., and Parada, L. F. (1991a). Science 252,554-557. Kaplan, D. R., Martin-Zanca, D., and Parada, L. F. (1991b).Nature (London) 350, 158-160. Katzen, A. L., Kornberg, T., and Bishop, J. M. (1991). Dev. Bzol. 145, 287-301. Keegan, K., Johnson, D. E., Williams, L. T., and Hayman, M. J. (1991).Proc. Natl. Acud. Sn‘. U.S . A. 88, 1095-1099. Kishet, E., Lyman, S. D., Williams, D. E., Anderson, D. M., Jenkins, N. A., Copeland, N. G., and Parada, L. F. (1991). EMBOJ. 10, 2425-2435u. Klein, R., Parada, L. F., Coulier, F., and Barbacid, M. (1989). EMBOJ. 8, 3701-3709, Klein, R., Jing, S., Nanduri, V., ORourke, E., and Barbacid, M. (1991a). Cell (CamMge, M a s . ) 65, 189-197. Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapely, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., and Barbacid, M. (1991b).Cell (Cambridge, Mars.) 66,395403. Koda, T. (1988). Hokhaida. Med. Sci. 63, 913-924. Kornbluth, S., Paulson, K. E., and Hanafusa, H. (1988). Molec. Cell. Bwl. 8, 5541-5544. Kozma, S. C., Redmond, S. M.S., Xiano-Chang, F., Saurer, S. M.,Groner, B., and Hynes, N. E. (1988). EMBOJ. 7, 147-154. Kraemer, H., Cagan, R. L., and Zipursky, S. L. (1991). Nature (London) 354, 207-212. Kraus, M. H., and Aaronson, S. A. (1991).In “Methods in Enzymology”(T. Hunter and B. M. Sefton, eds.), 200, pp. 546-556. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. (1989). Proc. Natl. Atad. Sci. U . S . A. 86,9193-9197.
70
ANDREW F. WILKS
Krontiris, T. G., and Cooper, G. M. (1981). Proc. Natl. A c d . Scz. U . S. A. 78, 1181-1184. Lalley, P. A . , Davisson, M. T., Graves, J. A. M., OBrien, S. J., Womack, J. E., Roderick, T. H., Creau-Goldberg, N., Dooloittle, A. L., and Rogers, J. A. (1989). Cytogenet. Cell Genet. 51, 503-532, Lamballe, F., Klein, K.,and Barbacid, M. (199I). Cell (Cambridge, Mass.) 66, 967-979. Lee, P. L., Johnson, D. E., Cousens, L. S., Fried, V. A., and Williams, L. T. (1989). Science 245, 57-60, Letwin, K., Yee, S.-P., and Pawson, T. (1988). Oncogene 3,621-627. Lhotak, V., Greer, P., Letwin, K., and Pawson, T. (1991). Mol. Cell. Biol. 11, 2496-2502. Lindberg, R. A., and Hunter, T. (1990). Mol. Cell. Bzol. 10, 631645324, Lindberg. R.A., and Pasquale, E. B. (1991). In “Methods in Enzymology” (T. Hunter and B. M. Sefton, eds.), 200, pp. 557-564. Academic Press, San Diego. Lindberg, R. A,, Thompson, D. P., and Hunter, T. (1988). Oncogene 3, 629-633. Little, C. C. (1915). A m . Nat. 49, 727-740. Livneh, E., Glazer, L., Segal, D., Schlessinger, J., and Shilo, B.-Z. (1985). Cell (Cambridge, Mus.) 40, 599-607. Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., and Lippman, M. E. (1990). SciPnce 249, 1552-1555. Lyon, M . F., and Searle, A. G. (1989). “Genetic Variants and Strains of the Laboratory Mouse,” 2nd ed. Oxford Univ. Press, London and New York. Margiolis, B. L., Lax, I., Kris, R., Dombalagian, M., Honegger, A. M., Hawk, R.,Givol, D., Ullrich, A., and Schlessinger, J. (1989).J. Biol. Chem. 264, 10667-10671. Martin, F. H.. Suggs, S. V., Langley, K. E., Lu, H. S., Ting, J., Okino, K., Morris, C. F., McNiece, I., Jacobsen, F. W., Mendiaz, E. A., Birkett, N. C., Smith, K. A., Johnson, M. J.. Parker, V. P., Flores, J. C., Patel, A. C., Fisher, E. F., Erjavec, H. O., Herrera, C. J., Wypych, J., Sachdev, R. K., Pope, J. A., Leslie, I., Wen, D., Lin, C.-H., Cupples, R. L., and Zsebo, K. M. (1990). Cell (Cambndge, iMass.) 63, 203-21 1 . Martin-Zanca, D., Hughes, S. H., and Barbacid, M. (1986). Nature (London) 319, 743-748. Martin-Zanca, D., Barbacid, M., and Parada, L. F. (1990a). Genes Dev. 4, 683-694. Martin-Zanca, D., Oskram, D. R., Mitra, G., Copeland, T., and Barbacid, M. (1990b).Mol. Cell. Bwl. 9, 24-33. Maru, Y., Hirai, H., and Takaku, F. (1990). Oncogene 5, 445-447. Matsushime. H., and Shibuya, M. (199O).J. Virol. 64,2117-2125. Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D., and Lemischka, I. R. (1991a).Cell (Cambndge, illass.) 65, 1143-1 152. Matthews, W., Jordan, C. T.,Gavin, M., Jenkins, N. A., Copeland, N. G., and Lemishka, I. R. (1991b). Proc. Nutl. Acad. Scz. U . S. A. 88, 9026-9030. McDonough, S. K., Larsen, S., Brody, R. S., Stock, N. D., and Hardy, W. D., Jr. (1971). Cancer Res. 31, 953-956. Mintz, B.. and Russell, E. S. (1957).J. Exp. Zool. 134, 207-237. Morgan, J. (1786). Trans. A m . Philos. SOC.2, 392-395. Muller, H. J. (1932). Pror. 6th Int. Congr. Genet., 6th, I932 Vol. 1, pp. 213-255. Murray, M. J., Shilo. B.-Z., Shih, C., Cowing, D., Hsu, H. W., and Weinberg, R. A. (1981). Cell (Cambndge, Mass.) 25, 355-361. Musci, T. J., Amaya, E., and Kirschner, M. W. (1990). Proc. Natl. Acad. Sci. CJ. S . A. 87, 8365-8369. Nakatani, H., Sakamoto, H., Yoshida, T., Yokota, J., Tahara, E., Sugimura, T., and Terada, M. (199O).Jp.J . Cancer Res. 81, 707-710. Naldini, L., Vigna, E., Narshiman, R., Gaudino, G., Zarnegar, R., Michalopoulos, G., and Comoglio, P. M. (1991). Oncogme 6, 501-504.
PROTEIN TYROSINE KINASE GFR
71
Neckarnayer, W. S., and Wang, L.-H. (1985).J. Virol. 53, 879-884. Niwa, Y., Kasugai, T.,Ohno, K., Morimoto, M., Yamazaki, M., Dohmae, K., Nishimune, Y., Kondo, K., and Kitamura, Y. (1991). Blood 78, 1936-1939. Nocka, K., Tan, J. C., Chiu, E., Chu, T. Y., Ray, P., Traktman, P., and Besmer, P. (1990). E M B O J . 9, 1805-1813. Noda, M., Shizimu, S., Tanabe, T., Takai, T., Ikeda, T., Takahashi, H., Nakayama, H., Kanaoka, Y.,Minamino, N., Kangawa, K., Matsuo, H., Raftery, Hirose, T., Inayama, S., Hayashida, H., Miyata, T., and Nurna. S. (1984). Nature (London) 312, 121-127. Niisslein-Volhard, C., and Wieschaus, E. (1980). Nature (London) 287, 795-801. Niisslein-Volhard, C., Wieschaus, E., and Kluding, H. (1984). Wilhelm Ruux’s Arch. Dev. Biol. 193, 267-282. OBryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C., Espinosa, R., 111, Le Beau, M. M., Earp, H. S., and Liu, E. T. (1991). Mol. Cell. Biol. 11, 50165031. Oskam, R., Coulier, F., Ernst, M., Martin-Zanca, D., and Barbacid, M. (1988). Proc. Natl. Acad. Sti. U . S. A . 85, 2964-2968. Partanen, J., Makela, T. P., Eerola, E., Korhonen, J., Hirvonen, H., Claesson-Welsh, L., and Alitalo, K. (1991). E M B O J . 10, 1347-1354. Pasquale, E. B. (1990). Proc. Natl. Acad. Sci. U.S . A . 87, 8913-8917. Perucho, M., Goldfarb, M., Shizirnu, K., Lama, C., Fogh, J., and Wigler, M. (1981). Cell (Cambridge, Mass.) 27, 467-476. Poon, B., Dixon, D., Ellis, L., Roth, R. A., Rutter, W.J., and Wang, L.-H. (1991). Proc. Natl. Acad. Sci. U . S. A . 88, 877-881. Price, J. V., Clifford, R. J., and Schuepbach, T. (1989). Cell (Cambruige, Mass.) 56, 10851092. Ready, D. F., Hanson, T. E., and Benzer, S. (1976). Dev. Biol. 53,217-240. Regenstreif, L. J. and Rossant, J. (1989). Dev. Biol. 133, 284-294. Reid, H. H., Wilks, A. F., and Bernard, 0. (1990). Proc. Natl. Acad. Sci. U . S. A. 87, 15961600. Reinke, R., and Zipursky, S. L. (1988). Cell (Cambruige, Mass.) 55, 321-330. Reith, A. D., Rottapel, R., Giddens, E., Brady, C., Forrester, L., and Bernstein, A. (1990). Genes Dev. 4, 390-400. Rizzoli, F. (1877). Boll. SOC.Med.-Chir. Bologna, Ser. V. 23, 102. Rizzoli, F. (1878). Virchows Arch. Pathol. Anal. Physiol. 73, 623. Rosnet, O., Marchetto, S., de Lapayriere, 0. T., and Birnbaum, D. (1991). Oncogene 6, 1641- 1650. Rothwell, V. M., and Rohrschneider, L. R. (1987). Oncogene Res. 1, 311-324. Roussel, M. F., Dull, T. J., Rettenmeier, C. W., Ralph, A., and Sherr, C. J. (1987). Nature (London) 325, 549-552. Roussel, M. F., Downing, J. R., and Sherr, C. J. (1990). Oncogene 5,25-30. Russell, E. S . (1970).J. Hered. 48, 119-123. Russell, E. S. (1979). Adv. Genet. 20, 357-459. Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, S. J., Greene, M. I., and Weinberg, R. A. (1984). Nature (London) 312, 513-516. Schechter, A. L., Hung, M.-C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T., Franke, U . , Ullrich, A., and Coussens, L. (1985). Science 229,976-978. Schejter, E., and Shilo, B.-Z. (1989). Cell ( C a m M g e , Marc.) 56, 1093-1104. Schuepbach, T. (1987). Cell (Cambndge, Mass.) 49,699-707. Shibuya, M., Yarnaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. (1990). Oncogene 5, 519-524.
72
ANDREW F. WILKS
Shier, P., and Watt, V. M. (1989).J. Biof. Chem. 264, 14605-14608. Shih, C., Shilo, B.-Z., Goldfarb, M., Dannenberg, A., and Weinberg, R. (1979). Proc. Natl. Acad. Sci. U . S . A. 76,5714-5718. Simon, M. A., Bowtell, D. D. L., and Rubin, G. M. (1989). Proc. Natl. Acad. Sci. U. S. A. 86, 8333-8337. Simon, M. A., Bowtell, D. D. L., Dodson, G. S., Laveny, T. R.,and Rubin, G. M. (1991).Cell (Cambndge, M a s . ) 67, 701-716. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). Science 935, 177-182. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. (1989). Science 244, 707-712. Smith, D. R., Vogt,P. K., and Hayman, M. J. (1989).Proc. Natl. Acad. Sci. U . S. A. 86,52915295. Smith, E. A., Seldin, M. F., Martinez, L., Watson, M. L., Chodhury, G. G., Lalley, P. A,, Pierce, J., Aaronson, S., Barker, J., Naylaor, S. L., and Sakaguchi, A. Y. (1991). Proc. Natl. Acud. Sci. U. S . A. 88, 481 1-4815. Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Reid, S. W., Blair, J., Burton, L. E., Stanton, B. R., Kaplan, D. R., Hunter, T., Nikolics, K., and Parada, L. F. (1991). Cell (Cambndge, Mass.) 65, 895-903. Sprenger, F., Stevens, L. M., and Nuesslein-Volhard, C. (1989).Nature (London) 338,478483. Squinto, S. P., Stitt, T. N., Aldrich, T. H., Davies, S.. Bianco, S. M., Radziejewski, C., Glass, D. J., Masiakowski, P., Furth, M. E., Valenzuela, D. M., DiStefano, P. S., and Yancopoulos, G. D. (1991). Cell (Cambndge, Mass.) 65, 885-893. Stark, K. L., McMahon, J. A., and McMahon, A. P. (1991).Development (Cambridge, U K ) 113, 64 1-651. Stevenson, D. A., Mercola, M., Anderson, E., Wang, C., Stiles, C. D., Bowen-Pope, D. F., and Chapman, V. M. (1991). Proc. Natl. Acad. Sn'. U . S. A. 88, 6-10. Strecker, T. R., Yip, M. R., and Lipshitz, H. D. (1991). Proc. Natl. Acad. Sci. U . S. A. 88, 5824-5828. Takahashi, M., and Cooper, G. M. (1987). Mol. Cell. B i d . 7, 1378-1385. Takahashi, M., Ritz, J., and Cooper, G. M. (1985). Cell (Cambridge, Mass.) 42, 581-588. Takahashi, M., fnaguma, Y., Hiai, H., and Hirose, F. (1988). Mol. CeU. Biol. 8, 1853-1856. Tan, J. C., Nocka, K., Ray, P., Tractman, P., and Besmer, P. (1990). Science 247,209-212. Tarakhovsky, A., Zaichuk, T., Prassolov, V., and Butenko, Z. A. (1991). Oncogene 6,21872196. Tomlinson, A. (1988). Development (Cambndge, U K ) 104, 183-189. Tomlinson, A., and Ready, D. F. (1986). S c k e 231, 400-402. Tsujimura, T., Hirota, S., Nomura, S., Niwa, Y., Yamazaki, M., Tono, T., Morii, E., Kim, H.-M., Kondo, K., Nishimune, Y., and Kitamura, Y. (1991). Blood 78, 1942-1946. Ullrich, A,, and Schlessinger, J. (1990). Cell (Cambridge, M a $ . ) 61, 203-212. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A,, Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. (1984). Nature (London) 309, 418-425. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T. L., Tsubkawa, M., Collins, C., Henzel, W., LeBon, T., Katthuria, S., Chen, E., Jacobs, S., Franke, U., Ramachandran, J., and FujitaYamaguchi, Y. (1986). EMBOJ. 5, 2503-2512. Van Vactor, D. L;, Jr.. Cagan, R. L., Kraemer, H., and Zipursky, S. L. (1991). Cell (Cambridge, Mass.) 68, 1-20. Wilks, A. F. (1989). Proc. Nail. Acad. Sn'. U.S. A. 86, 1603-1607.
PROTEIN TYROSINE KINASE GFR
73
Wilks, A. F. (1991). In “Methods in Enzymology”(T. Hunter and B. M. Sefton, eds.), 200, pp. 533-545. Academic Press, San Diego. Williams, D. E., Eisenmann, J., Baird, A., Rauch, C., Van Ness, K., March, C. J., Park, L. S., Martin, U., Mochizuki, D. Y., Boswell, H. S., Burgess, G. S., Cosman, D., and Lyman, S. D. (1990). Cell (Cambridge, Mass.)63, 167-174. Wittbrodt, J., Adam, D., Malitschek, B., Maeuler, W., Raulf, F., Telling, A., Robertson, S. M., and Schartl, M. (1989). Nature (London) 341,415-421. Yarden, Y., and Ullrich, A. (1988). Annu. Rat. Bzochem. 57,443-478. Yarden, Y., Escobedo, J. A., Kuang, W-J., Yang-Feng, T. L., Daniel, T. O., Tremble, P. M., Chen, E. Y., Ando, M. E., Harkins, R. N., Franke, U., Fried, V. A., Ullrich, A,, and Williams, L. T. (1986). Nu8ure (London) 323, 226-232. Yarden, Y.,Kuang, W-J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Franke, U., and Ullrich, A. (1987). EMBOJ. 6, 3341-3351. Zak, N. B., Wides, R. J., Schejter, E. D., Raz, E., and Shilo, B.2. (1990). Development (Cambridge, VK) 109, 865-874. Zhang, X., Silva, E., Gershenson, D., and Hung, M.-C. (1989). Oncogene 4,985-989. Zierniecki, A., Mueller, R. G., Xiao-Chang, F., Hynes, N. E., and Kozrna, S. (1990). EMBOJ. 9, 191-196. Zsebo, K. M., Wypych, J., McNiece, I. K., Lu, H. S., Smith, K. A., Karkare, S. B., Sachdev, R. K., Yuschenkoff, V. N., Birkett, N. C., Williams, L. R., Satyagal, V. N., Tung, W., Bosselman, R. A., Mendiaz, E. A., and Langley, K. E. (1990a). Cell (CamMge,Mass.)63, 195-201. Zsebo, K. M., Williams, D. A., Geissler, E. N., Broudy, V. C., Martin, F. H., Atkins, H. L., Hsu, R.-Y., Birkett, N. C., Okino, K. H., Murdock, D. C., Jacobsen, F. W., Langley, K. E., Smith, K. A., Takeishi, T., Cattanach, B. M., Galli, S. J., and Suggs, S. V. (199Ob). Cell (Cambridge, Mass.)63, 213-224.
This Page Intentionally Left Blank
THE MOLECULAR AND GENETIC CHARACTERIZATION OF HUMAN SOFT TISSUE TUMORS Colin S. Cooper Molecular Carcinogenesis Section, The Institute of Cancer Research, The Haddow Laboratories, 15 Cotswold Road, Belmont, Sutton. Surrey, SM2 5NG, United Kingdom
I. Introduction 11. Tumor Etiology 111. Genetic Susceptibility to Soft Tissue Tumors
IV. V.
VI.
VII. VIII.
IX. X.
A. Fibromatosis B. Li-Fraumeni Syndrome C. Von Recklinghausen’s Neurofibromatosis D. Sarcoma in Retinoblastoma Families E, Beckwith-Wiedemann Syndrome F. Benign Tumors Detection of YUJ Gene Activation Chromosomal Abnormalities A. Lipomas B. Leiomyomas C. Lipsarcomas D. Synovial Sarcomas E. Rhabdomyosarcomas F. Malignant Fibrous Histiocytomas G. Other Tumor Types Tumor Suppressor Genes A. The p53 Gene B. The RBI Gene C. Studies on Chromosome Loss Gene Amplification Predictors of Tumor Behavior A. Tumor Cell Ploidy B. Multidrug Resistance Molecular Cloning of Translocation Breakpoints Future Developments References Note Added in Proof
I. Introduction Soft tissue is defined as “nonepithelial extraskeletal tissue of the body exclusive of the reticuloendothelial system, glia, and supporting tissue of various parenchymal organs” (Enzinger and Weiss, 1988).This includes 75 ADVANCES IN CANCER RESEARCH, VOL. 60
Copyright B 1993 by Academic Press, Inc. All rights of reproduction in any form reserved.
76
COLIN S. COOPER
smooth and striated muscle, fat, fibrous tissue, and the vessels that serve these tissues. By convention it also encompasses the peripheral nervous system. Soft tissue tumors are a heterogeneous group of tumors that arise as soft tissue masses and usually exhibit the differentiated features of adult soft tissue although in some cases there is no clearly defined normal tissue homolog. The major histogenic categories of malignant soft tissue tumor (Table I) include leiomyosarcoma (smooth muscle), rhabdomyosarcoma (striated muscle), liposarcomas (fat), and malignant peripheral nerve sheath tumors (Schwann cells and perineurial cells). Examples of sarcomas that apparently have no obvious normal counterpart are malignant fibrous histiocytoma and synovial sarcoma. The term malignant fibrous histiocytoma was originally used to describe a group of soft tissue tumors that were thought to be derived from histiocytes (Ozello et al., 1963; OBrien and Stout, 1964; Newland et al., 1975). However, the majority of evidence now indicates that cells from these tumors are more closely related to fibroblasts (Roholl et al., 1985a,b; Wood et al., 1986). The term synovial sarcoma was originally used to describe a group of tumors that commonly occurred around the large joints and that had a microscopic resemblance to normal synovium (Smith, 1927; Knox, 1936). Its origin from synovid tissue has, however, never been proven. The label soft tissue sarcoma can also be extended to include mesotheliomas, extraskeletal Ewings sarcoma, and extraskeletal TABLE I MAJORHISTOLOGICAL CLASSES OF S o n TISSUE TUMORS ~
~
_
_
_
Tumor type
Related normal tissue
Malignant Liposarcoma Leiomyosarcoma Rhabdomyosarcoma Malignant fibrous histiocytoma Fibrosarcoma Deep fibromatosis Synovial sarcoma Malignant peripheral nerve sheath tumor Mesothelioma Extraskeletal chondrosarcoma Angiosarcoma
Fat Smooth muscle Striated muscle Unknown Fibroblasts Fibroblasts Unknown Schwann cells and perineurial cells Mesothelial cells Chondroblasts Endothelial cells
Benign Lipoma Leiomyosarcoma
Fat Smooth muscle
HUMAN SOFT TISSUE TUMORS
77
osteosarcoma but these particular tumors will not be considered in detail in this review. Malignant soft tissue tumors occur at frequencies of around 1-2 per 100,000 population accounting for about 1% of all cancers and 2% of cancer deaths. There have been reports of increases in the incidence of sarcomas but it is not clear whether this genuinely represents an upward trend or whether it is a reflection of improvements in diagnostic procedures and/or greater interest in this tumor type. Soft tissue sarcomas can occur anywhere in the body and at any age although the age distribution varies according to the histological type. For example, rhabdomyosarcomas occur most frequently in children, accounting for 6-7 % of childhood cancer, whereas malignant fibrous histiocytoma occurs predominantly in old age. Benign tumors are at least 100 times more common than their malignant counterparts and represent the most common group of human neoplasms. Benign tumors closely resemble normal tissue, are noninvasive, and are usually not life-threatening. Nonetheless in particular instances (e.g., for leiomyoma of the uterus) they may require surgical intervention. Many of the major conceptual advances in our understanding of the process of malignant transformation have been provided through studies on the transformation of mesenchymal cells (usually fibroblasts) in culture and 6n the induction of soft tissue sarcomas in animal models. Such studies have provided evidence that malignant conversion is a multistep process and in particular have given rise to the concept that immortalization and transformation can represent different steps along this pathway. Thus Newbold and Overall (1983) demonstrated that although primary hamster dermal fibroblasts could be immortalized following treatment with chemical carcinogens an additional transformation step is required to obtain the fully malignant phenotype. Similarly, the experiments of Land et al. (1983) demonstrated that malignant transformation of mesenchymal cells (e.g., primary rat embryonic fibroblasts) can be achieved through cooperation between different classes of activated oncogenes (e.g., the ras and m y genes). Studies on virally and chemically induced sarcomas have, for example, led to the identification and isolation of retroviral oncogenes and provided the original identification of the p53 suppressor protein as a protein overexpressed in chemically induced sarcomas cells (DeLeo et at., 1979). Mesenchymal cells have also been used in developing assays, such as the NIH3T3 mouse fibroblast transfection-transformation assay, that can be used to detect activated oncogenes in human tumors. Although studies on human soft tissue tumors have in general lagged
78
COLIN S. COOPER
behind those on the more common malignancies, such as cancer of the breast, lung, and colon, in the last 5 years a number of key advances have been made in understanding the molecular mechanisms underlying sarcoma development and in the identification of new diagnostic and prognostic indicators for this tumor group. It is well established that certain families show an inherited predisposition to soft tissue tumors and many of the genes involved in these disorders have now been localized and cloned. There have been a number of reports describing the involvement of tumor suppressor genes and dominant transforming genes in sarcoma induction and exciting advances have been provided by cytogenetic analysis demonstrating the presence of specific chromosomal translocations in certain classes of soft tissue tumor. The discovery of these tumor-specific translocations and the identification of genes that control differentiation cloning soft tissue lineages have, in addition, provided new molecular markers that can be used in tumor diagnosis. Finally, studies in which attempts have been made to correlate the presence of specific classes of genetic alteration or abnormalities in gene expression with tumor behavior have identified a number of new prognostic indicators. It is these recent developments that are the subject of this review.
II. Tumor Etiology
Although the factors responsible for the development of the human soft tissue tumors are in most cases still unknown, a variety of causes have been suggested, including exposure to chemical carcinogens and radiation, physical trauma, immunological factors, and constitutional genetic abnormalities. Identification of the precise cause is, however, often extremely difficultbecause of the relative rarity of many individual types of soft tissue tumor and the possibility of long latency periods between exposure and sarcoma development. A small proportion (< 1%) of patients undergoing intensive radiotherapy for breast carcinoma or other malignant tumors develop soft tissue sarcomas within the field of radiation (Laskin et al., 1988). The mean latency period is around 10 years and although any type of soft tissue sarcoma may arise the most commonly observed tumors are malignant fibrous histiocytomas, extraskeletal osteosarcomas, and fibrosarcomas (Laskin et al., 1988). A variety of chemical agents have been suggested as possible causes of soft tissue sarcoma. This is an attractive hypotheses because it is well established that many structurally distinct classes of chemical carcinogens can induce soft tissue sarcomas in animals. There have been somewhat conflicting results about the possible
HUMAN SOFT TISSUE TUMORS
79
association of soft tissue sarcomas and occupational exposure to herbicides and pesticides in, for example, forestry and agricultural workers. An excess of soft tissue sarcoma was found in workers in Sweden (Hardell and Sandstrom, 1979; Eriksson et al., 1981; Wingren et al., 1990), Denmark (Lynge, 1985), Italy (Veneis et al., 1987), and New Zealand (Reif et al., 1989) exposed to phenoxyherbicides and chlorophenols. In contrast, other studies have failed to confirm this finding (Balarajan and Acheson, 1984; Wiklund and Holm, 1986; Hoar et al., 1986; Wiklund et al., 1988). Dioxin exposure has also been suggested as a possible etiological factor because an increased incidence of sarcomas has been reported in some forestry and agricultural workers exposed to dioxincontaining herbicides (Hardell and Sandrom, 1979) and in workers exposed to dioxin in industrial accidents. However, this idea was not supported by case-control studies that failed to demonstrate an elevated incidence of sarcoma in soldiers exposed to the dioxin-containing defoliant Agent Orange (Smith et al., 1984; Kang et al., 1986; Wiklund and Holm, 1986). Furthermore, angiosarcomas of the liver have been attributed to exposure to thorotrast (da Motta et al., 1979; Falk et al., 1979), vinyl chloride (Popper et al., 1978; Falk et al., 1979), inorganic arsenic (Popper et al., 1978), and androgenic steroids (Falk et al., 1979). Preliminary epidemiological studies have indicated that exposure to a variety of other agents including chloramphenicol and chewing tobacco or snuff may also be risk factors in sarcoma induction (Zahm et al,, 1989). Exposure to asbestos, mainly in the form of crocidolite and chrysolite, has been implicated in the induction of mesothelioma in miners and industrial workers and in those who come in contact with asbestos used in insulation, building, etc. (Wagner et al., 1960; Selikoff et al., 1964). There is also some epidemiological evidence suggesting higher incidence of other types of soft tissue sarcoma in workers exposed to asbestos (Wingren et al., 1990). Isolated reports of sarcomas arising at the site of an injury in scar tissue following surgical procedures, at fracture sites, and adjacent to plastic or metal implants have led to the suggestion that trauma or injury may be a factor in determining sarcoma development. More thorough epidemiological studies are, however, required before a firm link between injury and sarcoma induction can be established. A small fraction of cases may result from genetically determined immunodeficiency diseases (Spector et al., 1978) or from immunosuppression following the administration of immunosuppressive drugs during organ transplants (Hoover and Fraumeni, 1973; Kinlen et al., 1979). In addition immunosuppression resulting from HIV infection has been implicated in the development of Kaprosi's sarcoma (Ross et al., 1985). Apart from this
80
COLIN S . COOPER
there is no clear evidence for the involvement of viral agents in the etiology of human soft tissue sarcoma. 111. Genetic Susceptibility to Soft Tissue Tumors There is now a considerable body of evidence demonstrating that genetic factors can predispose toward the development of most types of human cancer including both benign and malignant soft tissue tumors. A genetic susceptibility to cancer development may be recognized in several different ways. In the most dramatic cases families can be identified in which there is a clear excess of cancer. In certain families the predisposition is inherited as a well-defined Mendelian trait associated with a greatly elevated risk of developing cancer. This includes autosoma1dominant disorders such as familial adenomatous polyposis where individuals may develop colon cancer as well as autosomal recessive cancer-prone diseases such as xeroderma pigmentosum where affected individuals have an elevated incidence of skin cancer. Other families may have an unquestionably elevated risk of cancer development but it may be difficult to identify a clear pattern of inheritance. In many cases these families adhere to strictly defined criteria and are unlikely to arise by chance. For example, in the Li-Fraumeni syndrome (see Section II1,B) families exhibit clustering of breast cancer, soft tissue sarcoma, and a variety of other cancers. Finally, even where family clustering is not apparent there may nonetheless be associations of a particular trait with an increased risk of cancer development. T h e association of nasopharyngeal carcinoma with certain HLA types (Simons et al., 1974) and the correlation between ability to metabolize 4-hydroxydebrisoquine and lung cancer risk (Ayesh et al., 1984) are good examples of this. The development of cancer is a multistep process requiring the mutation of several genes for the expression of the fully malignant phenotype. A genetic abnormality associated with an increased risk of cancer development may substitute for one of these mutations, thus reducing the number of genetic events that need to occur during tumor induction. This type of effect is observed in, for example, familial retinoblastoma and familial polyposis coli. Alternatively the abnormality may predispose to the accumulation of mutations, for example, by affecting the metabolism of carcinogenic chemicals or by interfering with DNA repair.
A. FIBROMATOSIS The term fibromatosis refers to fibrous neoplasia that are intermediate in character between benign fibrous lesions and fibrosarcomas.
HUMAN SOFT TISSUE TUMORS
81
These tumors are locally infiltrating with a high rate of recurrence but are never metastatic. Two groups of fibromatosis can be distinguished (Enzinger and Weiss, 1988). Superficial fibromatoses, which are slow growing and usually quite small, arise in the palm, sole of the foot, penis, and knuckle pad. By comparison deep fibromatoses (also referred to as desmoids), which most commonly involve deep structures, are more aggressive than the superficial fibromatosis and have the potential to grow to large size. For both superficial and deep fibromatoses there is evidence for heritable predisposition. Desmoids are found asa complication in around 10%of patients with familial adenomatous polyposis (FAP). Familial adenomatous polyposis is an autosomal dominant disease that affects around 1 in 10,000 individuals. Affected patients develop multiple adenomatous polyps in the colon and rectum that, if not surgically treated, can progress to malignant tumors. The association of FAP with desmoids, osteomata, cutaneous cysts, and other soft tissue tumors such as lipomas and leiomyomas is known as Gardner syndrome (GS). Gardner syndrome is believed to be a variant form of FAP rather than a separate genetic disorder. This hypothesis was initially supported by the observation that these two disorders can occur in different individuals within the same family (McAdam and Goligher, 1970;Jones et al., 1986;Jagelman, 1987) and by the finding that they appear to be linked to the same genetic locus at chromosome 5q21-22 (Hererra et al., 1986; Bodmer et al., 1987; Leppert et al., 1987; Hockey et al., 1989). Several candidate genes that are closely linked to the FAP locus at 5q21-22 have been cloned and sequenced (Kinzler et al., 1991a,b; Nishisho et al., 1991; Groden et al., 1991). Two of these genes, called MCC and APC, were mutated in tumors from sporadic colon cancer patients but only APC was mutated in the germ line of FAP and GS patients. These observations demonstrated that both APC and MCC may be involved in the genesis of colonic cancer and that mutations of the APC gene were responsible for both FAP and GS. Nishisho et al. (199 1) extended these findings by demonstrating that individuals with a G + T transition of codon 302 of the APC gene can either have the range of symptoms associated with GS or have FAP with no evidence of extracolonic manifestations. These observations indicate that the conditions specifically associated with GS may be controlled by other genetic or environmental factors. Clearly it will be important in future studies to identify those factors and to establish the role of the MCC and APC genes in the development of fibromatoses. There have been reports of kindreds containing multiple desmoids as the only manifestation of a genetic abnormality (Zayid and Dihmis, 1969). The existence of these
82
COLIN S. COOPER
families provides further support for the idea that a second genetic locus distinct from APC may predispose toward the development of desmoids. Alternatively, it is conceivable that particular types of mutations of the APC gene predispose toward the development of desmoids without resulting in other symptoms associated with GS. Molecular analysis of the APC gene in these rare desmoid families should resolve this issue. There is also evidence that superficial fibromatoses may, in some cases, arise through a genetic predisposition. Support for this idea is provided by the observation superficial fibromatoses are often bilateral and occur in many generations of the same family (Ling, 1963). However, the genetic abnormalities responsible for such kindreds have not been characterized at the molecular level.
B. LI-FRAUMENI SYNDROME In 1969 Li and Fraumeni carried out a review of archival documents for 648 children who had developed rhabdomyosarcoma, and identified four families in which there was a higher than expected incidence of childhood soft tissue tumors, breast cancer, and other neoplasms (Li and Fraumeni, 1969a,b). Confirmation of the existence of this syndrome (the Li-Fraumeni syndrome) has been provided through prospective observations of the original families, segregation analysis of a consecutive series of children with soft tissue sarcoma, studies on breast cancer among mothers of unselected children with sarcoma, and other descriptive reports (Li and Fraumeni, 1975, 1982; Strong et al., 1987; Li, 1988; Li et al., 1988; Birch, 1990). T h e spectrum of cancers associated with the Li-Frdumeni syndrome is now known to include soft tissue sarcoma, breast cancer, brain tumors, osteosarcomas, leukemia, and adrenocortical carcinoma and possibly also melanoma, germ cell tumors, lung cancer, prostate cancer, and pancreatic cancer. Frequently multiple tumors are observed in individual family members and tumors may have an unusually early onset. Difficulties encountered in carrying out linkage analysis on LiFraumeni families due to the relative rarity of the families and high mortality prompted Malkin et al. (1990) to examine the p53 suppressor gene as a possible candidate. T h e p53 gene was selected because previous studies had shown that it was inactivated in sporadic forms of many of the tumors associated with the Li-Fraumeni syndrome. Remarkably mutations in the p53 gene were found in all five families examined in this study and in a single Li-Fraumeni family examined by Srivastava P t al. ( 1990), demonstrating that inherited mutations on the p53 gene are
HUMAN SOFT TISSUE TUMORS
83
probably responsible for the Li-Fraumeni syndrome. An example of one of the families examined in these studies in shown in Fig. 1. Mutations of the p53 gene in sporadic tumors occur at a variety of sites but are most commonly found in exons 5-9. By comparison the mutations initially reported for the Li-Fraumeni syndrome appear to have a more restricted distribution since all were located within exon 7 of the p53 gene at positions 245,248,252, and 258. These mutations are found together with a normal copy of the p53 gene in noncancerous cells and presumably do not interfere with growth and development of the individuals carrying them. Furthermore the levels of p53 found in fibroblasts from members of Li-Fraumeni families were low compared to those usually found in tumor cell lines containing p53 mutations. The presence of the altered p53 gene appears to have a predisposing effect in carcinogenesis.Consistent with this view Bischoff et at. (1991) found that fibroblasts from Li-Fraumeni patients, in contrast to those from normal controls, become immortal spontaneously when grown in culture.
C. VON RECKLINGHAUSEN’S NEUROFIBROMATOSIS Von Recklinghausen’s (Type I) neurofibromatosis (NF1) is a disease that affects an estimated 1 in 3500 individuals. This autosomal dominant
Li-Fraumeni family
BR.30
BR.28
STS.l Brain.5 OS.8
FIG. 1. Li-Fraumeni pedigree. Symbols represent females with cancer (O),females males with cancer males without cancer (0),and the presence of a without cancer, (0), constitutional mutation the p53 gene (*). The abbreviations used are BR, breast; STS, soft tissue sarcoma; and OS, ostosarcoma. Ages at which the tumors arose are indicated. Adapted from Malkin et al. (1990).
(m),
84
COLIN S. COOPER
disorder is characterized by the presence of cafe-au-lait spots, skin neurofibromas, and pigmented iris hamartomas called Lisch nodules. In addition, a variety of other abnormalities may also be observed in a proportion of cases (Ponder, 1990). Around 5 % of individuals with NF1 develop Schwannomas of the peripheral nerves and 2% of cases develop malignant peripheral nerve sheath tumors (MPNST). The locus (called NFl) that is responsible for this disease was originally mapped to the long arm of chromosome 17 (17q11.2) (Barker et al., 1987; Seizinger et al., 1987) and a candidate gene has now been cloned and characterized (Cawthon et al., 1990; Viskochil et al., 1990; Wallace et al., 1990). Sequence comparisons have shown that the NF1 gene encodes a protein with substantial homology to mammalian GAP that is responsible for activating the GTPase activity of ras proteins. Germ line mutations of the NFI gene have been detected in NFl patients and it will be interesting to assess the role of this gene in the development of neurofibromosis and MPNST in von Recklinghausen’s patients as well as in tumors occurring spontaneously. IN RETINOBLASTOMA FAMILIES D. SARCOMA
Retinoblastoma is an intraocular eye tumor that is usually found in children under 5 years of age. Like many cancers both sporadic and hereditary forms can be distinguished. The sporadic disease accounting for around 70% of cases is characterized by solitary tumors with an average age of onset of 18 months. By comparison the hereditary form is almost always bilateral and multifocal (four to five tumors per eye) with a mean age of onset of 10 months. Around 10-20% of patients with the hereditary disease develop secondary tumors later in life (Draper et al., 1986; Derkinderen et al., 1988). Osteosarcoma is the most common secondary tumor in the decade following the presentation of retinoblastoma, whereas soft tissue sarcomas are more frequent later in life. Knudson (1971) noted that the number of tumors that developed in hereditary cases followed a Poisson distribution, suggesting that a single random event was required for transformation of a retinal cell in those individuals. On the basis of this observation he proposed that two events were required for tumor development in both the hereditary and the nonhereditary forms. In hereditary retinoblastoma one hit or mutation is carried in the germ line; only a single additional hit is therefore required for tumor development. By comparison, in the sporadic retinoblastoma both hits must be acquired by somatic mutation. The location of the gene mutated in the germ line in hereditary retinoblastomas was deduced from the presence of constitutional deletions of chromo-
HUMAN SOFT TISSUE TUMORS
85
some 13q14 in a small proportion of patients (Knudson et al., 1976; Cowell et al., 1986) and from genetic linkage studies (Sparkes et al., 1983).Examination of chromosome abnormalities in retinoblastoma further suggested that the second hit may involve the same region of chromosome 13 (Balaban-Malenbaum et al., 1981). The gene located at 13q14 that is responsible for the inherited predisposition to the development of retinoblastoma in children and osteosarcoma and soft tissue sarcoma in adults has now been cloned and characterized (Friend et al., 1986; Fung et al., 1987). This gene (called RB1) appears to play a key role in controlling transition through the cell cycle and has the functional attributes of a tumor suppressor gene. Thus its introduction into human cell line lacking functional RB 1 protein can result in suppression of the malignant phenotype (Huang et al., 1988). E. BECKWITH-WIEDEMANN SYNDROME
Beckwith-Wiedemann syndrome (BWS) is a condition characterized by an enlarged tongue and abdominal organs, neonatal hypoglycemia, and atypical cranio-facial features. The 1lp15 region of human chromosome 11 seems to contain a gene or genes involved in determining this condition and in the genesis of several types of childhood tumors, including Wilms’ tumor, rhabdomyosarcoma, and hepatoblastoma, that are associated with BWS (Sotelo-Avila et al., 1980). Support for the importance of this chromosomal region has been provided by reports of cytogenetically identifiable germ line deletions of the short arm of chromosome 11 in BWS patients (Pettenati et al., 1986) and by studies demonstrating linkage to genetic markers from 1lp15 in BWS families (Koufos et al., 1989; Ping et al., 1989).Further support is provided by the observation that uniparental paternal disomy (both alleles at a particular locus derived from a single parent) frequently occurs in the 1lp15 region in BWS patients (Henry et al., 1991). The potential importance of a gene located at the end of the short arm of chromosome 11 in the development of soft tissue tumors has also deduced from analysis of allele loss in rhabdomyosarcoma (see Section V1,C). F. BENIGNTUMORS 1 . Lipomas
There is also good evidence that genetic factors can predispose toward the development of benign soft tissue tumors such as lipomas and leiomyomas. Lipomas are benign tumors that differ little in microscopic
86
COLIN S. COOPER
appearance from surrounding fat. T h e cutaneous or superficial lipomas are most common, occurring predominantly in the regions of the back, shoulders, upper neck, and abdomen. Approximately 1 in 20 individuals with lipomas have multiple tumors and in a small proportion of patients with this condition, there is evidence of a hereditary trait that has features of autosomal dominant transmission (Humphrey and Kingsley, 1938; Kurzweg and Spencer, 1951; Shanks et al., 1957; Stephens and Isaacson, 1959; Enzinger and Weiss, 1988). An example of a multiple lipoma family where three successive generations are affected is shown in Fig. 2. In patients that have multiple lipomas or the related angiolipomas, apparently without a family history, it is possible that nonhereditary factors account for the multiple tumors. Alternatively it is possible that they represent a less penetrant form of genetic predisposition. There is no evidence indicating that multiple lipoma families have a excess of liposarcoma o r of other types of cancer. 2. L e i o m y o m
Leiomyomas are benign tumors that show the differentiated features of smooth muscle. Leiomyomas are found most commonly in the uterus where they pose a major clinical problem and are known as fibroids. It has been proposed that there is an inherited predisposition to developing uterine leiomyomas but it is extremely difficult to prove this for a tumor that may be present in up to one in four women. More rarely leiomyomas, either solitary or multiple, may be found in the skin of young adults where they frequently arise from the pilar erector muscles. Multiple liporna family
I
m
FIG. 2. Multiple lipoma family pedigree. Symbols represent affected males (B)and females (0).and unaffected males (0)and females (0).
HUMAN SOFT TISSUE TUMORS
87
For a proportion of patients with multiple leiomyomas there is evidence of an inheritance as an autosomal dominant tract (Kloepfer et al., 1958; Fisher and Helwig, 1963; Verma et al., 1973). Multiple leiomyomas have however been associated with a variety of other conditions including HLA-B8, dermatitis herpetiformis, and Type I multiple endocrine adenomatosis. VI. Detection of ras Gene Activation
DNA transfection into NIH3T3 mouse fibroblasts has been used extensively to screen human tumors for the presence of dominantly acting oncogenes. In this technique tumor DNA is introduced into NIH3T3 cells as a coprecipitate with calcium phosphate and cultures are monitored for the appearance of foci or morphologically transformed cells that are formed when the mouse cells stably incorporate an activated oncogene. The majority of the genes detected using this assay are members of the ras gene family (H-, K-, and N-) although non-ras gene, such as met, raf, trk, and ret are occasionally observed (Hall, 1990). A selection of 46 soft tissue tumors and tumor cell lines that includes all the major classes of adult tumors has been examined using this assay (Krontiris and Cooper, 1981; Perucho et al., 1981; Pulciani et al., 1982; Marshall et al., 1982; Fukui et al., 1985; Stanton and Cooper, 1987; Gill et al., 1991). Activated K-ras was detected in a primary embryonal rhabdomyosarcoma (Pulciani et al., 1982) and in a primary leiomyosarcoma (Gill et al., 1991), whereas activated N-ras was detected in the RD rhabdomyosarcoma cell line (Hall et al., 1983; Chardin et al., 1985) and in the HT1080 fibrosarcoma cell line (Hall et al., 1983). In one study an activated gene apparently unrelated to ras was transferred from a leiomyosarcoma but the detailed characterization of this gene has not been reported (Fukui et al., 1985). In a more recent study, a non-ras gene was transferred from a liposarcoma (Gill et al., 1991). Cloned regions of this gene were localized to human chromosome 19 and were found to detect a 3-kb transcript in most human cell lines. Stratton et al. (1989a) used a different approach to screen a series of childhood rhabdomyosarcoma for the presence of activated ras genes. In this study DNA was prepared from formalin-preseved tumors from histopathological archives and the regions of the ras genes where activating mutations occurred (codons 12, 13, and 61) were amplified using the polymerase chain reaction (PCR). Mutant ras genes were detected by hybridization of amplified DNA to specific oligonucleotide probes. Using this approach mutated versions of N-ras and K-ras were detected in 35% (5/14) of embryonal rhabdomyosarcomas. It was also noted that
88
COLIN S. COOPER
a high proportion of tumors located around the urogenital tract (5/7) contained ras genes mutations, whereas mutations were not observed in tumors from other locations (0/7). When taken together these studies demonstrate that ras activation is implicated in the development of childhood rhabdomyosarcorna but is a relative rare event in major classes of adult tumors. V. Chromosomal Abnormalities
Because of problems such as low mitotic index and difficulties in obtaining satisfactory quality of mitotic figures, cytogenetic analyses of human solid tumors have lagged behind analogous studies on leukemia. However, recent important rnethological improvements have resulted in the identification of several specific chromosomal abnormalities in solid tumors. The methodological advances include (a) procedures for tissue dissagregation by prolonged incubation with collagenase that allow tumor cells to be grown in culture for a few days to increase the mitotic index; (b) improved methods of preparing mitotic figures; and (c) improvements in banding procedures (Gibas et al., 1984; Limon et al., 1986d; Trent et al., 1986). One of the most exciting consequences of these developments has been the discovery of specific chromosomal translocations that are unique to certain classes of soft tissue sarcoma. Moreover, these translocations commonly occur in a high proportion of tumors and are frequently found as the only karyoptypic abnormality. Cytogenetic analysis of leukemia is widely used in diagnosis and in distinguishing between subgroups of this disease that have different prognoses. Similarly the discovery of specific translocations in soft tissue tumors offers the prospect of their use in tumor diagnosis and prognosis. Where consistent chromosomal translocations have been documented in other classes of human neoplasm they usually correspond at the molecular level to rearrangements involving particular genes. For example, the translocation involving chromosomes 8 and 14 found in Burkitt’s lymphoma involves the c-myc protooncogene on chromosome 8 and the immunoglobin heavy chain locus on chromosome 14 (Dalla Favera et al., 1982; Croce et al., 1985). Similarly the t(9:22) translocation detected in almost all chronic myelogenous leukemia arises through the joining of c-abl locus on chromosome 9 to the bcr locus on chromosome 22 (Witte, 1986). By analogy it is assumed that the translocations found in soft tissue tumors correspond at the molecular level to alterations of particular genes and a major objective of work in this area is to clone and characterize the genes involved in these translocations. This work would not only provide important insights into the molecular mechanisms of
HUMAN SOFT TISSUE TUMORS
89
induction of soft tissue sarcoma but would also yield molecular probes that could be used to detect the translocations and hence aid in diagnosis. A. LIPOMAS From karyotype analyses carried out on over 50 lipomas it has become apparent that four cytogenetically distinct groups can be distinguished. (a) Around 30-35% of tumors have normal karyotype. (b) Another 3035% contain a reciprocal translocation involving the q13-14 region of chromosome 12 (Heim et al., 1986, 2988a; Turc-Care1 et al., 1986c, 1988c; Mandahl et al., 1987, 1988a; Sreekantaiah et al., 1990a,b,c, 1991b).Although chromosome 12 can have many different translocation partners, a reciprocal translocation involving chromosomes 3 and 12 [t(3;12)(q27-28;q13-14)]has been observed repeatedly (Fig. 3). Genes located around the q13-14 region of chromosome 12, which are therefore considered as candidates for involvement in these translocations, include the int-1 and gli protooncogenes, and the gene encoding the receptor for apolipoprotein E. Southern anaylses of DNA have, however, failed to reveal rearrangements of these genes in lipomas containing abnormalities of 12q13-14 (Arheden et al., 1989b; Myklebost et al., 1989; Paulien et al., 1990). ( c ) Fifteen percent of lipomas contain ring chromosomes (Heim et al., 1987, 1988a; Mandahl et al., 1987, 1988a; Turc-Care1et al., 1987a).Although the origin of these ring chromosomes has not been determined unequivocably, it has been proposed that they arise through the end-to-end joining of the 3q+ chromosome that is formed as a consequence of the 3;12 translocation (Heim et al., 1986). ( d ) Finally, a small proportion of lipomas exhibit other classes of abnormality (Sandberg et al., 1986; Mandahl et al., 1987, 1988a; Heim et al., 1988a;), including possible recurrent abnormalities of 6p (Sait et al., 1989b; Sreekantaiah et al., 1990a) and 13q12-13 (Sreekantaiah et al., 1989). Although the origin of the variant translocations involving 12q13-14but not 3q27-28 has not been determined, it is conceivable that they correspond at the molecular level to rearrangements between a specific gene on chromosome 12 and selection of other genes located at different sites on the human chromosome. Alternatively it is possible that the variant translocations involve rearrangements of chromosomes 3 and 12 that are masked at the molecular level. In this regard it is worth while to note that a parallel situation exists in chronic myelogenous leukemia (CML) where at the molecular level translocations always involve the c-abl protooncogene on chromosome 9 and the bcr gene on
90
COLIN S . COOPER 26 25 24
23
22 21 14
13 12 11 11
12 13
c
21
22 23 24
15 21
25
22
8
26 23
c
27
28 29
3
24
M
U
12
der(l2)
E
der(3) FIG. 3. Schematic presentation of the specific chromosomal translocation between chromosomes 3 and 12, t(3;12)(q27-28; q13-14). found in lipomas. The translocation occurs at the positions indicated by the arrows and gives rise to the der(3) and der(l2) chromosomes.
chromosome 22. In contrast the involvement of chromosome 9 in CML is not always apparent at the cytogenetic level (Dube et al., 1989). Studies on multiple lipoma have been undertaken to determine the origin of the individual tumors. In one study three lipomas from the same region of a single patient were examined (Dal Cin et al., 1988~). Two contained the t(3;12) translocation shown in Fig. 3 and the third contained a 1:12 translocation that also involved the q13-14 region of chromosome 12. These observations were thought to provide support
91
HUMAN SOFT TISSUE TUMORS
for the idea that each lipomas arises independently rather than by spread from a single tumor. Heterogeneity has been observed between different regions of a single lipoma. Thus Sreekantaiah et al. (1991a) found that a biopsy from a lipoma in a 64-year-old man contained three abnormal clones. One clone contained a t( 12;21) translocation, the second contained t(2; 12) and t( 19;20)translocations, and the third contained a ring chromosome. In a subsequent specimen the predominant abnormal clone contained the same t(2; 12) translocation but, in addition contained a t(3; 11) translocation and a ring chromosome. B. LEIOMYOMAS Cytogenetic studies of uterine leiomyomas reveal that the majority of tumors (30-80%) appear to be karyotypically normal, whereas those tumors exhibiting cytogenetic abnormalities can be divided into a number of distinct groups. Twenty-five to 30% of tumors with clonal alterations contain reciprocal translocations. Most commonly these involve 12q14-15 usually as t(12; 14)(q14-15;q23)(Fig. 4) but occasionally
i1
;; @
a -
c
22 21 15
der( 12)
23
22
24 31 32
24
12
14
der( 14) FIG. 4. Schematic presentation of the specific chromosomal translocation between chromosomes 12 and 14, t(12;14)(q14-15;q23), found in leiomyonas. The translocation occurs at the positions indicated by the arrows and gives rise to the der(l2) and der(l4) chromosomes.
92
COLIN S. COOPER
as translocations with other chromosomes (Heim et al., 1988b; Nilbert et al., 1988b; Turc-Care1 et al., 1988b; Vanni and Lecca, 1988; Mark et al., 1989a; Sait et al., 1989a; Vanni et al., 1989, 1991; Nilbert and Heim, 1990; Kiechle-Schwarz et al., 1991; Rein et al., 1991). High-resolution mapping of this translocation has recently defined the breakpoints in chromosomes 12 and 14 to 12q15 and 14q24.1 (Pandis et al., 1990). Translocations involving 12914-15 are frequently observed as the only karyotypic abnormality, indicating that they may represent a primary event in tumor formation. Southern analysis of tumor DNA has been used to assess the involvement of the int-1 and gli protooncogenes and the COL2Al collagen gene, which all map around 12q13-14, but no alterations of these genes were detected (Arheden et al., 1989a). It is also worth while to note that a translocation involving chromosomes 1 and 2, [t(1 ;2)(p36:p24)], has recently been reported in a small proportion of tumors (Mark et ai., 1989a). Other classes of primary cytogenetic abnormality that are also observed, often as the only karyotypic alteration, include alterations of 6p, trisomy of 12, and interstitial deletions of the long arm of chromosome 7 (Boghosian et al., 1988; Nilbert et al., 1988c, 1989b, 1990b; Mark et al., 1989a; Sait et al., 1989a; Nilbert and Heim, 1990; Kiechle-Schwarz et al., 1991; Rein et al., 1991; Vanni at al., 1991). Together these account for a further 50% of leiomyomas containing clonal abnormalities. Deletions of the long arm of chromosome 13 have also been reported as the only cytogenetic abnormality in two leiomyomas, suggesting that in some cases this alteration may represent an important event (Meloni et al., 1991). A variety of nonrecurrent translocations account for the remaining 20-25% of abnormalities (Gibas et al., 1988; Mugneret et al., 1988; Nilbert et al., 1988c, 1989a; Mark el al., 1989a). Ring chromosomes and alterations of chromosome 1 are also found but these usually occur together with other cytogenetic abnormalities and are therefore considered to represent secondary changes (Nilbert et al., 1988b). Other recurrent chromosomal abnormalities include monosomy 22 (KiechleSchwartz rf ai., 1991) and changes of chromosomes 2 and 19 (Mark et al., 1990; Vanni et al., 1991). Karyotypes of tumors from individuals with multiple leiomyomas in a single uterus have been obtained (Mark et al., 1989b, 1991; Nilbert et al., 1989b). In some individuals different abnormalities were observed in two or more leiom yomas suggesting that individual tumors are entirely independent. In other patients similar abnormalities were observed in separate leiomyomas from a single patient, apparently indicating that independent leiomyomas may in fact arise from the same initial neoplastic clone. An alternative explanation suggested by Mark et al. (1991)
93
HUMAN SOFT TISSUE TUMORS
is that similar patterns of cytogenetic abnormalities could arise from the involvement unidentified etiological factors that favor particular chromosomal alterations. In support of this idea he pointed out that abnormality involving deletion of the region of chromosome 7 that they observed in two leiomyomas from a single patient was also detected in tumors from other individuals. These cytogenetic studies are of considerable interest because together with the studies on lipomas described above they show that clonal chromosomal abnormalities are not restricted to malignant tumors and that the presence of cytogenetic alterations cannot, by itself, be used as an indication of malignancy.
C. LIPOSARCOMAS Cytogenetic analysis of these malignant proliferations has identified a specific translocation involving chromosomes 12 and 16, t( 12;16) (q13:pl l), that is frequently found as the only cytogenetic abnormality (Limon et al., 1986a; Turc-Care1et al., 1986d; Mertens et al., 1987; Smith et al., 198713; Bridges et al., 1988; Walters et al., 1988). Liposarcomas, which occur primarily in adult life between ages 40 and 60 years, are classified into four categories based on histological appearance: myxoid, round cell, well differentiated, and pleomorphic (Enzinger and Weiss, 1988). The t(12;16) translocation (Fig. 5 ) is found in around 50% of 13 12
11 11 12 13
c
13 14
12
15
1-1
21
11 12 13 21
22 23
22 23 24
24 ~
12
der(l2)
16
der(l6)
FIG.5. Schematic presentation of the specific chromosomal translocation between chromosomes 12' and 16, t(12;16)(q13;pl l), found in liposarcomas. The translocation occurs at the positions indicated by the arrow and gives rise to the der(l2) and der(l6) chromosomes.
94
COLIN S. COOPER
myxoid tumors but is apparently not present either in the other histological categories of liposarcoma or in other types of myxoid tumor (e.g., myxoid chondrosarcomas). Recently the chromosomal breakpoints of the t(12;16) have been localized to subbands 12q13.3 and 16pl1.2 (Ener0th et al., 1990). Furthermore it has been suggested that trisomy of chromosome 8 may represent a nonrandom secondary change in myxoid liposarcoma (Sreekantaiah et al., 1991~). T h e region of chromosome 12 involved in this translocation is similar, perhaps identical, to that commonly found in lipomas. This observation raises the possibility that the same gene located on chromosome 12 might be implicated in the development of both benign and malignant adipose tissue tumors. Furthermore the genes mentioned above that are located on chromosome 12 and are candidates for involvement in the lipoma and leiomyoma translocations are also candidates for involvement in the t( 12; 16) translocation. Southern analysis of DNA from liposarcomas containing the t( 12;16) translocation has, however, failed to reveal rearrangement in the int-1 protooncogenes (Turc-Carel et al., 1987~).In addition Paulien et nl. (1990) used pulsed-field gel electrophoresis to construct a 600-kb restriction map spanning the gli protooncogene locus at 12q13-14. Their analysis demonstrated that both the liposarcoma 12:16 breakpoint and the lipoma 12q13-14 breakpoint (see Section V,A) lie outside this region. However, they also found that myxoid liposarcoma DNA contained altered restriction fragments detectable with gli probes that were highly specific and reproducible from case to case. These altered fragments resulted from highly specific and reproducible methylation differences that were unique to myxoid liposarcoma DNA. It was also suggested that those methylation differences might provide a useful diagnostic tool for distinguishing different subtypes of liposarcoma. I t is generally believed that liposarcomas are derived from primitive niesenchymal cells rather than mature fat cells and only very rarely arise by progression from existing lipomas. Support for this hypothesis is provided, for example, by the observation that liposarcomas occur only very infrequently in subcutaneous fat, which is a common site of lipomas (Enzinger and Weiss, 1988). Cytogenetic studies also provide support for the idea that liposarcomas are not derived from lipomas because the types of karyotypic abnormalities found in liposarcomas are not the same as those found in lipomas. In an attempt to assess the role of chromosomal abnormalities in the progression of myxoid liposarcomas Orndal et al. (1990) determined the karotype of different regions of a single tumor that exhibited histological heterogeneity. In one of three myxoid nodules and in the surrounding “lipoma-like” tissue the translocation t( 12; 16)(q13;pl1) was
HUMAN SOFT TISSUE TUMORS
95
found as the only chromosomal abnormality. In the other two nodules additional alterations involving chromosomes 1, 12, and 16, which were probably secondary to the t( 12;16) translocation, were also found. The presence of these more complex alterations in regions of the tumor that had a more malignant histology led the authors to suggest that acquisition of secondary chromosomal aberrations may arise during tumor progression.
D. SYNOVIAL SARCOMAS Synovial sarcomas occur most commonly in young adults between ages 15 and 40 and are usually found at the extremities in the vicinity of the large joints (Enzinger and Weiss, 1988). Although estimates of its incidence vary, it is generally considered to account for 5-10% of soft tissue tumors. Two histologically distinct pattern of synovial sarcoma can be distinguished: the biphasic pattern, containing both epithelial-like cells and spindle cells, and the monophasic pattern, containing only spindle cells. Cytogenetic studies have demonstrated that a specific translocation involving chromosome X and 18 is found in a high proportion of both biphasic and monophasic synovial sarcoma (Limon et al., 1986d, 1989; Turc-Care1et ah, 1986b, 1987b; Smith et al., 1987a; Griffin and Emanuel, 1987; Noguera et al., 1988; Ueda et al., 1988; Nojima et al., 1990b). This translocation (Fig. 6) can be found as the only karyotipic abnormality. Usually chromosomes X and 18 are involved in a simple reciprocal translocation [t(X;18)(pl1.2;ql1.2)] giving rise to the der(X) and der( 18) chromosomes shown in Fig. 6. However, complex translocation involving a third chromosome in addition to chromosomes X and 18 are occasionally observed; for example, the (X;18;21)(pl1.2;ql1.2;p13) translocation detected by Turc-Care1et al. (1987b).There have also been reports of the X;18 translocation in a fibrosarcoma (Mandahl et al., 1988b) and in a malignant fibrous histocytoma (Turc-Care1et al., 1987b) but the significance of these reports is unclear because it is often difficult to distinguish these tumors from the monophasic variant of synovial sarcoma. Genes located around the position of the translocation on the X chromosome that are considered candidates for involvement in the X; 18 translocation include the c-elk and hA-raf protooncogenes, a gene called A1S9 that is involved in cell cycle control, the gene encoding a protein designated TIMP that has a dual role of inhibitor of metalloproteinase and as an erythroid potentiating factor, the gene encoding on the TFE3 helix-loop-helix transcription factor, and an anonymous gene designated SB1.8 (Huebner et al., 1986; Rao et al., 1989; Beckmann et al.,
96
COLIN S . COOPER
22.3 22.2 1
n. 21 11.4 11.3 11.2 11.1 11 12 11.32 11.31
13
11.2 11 1 11.1 11.2 12.1 12.2 12.3 21.1 21.2 21.3
21
22
23 24 25
26 27
22
28
23
X
der(X)
18
der(l8)
FIG.6. Schematic presentation of the tumor-specific translocation t(X, 18)(p11.2; q l l . 2 ) , found in a high proportion of synovial sarcomas. The arrows indicate the position of the translocation.
1990; Zacksenhaus et al., 1990). Other genes located in these regions are those encoding, synapsin I and monoamino oxidase (Human Gene Mapping 10, 1989). There is, however, currently no evidence that any of these genes are altered in synovial sarcomas. Conflicting reports have been obtained in attempts to map the position of the breakpoint relative to representative genes and markers on the X chromosome. Both Reeves et at. (1989a,b) and Gilgenkrantz et al., (1990) prepared hybrids containing the der(X) chromosome in the absence of other material from human chromosomes X and 18 by fusing synovial sarcoma cells to rodent cells. In the der(X) examined by Reeves et d. (1989a) the breakpoint was mapped close to the centromere between two markers designated DXS146 and DXS14. By comparison the der(X) examined by Gilgenkrantz et al. (1990) appears to contain the breakpoint further away from the centromere between markers DXS146 and TIMP. These differences might reflect heterogeneity of the breakpoint on the X chromosome or could result from a secondary rearrangement or deletion in one of the der(X) chromosomes. To distinguish between the possibilities additional tumors must be examined.
HUMAN SOFT TISSUE TUMORS
97
E. RHABDOMYOSARCOMAS Rhabdomyosarcoma is the most common soft tissue sarcoma in children and adolescents. In the majority of cases the tumors can be assigned to one of three histological groups (Enzinger and Weiss, 1988). However, it is difficult to draw sharp divisions between the different groups, and for some individual tumors it is not clear in which group they should be placed. Embryonal rhabdomyosarcoma, which mainly affects children under 15 years of age, accounts for around 70% of all rhabdomyosarcomas. Alveolar rhabdomyosarcoma, which occurs predominantly in subjects between 10 and 25 years of age, are less frequent, accounting for 20% of tumors. Finally, pleomorphic rhabdomyosarcomas, the rarest group, occur predominantly in mature adults. Cytogenetic analyses of rhabdomyosarcomas have revealed that one of the most common karyotypic abnormalities is a reciprocal translocation involving chromosomes 2 and 13, t(2; 13)(q37;q14) (Seidal et al., 1982; Garvin et al., 1986; Turc-Care1 et al., 1986a; Lai et al., 1987; LizardNacol et al., 1987; Rowe et al., 1987; Douglass et al., 1987; Engel et al., 1988; Wang-Wuu et al., 1988; Nojima et al., 1990a). This translocation (Fig. 7) is frequently observed as the only cytogenetic abnormality, suggesting that it may be a primary pathological event, but in one study it was observed in late but not in early passages of a cultured rhabdomyosarcoma, indicating that it could also play a role in tumor progression. The t(2; 13) translocation is observed in around 50% of alveolar rhabdomyosarcomas, but there are isolated reports of its occurrence in embryonal tumors and in tumors designated undifferentiated (Douglass et al., 1987). Furthermore the derivative chromosome 13 is absent in many tumors, indicating that it is the formation of der(2) that is important in tumor development. Variant translocations have been detected in an alveolar tumor, t(2; 1l)(q37; 13), and in an embryonal tumor, t(2;8)(q37;q13) (Whang-Peng et al., 1986; Hayashi et al., 1988), whereas constitutional translocation involving 2q37, t(2;5)(q37;q3l), has been observed in a patient with embryonal rhabdomyosarcoma (Morijama et al., 1986). Although embryonal rhabdomyosarcomas have no common structural abnormality Wang-Wuu et al. (1988) found trisomy 2 in all eight tumors examined in their study. In addition, in these eight tumors seven had +20, six had + 13, six had +8, five had + 11, and five had + 19. Two different approaches have been used to map the breakpoint relative to markers from chromosome 13. Mitchell et al. (1991) created somatic cell hybrids containing the derivative chromosome 13. This derivative chromosome hybridized to the loci p7F12 and pHUlO but failed
98
COLIN S. COOPER 25 24 23 22 21 16
15 14 13
;; %?
12 11 11 12 13 14
!I
der( 13)
21 22
22
23
31
24
32 33 34
31
13
32 33 34 35 36
37
2
der(2) FIG. 7. Schematic presentation of the specific chromosomal translocation t(2;13) (q37;q14)foundin rhabdomyosarcoma.The arrows indicate the position of the translocation.
to hybridize to the esterase D and RB1 gene probes and to pG14E1.9 and pG24E6.8 probes. When considered together with order of these loci deduced from genetic linkage studies, these studies indicated that the breakpoint occurs between pG14E1.9 (DS1322) and either p7F12 (D1351) or pHUlO (D1356). These conclusions are in agreement with the results obtained by Valentine et al. (1989), who has used in situ hy-
HUMAN SOFT TISSUE TUMORS
99
bridization to place the breakpoint distal to pHUlO and p7F12 but proximal to esterase D and RB 1. Barr et al. ( 1991) examined the involvement of five groups of candidate genes mapped to either chromosome 2 or 13. These included the genes for signal transduction proteins (RB1, inhibin a, FLT1, and Hox4B), muscle-specific proteins (myosin light chain, desmin, nictonic cholinergic receptor subunits y and 6), extracellular matrix proteins (collagen type V1 a 3 chain, elastin, and fibronectin), transformation-associated products (intestinal alkaline phosphatase and Lplastin), and esterase D. Southern blot analysis of DNA separated on conventional gels or by pulsed-field gel electrophoresis failed to detect rearrangements of these genes. HISTIOCYTOMAS F. MALIGNANTFIBROUS There have been a number of studies reporting karyotypic abnormalities in MFHs (Bridges et al., 1987, 1990; Genberg et al., 1989; Mandahl et al., 1985, 1989; Rydholm et al., 1990; Kanzaki et al., 1991) but perhaps the most interesting observation was the identification of a rearrangement involving 1 9 ~ 1 in 3 primary tumors. Other abnormalities include ring chromosomes, translocations and deletions of l l p and 3p, and the presence of the cytogenetic signs of gene amplification (homogeneously staining regions and double minute chromosomes). Furthermore, there appeared to be a correlation between the presence of the 19p marker chromosome and tumor behavior, since distant metastases and/or local recurrence occurred in 8 of the 9 patients with the 19p+ marker but in only 4 of the 13 without (Mandahl et al., 1989; Rydholm et al., 1990). The only other cytogenetic parameter that appeared to affect tumor relapse was the presence of ring chromosomes; relapse was found in 2 of 8 patients with ring markers compared to 10 of 14 patients without. +
G. OTHERTUMOR TYPES Cytogenetic studies have also been carried out on other tumor types, including fibrosarcomas (Adam et al., 199l), chondrosarcomas (Hinrichs et al., 1985; Turc-Care1et al., 1988a; Fletcher et al., 1989; Bridges et al., 1989; Mandahl et al., 1990), and leiomyosarcomas (Limon et al., 1986b; Dal Cin et al., 1988a,b,d; Nilbert et al., 1988a, 1990a,c; Sait et al., 1988; Boghosian et al., 1989; Mark et al., 198913; Sreekantaiah and Sandberg, 1991). It has been suggested that leiomyosarcomas can be divided into three karyotypically distinct groups: a pseudodiploid group that frequently contains simple reciprocal translocations that are unique to indi-
100
COLIN S. COOPER
vidual tumors; a hypodiploid subgroup that often exhibits monosomy of chromosomes 18 and 22; and a third group with more complex karyotypes (Boghosian et al., 1989). Other observations of particular note include the preliminary indication that myxoid chondrosarcomas may contain translocations involving 9p3 1 and 2 2 ~ 1 3(Hinrichs et al., 1985; Turc-Carel et al., 1988a) and the report of a congenital fibrosarcoma containing a deletion of the short arm of chromosome 17, the location of the p53 gene, as the sole chromosomal abnormality (Adam et al., 1991). VI. Tumor Suppressor Genes
In contrast to ras and other oncogenes where the inappropriate function of specific genes can cause cancer in the case of tumor suppressor genes (also called recessive oncogenes or anti-oncogenes) loss or inactivation of both copies of the gene is usually required for tumor development. Several suppressor genes and putative suppressor genes have now been cloned and characterized. These include the RB1 gene located at 13q14, the p53 gene located at 1 7 ~ 1 3the , Wilms’ gene at llp13, the DCC gene at 18q2 1, the APC gene at 5q2 1-22, and the NF1 gene located at 17q 1 1.2. A role for the RB 1 and p53 genes in sarcoma development has now been established and the evidence for this is reviewed. In addition, as described in Sections Il1,A and III,C the APC and NF1 genes have been proposed as candidates for involvement in the genesis of, respectively, fibromatoses and MPNSTs. A. THEp53 GENE
It is now emerging that mutations in the p53 gene are one of the commonest abnormalities in human cancer (Hollstein et al., 1991). The p53 nuclear phophoprotein was originally detected in a protein that bound to the large T antigen of the simian virus SV40 (Lane and Crawford, 1979; Linzer and Levine, 1979) and also as a transplantation antigen expressed in 3-methylcholanthrene-induced mouse fibrosarcomas (DeLeo et al., 1979). Genomic and cDNA clones of p53 were isolated and it was demonstrated that the cloned p53 gene could immortalize cells in culture and cooperate with other oncogenes such as as to fully transformed primary rodent embryo fibroblasts (Eliyahu et al., 1984; Parada et al., 1984; Jenkins ct al., 1984). These observations suggested that the p53 gene had the properties of a dominant transforming gene. However, the interpretation of these experiments came under scrutiny when it was discovered that the constructs used in immortaliza-
HUMAN SOFT TISSUE TUMORS
101
tion and transformation studies contained mutated versions of p53 (Hinds et al., 1989). Recent studies suggest that p53 in fact has many of the properties of a tumor suppressor gene. For example, the wild-type p53 gene can eliminate the tumorigenic potential of cells in culture (Chen et al., 1990), cause arrest of cells at the G1 phase of the cell cycle (Baker et al., 1990; Diller et al., 1990), and inhibit the transformation of cells in culture by other oncogenes (Finlay et al., 1989; Eliyahu et al., 1989). However, it is also apparent that versions of the p53 allele containing point mutations can, in some cases, negate the normal suppressor function of p53. This might occur if mutated p53 acquires a new activity that overcomes the effect of wild-type p53. Support for this idea is provided by the observation that introduction of mutated p53 into cells that do not express p53 can enhance their tumorigenicity (Wolf et al., 1984).Since oligmerization of mutated p53 protein has been reported, as an alternative hypothesis, it has also been proposed that an excess of mutated p53 protein may sequester smaller amounts of normal p53 protein through the formation of hybrid oligomers (Green, 1989). The p53 gene is located on a region of the short arm of chromosome 17 that is frequently lost in human cancer including cancer of the lung, breast, and colon. When one allele of the p53 gene is lost the remaining allele usually contains point mutations, indicating that loss or inactivation of both alleles of the p53 gene is required for tumor development (Nigro et al., 1989; Baker et al., 1989; Hollstein et al., 1991). Loss of the short arm of chromosome 17 and point mutation of p53 has also been reported in several types of soft tissue sarcoma including rhabdomyosarcoma, MFH, and leiomyosarcoma (Mulligan et al., 1990; Stratton et al., 1990).Homozygous loss (loss of both alleles) and gross rearrangement of the p53 gene have also been detected in soft tissue sarcomas (Mulligan et al., 1990; Stratton et al., 1990). These types of structural alterations were uncommon in many of the types of cancer previously examined (Baker et al., 1989; Nigro et al., 1989) but have been detected in osteosarcoma and blast crisis CML (Masuda et al., 1987; Ahuja et al., 1989). It is possible that the distinct patterns of inactivating mutations observed in different tumor types may reflect the nature of the carcinogen involved in tumor induction. This hypothesis is supported by studies on point mutations of the p53 gene in hepatocellular carcinoma, which in certain areas of the world is believed to arise through exposure to aflatoxin. In a study of hepatocellular carcinoma from the high-incidence region of Qidang, China, all eight p53 mutations occurred at codon 249 and seven were G to T transversions, precisely the mutations expected to arise following
102
COLIN S. COOPER
interaction of activated metabolites of aflatoxin with DNA (Hsu et al.,
1991). B. THERB1 GENE The discovery that soft tissue sarcomas frequently arise as secondary tumors in survivors of familial retinoblastomas (Draper et al., 1986; Derkinderen et al., 1988) prompted an examination of soft tissue sarcomas for loss of chromosome 13 and for abnormalities of the RBI gene. Loss of a single copy of the RBI gene was found in around 30-40% of tumors (Stratton et al., 1989b).Using RB1 cDNA probes several groups have detected homozygous alterations of the RBI gene and abnormalities of RB1 transcriptions (Friend et al., 1987;Mendoza et al., 1988; Stratton et al., 198913;Wunder et al., 1991).In some cases these alterations involve rearrangements within the RB 1 gene itself or deletions of specific regions of the RB 1 gene. Abnormalities have been detected most frequently in MFHs and leiomyosarcomas, but also in liposarcomas and synovial sarcomas. When considered together the data provided strong evidence that alteration of the RB 1 gene is involved in sarcoma development. In a combined study of 36 bone and soft tissue sarcomas Wunder et al. ( 1991)examined the association of deletions of the RB 1 gene with tumor grade. The RBI gene was altered in 10125 of high-grade tumors but in only 1 / 1 1 low-grade tumors. Accordingly it was proposed that RB 1 alterations may function as a marker for high-grade tumors and it was suggested that RBI gene status should be assessed as an independent prognostic indicator. Stratton et al. (1990)found that 4 of 1 1 tumors containing alterations of the p53 gene also had abnormalities of the RBI gene. Futhermore similar patterns of coincident inactivation of the p53 and RB1 genes have also been found in small cell lung cancer and in osteosarcoma. When considered together these observations suggest that for some tumor types inactivation of both the p53 and the RB1 suppressor genes may be required for tumor development. These observations are of particular interest in relation to recent studies demonstrating that proteins encoded by two viruses (SV40 and adenovirus) capable of inducing sarcomas in rodents interact with the products of the RBl and p53 genes. Thus the adenovirus Ela and Elb proteins bind respectively to the RBI (Whyte et al., 1988)and p53 (Sarnow et al., 1982)proteins, whereas the SV40 large T antigen binds to the products of both the p53 (Lane and Crawford, 1979;Linzer and Levine, 1979)and the RBI (DeCaprio et al, 1988)genes. It has been proposed that a consequence of these
HUMAN SOFT TISSUE TUMORS
103
interactions is to remove the tumor suppressing properties of the p53 and RBI proteins (Green, 1989). Thus alterations occurring at the genetic level in some human tumors appear to reproduce the pattern of effects caused by SV40 and adenovirous proteins at the level of protein interaction.
C. STUDIESON CHROMOSOME Loss Indirect evidence for the involvement of a suppressor gene can be obtained by demonstrating the consistent loss of particular chromosome segments using probes or PCR primers that allow individual alleles to be distinguished. Using this type of analysis frequent loss of the end of the short arm of chromosome 11 (1lp15) has been observed in embryonal rhabdomyosarcoma (Koufos et al., 1985; Scrable et al., 1987, 1989).Notably the loss of chromosome 11 was specific to the embryonal class of rhabdomyosarcomas and was not observed in alveolar tumors. It was therefore proposed that loss of chromosome 11 may act as a diagnostic marker that could be used to distinguish the alveolar and embryonal histological groups. Analysis of the mechanism of loss of chromosome 11 has been undertaken (Scrable et al., 1987). In around 50% of cases the loss of one entire homolog of chromosome 11 was accompanied by duplication of the remaining mutant allele. The other 50% of cases had lost heterozygosity of a variable number polymorphic loci on the short arm of chromosome 11 but retained constitutional heterozygosity on the long arm. Nonetheless cytogenetic and densitometric analyses revealed that each tumor had two complete copies of chromosome 11. It was therefore proposed that the loss of heterozygosity arose following mitotic recombination between the two progenitor copies of chromosome 11 (Fig. 8). Consistent loss of the end of the short arm of chromosome 11 has also been observed in Wilms’ tumor. Furthermore as mentioned above (Section II1,E) the Beckwith-Wiedemann syndrome, which is associated with a high risk of developing rhabdomyosarcoma, Wilms’ tumor, and hepatoblastoma, has been genetically linked to markers at 1lp15. When considered together these observations strongly support the idea that loss of a suppressor gene located at 1lp15 is required for the development of rhabdomyosarcoma and Wilms’ tumor. Although the end of the 1lp15 chromosomal region is currently the subject of considerable attention, the suppressor gene located in this region has not yet been cloned. This locus is, however, distinct from the Wilms gene located at llp13 (Call et al., 1990) and the muscle-specific MyoDI gene, which is also located on the short arm of chromosome 11 (Scrable et al., 1990).
104
COLIN S. COOPER
Chromosome 1 1
[m............................
Constitutional
.a.................-*.
..............................@..................
TlJmor genotype
*-
*.
...................
FIG. 8. Schematic model showing mitotic recombination of chromosome 1 1 in rhabdomyoscromas. "+" indicates wild-type allele and "*" indicates the presence of a mutated allele at 1 lp15. The figure shows the presumed genotype in a cell predisposed to rhabdomyosarcama by either an inherited or a somatic mutation at the 1 lp15 locus (constitutional) and the proposed structure of chromosome 1 1 that results from mitotic recombination between the two progenitor copies of chromosome 1 1 (tumor genotype). Adapted from Scrable et al. (1987).
VII. Gene Amplification Amplification and overexpression of protooncogenes have been observed in several classes of human cancer. For example, amplification of the N-myc gene is frequently observed in neuroblastoma (Hall, 1990), whereas c-erbB-2 is commonly amplified in breast cancer. The cytogenetic hallmarks of gene amplification (double minute chromosomes and homogeneously staining regions) have been found in malignant fibrous histiocytomes, liposarcomas, and in both alveolar and embryonal rhabdomyosarcoma (Douglass et al., 1987; Mertens et al., 1987; Wang-Wuu et al., 1988; Coccia et al., 1989; Mandahl et al., 1989). In agreement with these observations there have been isolated reports of N-my, c-myc, and gli protooncogene amplification in embryonal rhabdomyosarcomas (Garson et al., 1986; Mitani et al., 1986; Tsuda et al., 1988; Roberts et al., 1989; Hayashi et al., 1990) and in one study N-myc amplification was found in a tumor recurrence but not in the original embryonal tumors, suggesting that N-myc amplification may be involved in tumor regrowth (Carson et al., 1986). By comparison Dias et al. (1990) found a 5- to 20fold amplification of N - m y in 4 of 6 alveolar tumors but in none of 7 embryonal rhabdomyosarcomas. It has been reported that the c-myc gene is overexpressed in rhabdomyosarcomas and that increased c-myc expression may be linked to the loss of ability to differentiate in myogenic cell lines. However, Dias et al. (1990) failed to find abnormalities of the c-myc gene in their series of 13 tumors. Kopald et al. (1990) used DNA fingerprint analysis as a first step in identifying abnormalities in soft tissue sarcomas. In this procedure Southern blots of HaeIII- and HinfI-digested DNA was hybridized to
HUMAN SOFT TISSUE TUMORS
105
minisatellite probes. For all 14 soft tissue sarcomas the fingerprint of the tumor DNA exhibited changes when compared with the corresponding control DNA. In one liposarcoma a 1.5-kb DNA fragment was highly amplified. This sequence was cloned and mapped to human chromosome 7. Coccia et al. (1990) have used an in-gel renaturation technique to identify and isolate sequences amplified in soft tissue sarcomas. This technique allows the deletion and cloning of any sequences within the genome that are amplified greater than 15-fold. Using this procedure DNA amplification was detected in two of four malignant fibrous histocytomas with documented cytogenetic evidence of gene amplification and it was established that the amplification unit did not contain any of 15 known oncogenes including N-myc and c-my. Clones from the amplified region were isolated and screening of a panel of sarcomas identified amplification of these sequences in 218 MFH, 1/4 liposarcomas, and 1/1 leiomyosarcomas. Vlli. Predictors of Tumor Behavior
The identification of factors that can be used to predict the response of tumor to treatment and survival of individual patients is a major goal of clinical research. In addition to standard indicators such as grade, tumor size, and stage it is now recognized that, in certain tumors, the presence of particular genetic abnormalities correlates with clinical behavior. For example, in breast cancer amplification and overexpression of the c-erbB-2 gene are significant predictors of both overall survival and time to relapse (Slamon et al., 1987). Furthermore in neuroblastomas amplification and overexpression of the N-myc gene are frequently found in stage I11 and IV tumors, but rarely found in tumors at stages I and I1 (Brodeur et al., 1984).Similar correlations between the presence of specific genetic abnormalities or the expression of particular gene and clinical behavior have been observed for some types of soft tissue sarcoma. Correlations between the presence of a specific translocation involving chromosome 19 and tumor behavior and between the presence of alterations in the RBI gene and tumor grade were considered, respectively, in Sections V,F and V1,B. In this section studies on tumour ploidy and expression of multidrug resistance genes are reviewed. A. TUMOR CELLPLOIDY Abnormalities in the cells DNA content (ploidy) have been linked to prognosis in a variety of malignancies including breast cancer, neu-
106
COLIN S. COOPER
roblastoma, and acute lymphoblastic leukemia. In a study on unresectable rhabdomyosarcoma Shapiro et al. (1991) examined the relationship of tumor cell ploidy to histoglogical subtype and to patient response to treatment. They found the embryonal tumors had either a diploid DNA content or a hyperdiploid DNA content (1.1- 1.8 times the DNA content of diploid cells). By comparison alveolar tumors usually had either a diploid DNA content or a near tetraploid DNA content (1.8-2.0 times the DNA content of diploid cells). They also found that cell ploidy had a significant impact on treatment outcome. Patients with tumors with hyperdiploid DNA content had significantly longer survival times than did patients with diploid tumors. Patients with near tetraploid tumors exhibited a response intermediate between those observed for near diploid and diploid tumors. A similar association between hyperdiploid tumors and a favorable response has been observed for neuroblastoma and acute lymphoblastic leukemia. B. MULTIDRUCRESISTANCE The resistance of malignant cells to chemotherapeutic agents poses a major problem in the treatment of many cancers. Resistance may be intrinsic or may develop during the chemotherapy program and usually extends to several structurally and functionally unrelated agents. This phenomenon of multidrug resistance is associated with the expression of a 170-kDa membrane glycoprotein called P-glycoprotein, which is an energy-dependent pump that removes drugs from the cells. P-glycoprotein is encoded by a gene called mdr-1 that is frequently amplified and overexpressed in drug-resistant tumor cell lines. Chan et al. (1990) examined the relationship between expression of Pglycoprotein and prognosis in children with soft tissue sarcoma (mainly rhabdomyosarcoma) that were treated with chemotherapeutic agents (Fig. 9). In this study all nine patients that expressed P-glycoprotein relapsed after an initial response. By comparison, of 20 tumors that were consistently P-glycoprotein negative only one relapsed. This astonishing correlation between the absence of P-glycoprotein expression and longterm survival indicates that the expression of P-glycoprotein is a major factor in determining the long-term response of childhood sacomas to chemotherapy. These observations also raise hope that in the future novel treatment regimes involving the use of monoclonal antibodies against P-glycoprotein or inhibitors of P-glycoprotein such as cyclosporin, verapamil, and quinidine in combination with chemotherapy may improve long-term survival for patients with P-glycoproteinpositive tumors.
107
HUMAN SOFT TISSUE TUMORS
1.0m P-glycoprotein-negativesarcoma
3 0.8> .-
s
0 0
) . ) .
0.61 0.6-
w. c
a 0.4 Q
n 0.2-
I
L
2
4
6
8
1
0
Survival (years) FIG.9. Kaplan-Meier plot of the duration of survival in children with P-glycoproteinpositive and P-glycoprotein-negativesoft tissue sarcoma.
IX. Molecular Cloning of Translocation Breakpoints One of the most important goals of future research must be the cloning of genes involved in the set of specific chromosomal translocations found in soft tissue tumors. In this regard it is probable that there are lessons to be learned from the wealth of studies on translocation found in leukemias and lymphomas. Indeed, the application of molecular biological procedures to the analysis of specific translocations found in leukemias and lymphomas has resulted in profound insights into the molecular basis of development of these neoplasms. The translocations usually, but not exclusively, involve the immunoglobulin or Tcell receptor genes and are believed to result from errors in the gene rearrangement process (Hall, 1990). As a consequence of these errors the immunoglobin or T-cell receptor genes are juxaposed to a variety of genetic loci including genes that have been previously characterized (e.g., c-myc) together with an impressive array of novel candidate oncogenes (e.g., Lyl- 1, TallScl, Rhom- 1, and Rhom-2). These somatically acquired defects usually result in transcriptional deregulation of the transposed cellular gene. Many other translocations found in leukemias and lymphomas do not involve T-cell receptor or immunoglobulin loci. In some cases candidate genes previously localized to the general region of the chromosome involved in the translocation have been implicated. For example, it was discovered that the c-abl protein tyrosine kinase gene located on chromosome 9 is joined to the bcr gene in the t(9;22) translocation found in
108
COLIN S. COOPER
chronic myelogenous leukemia (Witte, 1986), whereas the E2A transcriptional factor gene located on chromosome 19 becomes fused to a homeobox gene as a result of the t( 1 ;19) translocation observed in childhood pre-B-cell acute leukemia (Nourse et al., 1990; Kamps et al., 1990). Southern and Northern analyses have been used to assess the involvement of candidate protooncogenes that are located at the appropriate chromosomal regions in the translocations found in soft tissue sarcomas but so far without success. Nonetheless it is notable that a surprisingly high proportion of genes activated by translocations in leukemia and lymphomas encode proteins that are members of the helix-loop-helix (my,E2A, Lyl- 1, and Tal/Scl) homeobox (Hox 1 1) and cysteine-rich/zinc finger (Rhom 1 and Rhom2) families of transcriptional regulatory tnolecules. New members of these gene families must therefore be considered as particularly strong candidates for involvement in the translocations found in soft tissue tumors. T h e DNA transfection/transformation assay might also provide a method for detecting genes that are activated by translocations. Indeed the NIH3T3 mouse fibroblasts would seem to be an ideal target cell for detecting genes activated in mesenchymal tumors. Unfortunately these types of studies have failed to identify activated oncogenes in synovial sarcomas containing the t(X; 18) translocation and in rhabdomyosarcomas containing the t(2; 13) translocation. A non-ras gene was apparently detected by transfection of DNA from a liposarcoma but this gene mapped to chromosome 19, not to chromosome 12 or 16 (Gill et al., 1991). Genes involved in chromosomal translocations may also be involved using a more indirect procedure generally referred to as reverse genetics. In this approach a combination of techniques is used to clone and create long-range restriction maps of the chromosomal region spanning the breakpoint. Pulsed-field gel electrophoresis, a technique used to separate large fragments of genomic DNA, can be used to map chromosomal regions and localize translocations using probes that may be several hundred kilobases from the position of the translocation. Probes flanking the translocation can also be used in genomic DNA walking and jumping experiments to isolate sets of cosmid and yeast artificial chromosome (YAC) clones that span the breakpoint. Candidate genes may then be identified by locating CpG-rich islands, by looking for regions of DNA that are highly conserved among different species, and by hybridizing the cloned DNA to Northern blots or cDNA libraries. This type of approach has been used to isolate a new oncogene called can that is involved in a specific translocation between chromosomes 6 and 9 [t(6;9)(p23;q34)]found in a subtype of acute nonlymphocytic leukemia
HUMAN SOFT TISSUE TUMORS
109
(von Lindern et al., 1990)and to isolate the genes involved in the t( 15;17) translocation found in acute promyelocytic leukemia (Borrow et al., 1990).
X. Future Developments Tumor development is generally considered to be a multistep process. Evidence for this is provided by analysis of the pathology of cancer development, by studying the transformation of mesenchymal cells in tissue culture, and by studies on the kinetics of appearance of cancer (Nordling, 1953; Foulds, 1969). Furthermore transformation of primary cells in tissue culture can, in some cases, be achieved through cooperation between activated oncogenes. For example transformation of primary embryonic fibroblasts from rat can be achieved by cooperation between activated forms of myc and rus oncogenes, whereas each oncogene on its own is insufficient to induce transformation (Land et al., 1983).These observations suggest that several genetic alterations may be required to achieve full transformation. In agreement with this idea studies on the development colon cancer suggest that the stepwise activation of one oncogene (rus) and inactivation of three suppressor genes (APC, DCC, and p53) may be required for development of colon carcinoma (Nigro et al., 1989; Fearon et d., 1990; Kinzler et d., 1991a; Nishisho et al., 1991). For many classes of soft tissue sarcomas only a single consistent genetic abnormality has been detected (i.e., the presence of a specific chromosomal translocation, activation of a rus gene, or inactivation of a suppressor gene). The identification of other genetic changes and the elucidation of the ways in which the different types of genetic change cooperate during the development of sarcomas are clearly important areas for future studies. In this regard the assessment of the role of new suppressor genes such as NF1, DCC, and APC, mentioned above, in the development of sarcomas may be very important. As key genetic alterations are identified it will also of course be necessary to determine whether their presence has any prognostic significance. During the past decade there have been major changes in the classification of soft tissue sarcomas and improvements in diagnosis through the use of new immunohistochemical reagents and refinements in ultrastructural analysis. Despite these advances difficulties are still encountered in the diagnosis of certain tumor groups (Enzinger and Weiss, 1988). For example, it has recently been suggested that many tumors diagnosed as malignant fibrous histiocytomas may in fact belong to other tumor groups. Moreover it is often difficult to distinguish between
110
COLIN S. COOPER
poorly differentiated rhabdomyosarcoma and poorly differentiated examples of other types of childhood tumors (Carter et al., 1990). The recent identification of tumor-specific genetic alterations (see Section 111) and of genes that are expressed in a lineage-specific fashion offers a completely fresh approach that has the potential to further improve methods of diagnosis and to improve consistency of diagnosis among different centers. Examples of genes with lineage-specific expression that may be of use in the diagnosis of soft tissue tumors are provided by the MyoD 1 (or mrf) gene family. T h e four members of this family (myf3, myf4, m y p , and myfi) encode transcription factors that are expressed exclusively in striated muscule and that when introduced into fibroblasts cause their conversion into cells with myogenic characteristics (Davies et al., 1987; Braun et al., 1989a,b, 1990; Wright et al., 1989). Since rhabdomyosarcomas are believed to be derived from cells that are differentiated toward striated muscle (Enzinger and Weiss, 1988), all rhabdomyosarcomas would be expected to express one o r more members of the myf gene family. i n agreement with this prediction, expression of myf3 was found in 85-100% of tumors and myf4 was expressed in 75% of tumors (Hiti et al., 1989; Scrable et al., 1989; Clark et al., 1991). The myf genes were not expressed in other classes of soft tissue and pediatric tumors, indicating that expression of myf3 and myf4 many provide an extremely useful marker in the diagnosis of rhabdomyosarcoma. Although studies have so far been restricted to the use of myf genes, it is probable that families of tissue-specific transcription factors will also be involved in controlling differentiation along other soft tissue lineages. The cloning of the genes encoding such factors should in time yield probes that can be used in the diagnosis of other classes of soft tissue tumor. ACKNOWLEDGMENTS C.S.C. is funded by the Cancer Research Campaign, UK. Thanks are due to Dr. M. C. Poirer for providing the information shown in Fig. 2. REFERENCES
Adam, L. R., Davison, E. V., Malcolm, A. J.. Pearson, A. D. J., and Craft, A. W. (1991). Cuwer Genet. Cytogenel. 52, 37-4 1. Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S., and Cline, M. (1989).Proc. Null. Acad. SCZ.U . S. A. 86, 6783-6787. Arheden. K., Nilbert, M., Heim, S., Mandahl, N., and Mitelman, F. (1989a). Cancer Genet. Cytogenet. 39, 195-201. Arheden, K., Mandahl, N., Heim, S., and Mitelman, F. (1989b). Cancer Genet. Cytogenet. 42, 143-146.
HUMAN SOFT TISSUE TUMORS
111
Ayesh, R., Idle, J. R., Ritchie, J. G., Crothers, M. J., and Hetzel, M. R. (1984). Nature (London) 312, 169-171. Balaban-Malenbaum, G., Gilbert, F., Nichols, W. W., Hill, R., Shield, J., and Meadows, A. T. (1981). Cancer Genet. Cytogenet. 3, 243-250. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., and Vogelstein, B. (1989). Science 244, 217-221. Baker, S. J., Markowitz, S., Fearon, E. R., Wilson, J. K. U., and Vogelsten, B. (1990). Science 249, 912-915. Balarajan, R., and Acheson, E. 0. (1984).J. Epidemol. Commun. Health 38, 113-1 16. Barker, D., Wright, E., Nguyen, K., Cannon, L., Fain, P., Goldgar, D., Bishop, D. T., Carey, J., Baty, B., Kivlin, J., Willard, H., Waye, J. S., Greig, G., Leinwand, L., Nakamura, Y., OConnell, P., Leppert, M., Lalouel, J.-M., White, R., and Skolnick, M. (1987). Science 236, 1100-1 102. Barr, F. G., Biegel, J. A., Sellinger, B., Womer, R. B., and Emanuel, B. S. (1991). Genes Chromosomes Cancer 3, 153-161. Beckmann, H., Su, L. K., and Kadesch, T. (1990). Genes Deu. 4, 167-179. Birch, J. M. (199O).J. Pathol. 161, 1-2. Bischoff, F. Z., Strong, L. C., Yim, S. O., Pratt, D. R., Siciliano, M. J., Giovanella, B. C., and Tainsky, M. A. (1991). Oncogene 6, 181-186. Bodmer, W. F., Bailey, C. J., Bodmer, J., Bussey, H. J. R., Ellis, A., Gorman, P., Lucibello, F. C., Murday, V. A., Rider, S. H., Scambler, P., Sheer, D., Solomon, E., and Spurr, N. K. (1987). Nature (London) 328, 614-616. Boghosian, L., Dal Cin, P., and Sandberg, A. A. (1988). Cancer Genet. Cytogenet. 34, 207208. Boghosian, L., Dal Cin, P., Turc-Carel, C., Rao, U., Karakousis, C., Sait, S. J., and Sandberg, A. A. (1989). Cancer Genet. Cytogenet. 43, 39-49. Borrow, J., Goddard, A. D., Sheer, D., and Solomon, E. (1990). Science 249, 1577-1580. Braun, T., Bischhausen-Denker, G., Bober, E., Tannich, E., and Arnold, H. H. ( 1 989a). EMBO J. 8,701-709. Braun, T., Bober, E., Bischhausen-Denker, G., Kohtz, S., Grzeschik, K.-H., and Arnold, H. H. (1989b). EMBO J. 8,3617-3625. Braun, T., Bober, E., Winter, B., Rosenthal, N., and Arnold, H. H. (1990).EMBOJ. 9,821831. Bridges, J. A., Sanger, W. G., Shaffer, B., and Neff, J. R. (1987). Cancer Genet. Cytogenet. 29, 97-102. Bridges, J. A., Shaffer, B., Neff, J. R., Sanger, W. G., and Moran, J. (1988). Cancer Genet. Cytogenet. 34, 1 19- 120. Bridges, J. A., Sanger, W. G., and Neff, J. R. (1989). Cancer Genet. Cytogenet. 38, 83-88. Bridges, J. A., Sanger, W. G., Neff, J. R., and Hess, M. M. (1990). Pathology 22, 16-19. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., and Bishop, J. M. (1984).Science 224, 1121-1124. Call, K. M., Glaser, T., Ito, C. Y., Buckler, A., Pelletier, J., Haber, D. A., Rose, E. A,, Kral, A., Yeger, H., Lewis, W. H., Jones, C., and Housman, D. E. (1990). Cell (Cambridge, MUSS.)60, 509-520. Carter, R. J., Jameson, C. F., Philp, E. R., and Pinkerton, C. R. (1990). Histopathology 17, 301-309. Cawthon, R. M., Weiss, R., Xu, G., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., OConnell, P., and White, R. (1990).Cell (Cambridge, Mass.) 62, 193-201.
112
COLIN S. COOPER
Chan, H. S., Thorner, P. S., Haddad, G., and Long, V. (1990).J. Clin. Oncol. 8 , 689-704. Chardin, P., Yeramian, P., Madaule, P., and Tavitian, A. (1985). 1nt.J. Cancer 35,647-652. Chen, P.-L.. Chen, Y., Bookstein, R., and Lee, W.-H. (1990). Science 250, 1576-1580. Clark, J.. Rocques, P. J., Broun, T., Bober, E., Arnold, H. A., Fisher, C., Fletcher, C., Brown, K., Gusterson, B. A., Carter, R. L., and Cooper, C. S. (1991). Br. J. Cancer 64, 1039- 1042. Coccia, M., Meltzer, P., Dal Cin, P., Turc-Carel, C., Sait, S., Sandberg, A,, A., and Trent, J. (1989). Proc. Annu. Meet. Am. Assoc. Cancer Res. 30, A1682. Coccia, M., Meltzer, P., Sal Cin, P., Turc-Carel, C., Sandberg, A., and Trent,J. (1990).Proc. Annu. MeFt. Am. Assoc. Cancer Res. 31, A1820. Cowell, J., Rutland, P., Jay, M., and Hungerford, J. (1986). Hum. Genet. 72, 164-167. Croce, C. M.,Isobe, M., Palumbo, A., Puck, J., Ming, J., Tweardy, D., Erikson, J., Davis, M., and Roverra, G. (1985). S z k e 227, 1044-1047. Dal Cin, P., Boghosian, L., and Sandberg, A. A. (1988a). Cancer Genet. Cytogenet. 30,285